













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
The mechanisms of 
actions and roles of 5α-
reduced glucocorticoids 









Doctor of Philosophy 





Topical inflammatory diseases are most commonly treated with 
glucocorticoids, such as hydrocortisone, which have debilitating side effects including 
a range of systemic metabolic side effects as well as local effects such as to thin the 
skin and delay wound healing. Safer anti-inflammatory therapies are required and this 
thesis investigates a novel drug called 5α-tetrahydrocorticosterone (5α-THB) as a safer 
topical anti-inflammatory treatment. The main foci of this thesis are to assess the 
effects of 5αTHB on wound repair, as well as to characterise its mechanisms of action. 
Defective angiogenesis accounts for impaired wound healing brought about by 
steroids in many cases. 5αTHB suppressed vessel growth in a mouse ex vivo model of 
angiogenesis, but was less potent in this action than hydrocortisone, suggesting a safer 
therapeutic profile. To understand the underlying mechanisms, the effect of 5αTHB 
on gene expression in the mouse aorta during angiogenesis was compared with that of 
dexamethasone (a selective GR agonist) and hydrocortisone. Whereas dexamethasone 
and hydrocortisone caused differential expression of genes involved in inflammatory 
signalling and extracellular matrix remodelling, 5αTHB did not and instead selectively 
regulated Pecam1, involved in vasculature remodelling. This suggested that 5αTHB 
suppresses angiogenesis through different mechanisms of action in comparison to 
dexamethasone, and thus may not act through GR. Supporting this, dexamethasone 
increased the abundance of GR responsive transcripts (Per1, Hsd11b1, Fkbp51) 
whereas 5αTHB only increased the abundance of Per1. Furthermore, whereas the GR 
antagonist RU486 attenuated dexamethasone-regulation of genes, it had no effect on 
gene regulation by 5αTHB.  
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To assess GR-mediation of 5αTHB effects, model systems were used to investigate 
whether 5αTHB is able to bind GR, stimulate its nuclear translocation, and initiate 
changes in its interaction with co regulator peptides. In a competitive binding assay, 
dexamethasone and hydrocortisone both decreased the fluorescence polarisation of a 
GR specific ligand, consistent with GR binding. In contrast, 5αTHB only displaced the 
specific GR ligand at very high concentrations. In terms of nuclear translocation, 
5αTHB also did not have an effect on the ratio of GR in the nucleus and cytoplasm 
(N/C) of A549 cells, suggesting that GR remained predominantly in the cytoplasm 
after 5αTHB treatment and did not translocate into the nucleus, whereas 
dexamethasone increased the N/C ratio at three different time points. Likewise, 
whereas dexamethasone stimulated changes in the interaction between GR and many 
co regulator peptides, 5αTHB had no effect. Collectively these results from model 
systems suggest that 5αTHB does not work through the conventional GR mechanism 
of action. 
Finally, a hypothesis generating approach was taken in order to gain hints into how 
5αTHB may be working. A microarray was performed to compare the effects of 
5αTHB and dexamethasone on gene expression in human peripheral blood derived 
macrophages. Both dexamethasone and 5αTHB were able to cause differential 
expression of genes in these cells. However unexpectedly, out of the 350 genes 
regulated by dexamethasone, and the 165 genes regulated by 5αTHB, only 35 genes 
were commonly regulated by both steroids. This suggested that 5αTHB mainly acts 
through different mechanisms to dexamethasone also in macrophages. In an 
enrichment analysis of the differentially expressed genes, whereas the NFκB signalling 
pathway was the top enriched pathway in genes only regulated by dexamethasone, 
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enriched pathways in genes only regulated by 5αTHB included those related to 
phagocytosis, the TGF-beta signalling pathway, and Th1-Th2 cell differentiation.  
This thesis therefore provides evidence to suggest that 5αTHB may provide a safer 
topical anti-inflammatory steroid, less harmful to wound repair processes. In addition, 
the mechanisms underlying the action of 5αTHB differ from those of classical GCs, 
consistent with its reduced side-effect profile. Other potential mechanisms, such as 
















Inflammatory diseases of the skin, such as eczema, are most commonly treated with a 
type of drug called a glucocorticoid. But although glucocorticoids are good at reducing 
inflammation, they have side effects inside the body and on the skin. Glucocorticoids 
cause colouring and thinning of the skin, and also prevent wounds from healing. 
The way in which glucocorticoids prevent wounds from healing is by slowing the 
growth of new blood vessels, so that oxygen and nutrients cannot enter the wound. 
A safer drug is needed which treats inflammation but does not slow the growth of new 
blood vessels. Our group have found a new drug called 5αTHB, which also treats 
inflammation but so far seems to have fewer side effects than glucocorticoids inside 
the body. This thesis explores why this is and also tests whether 5αTHB also has fewer 
side effects than glucocorticoids on the skin. 
The results show that in mice, 5αTHB was less damaging to new blood vessel growth 
than glucocorticoids, and so is likely to be safer when applied to the skin. In 
comparison to glucocorticoids, 5αTHB also had different effects on the genes of both 
mice and humans. These differences could explain why 5αTHB is able to treat 
inflammation without having side effects. 
In summary, this thesis gives evidence that 5αTHB is safer than glucocorticoids for 
treating skin inflammation. It also provides a starting point for understanding why this 
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Inflammatory and immune diseases are highly prevalent, causing significant 
morbidity and mortality worldwide, as well as high costs for society (Amaya-Amaya, 
Montoya-Sanchez et al. 2014, Straub and Schradin 2016). Examples include 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and multiple sclerosis 
(Straub and Schradin 2016). It is reported that almost 5% of the European population 
are affected by an autoimmune disease, and one of the most serious complications is 
the increased risk of cardiovascular disease (CVD) (Amaya-Amaya, Montoya-
Sanchez et al. 2014, Generali, Folci et al. 2017). This is due both to a modulation of 
risk factors and to accelerated atherosclerosis and vascular damage resulting from the 
inflammatory condition (Amaya-Amaya, Montoya-Sanchez et al. 2014, Generali, 
Folci et al. 2017, Mahmoudi, Aslani et al. 2017). In fact in RA, which has an overall 
prevalence of 1% worldwide, an increased CVD risk is responsible for around 50% of 
premature deaths (Mahmoudi, Aslani et al. 2017). Inflammatory skin disease is also a 
huge burden, with eczema being reported to affect around 230 million people globally 
(Vos, Flaxman et al. 2012). The most effective anti-inflammatory agents known, for 
which 40 billion prescriptions are given out each year in the UK, are glucocorticoid 
(GC) steroid hormones (Nixon, Upreti et al. 2012, Yang, Ray et al. 2012, Newton 
2013, Nixon, Andrew et al. 2013). However, GC therapy is associated with debilitating 
side effects, such as impaired wound healing, obesity, type 2 diabetes and osteoporosis 
(Wei, MacDonald et al. 2004, De Bosscher 2010, Nixon, Upreti et al. 2012, Yang, Ray 
et al. 2012, Nixon, Andrew et al. 2013). Much work has focused on improving GC 
therapies. An alternative therapy is the use of nonsteroidal anti-inflammatory drugs 
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(NSAIDS). However these also have adverse effects, particularly gastrointestinal (GI) 
toxicity characterised by GI irritation, ulcers and bleeding. NSAIDS work in different 
ways to GCs, mainly by inhibiting the cyclooxygenase (COX) enzymes involved in 
prostaglandin biosynthesis. Since the COX 1 isozyme is expressed mainly in the 
stomach, whereas high COX 2 levels are present in inflammatory cells, selective COX 
2 inhibitors were produced in an attempt to eliminate the GI side-effects.  These drugs 
seemed promising but later had to be withdrawn from the market when their more 
serious cardiovascular side effects were identified (Suthar and Sharma 2014). There 
remains a large unmet medical need for safer therapies that maintain anti-inflammatory 
properties comparable to GCs but lack adverse effects (Vandevyver, Dejager et al. 
2013). This thesis will explore the properties of an alternative anti-inflammatory 
steroid, believed to have a better therapeutic index than conventional glucocorticoids. 
1.1. Glucocorticoids 
GCs (Figure 1.1) are steroid hormones composed of 21 carbon atoms and containing 
the general cyclo pentane perhydrophenanthrene ring structure as a scaffold. GCs such 
as hydrocortisone and dexamethasone are often administered pharmaceutically. 
However, GCs are also produced endogenously to enable the body to respond 
appropriately to stress (both emotional and physical) (De Bosscher 2010). GCs 
therefore have many roles in the regulation and maintenance of a wide variety of 
homeostatic and metabolic processes (De Bosscher 2010, Vandevyver, Dejager et al. 
2013). One role is in the metabolism of glucose, reflected in the name glucocorticoid 
(glucose+ cortex+ steroid). The many functions of GCs make them essential for health, 
and indeed either chronic elevation or chronic reduction of endogenous 
glucocorticoids produce the pathological conditions Cushing’s syndrome and 
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Addison’s disease, respectively (Nixon, Upreti et al. 2012, Kadmiel and Cidlowski 
2013). Tissues which possess high GC levels include the liver, adipose tissue, muscles 
and bone. GC function in muscle involves the breakdown of protein into amino acids. 
In Cushing’s syndrome GC levels are chronically elevated leading to symptoms of 
muscle wasting, growth retardation in children, and myopathy (Stahn, Lowenberg et 
al. 2007). Osteoporosis is another symptom of Cushing’s syndrome and occurs as a 
result of GC signalling in bone (Stahn, Lowenberg et al. 2007). Another important role 
of GCs is glucose homeostasis, since GCs stimulate gluconeogenesis and decrease 
glucose utilisation, acting in an antagonistic manner to insulin and ultimately 
increasing blood glucose levels (De Bosscher 2010). This is reflected in the common 
symptoms of insulin resistance and glucose intolerance in Cushing’s syndrome (De 
Bosscher, Beck et al. 2010). GCs also have effects on fatty acid metabolism (De 
Bosscher 2010). These effects on glucose and fat metabolism result in a plethora of 
increased metabolic and cardiovascular risk factors in Cushing’s syndrome, including 
central adiposity, dyslipidaemia, obesity, hypertension and type II diabetes (De 
















Figure 1.1: Glucocorticoid (GC) chemical structures. The endogenous GC in humans is 
cortisol (Nixon, Upreti et al. 2012), and in rodents is corticosterone, which is also present in 
human to a small extent (Nixon, Upreti et al. 2012, Chapman, Holmes et al. 2013). 
Dexamethasone is a synthetic GC which is commonly used pharmaceutically (Bledsoe, 
Montana et al. 2002, Nixon, Upreti et al. 2012, Kadmiel and Cidlowski 2013). Cortisol is also 
used as a pharmaceutical under the name ‘Hydrocortisone’. Synthetic GCs have a similar 
structure to the natural GCs, but have been modified to achieve increased selectivity and 
binding at the glucocorticoid receptor (GR)(Nixon, Upreti et al. 2012).  
 
 
Endogenous glucocorticoids are synthesised from the precursor cholesterol, in a 
series of enzymatic changes, known as ‘steroidogenesis’, mediated by hydroxysteroid 
dehydrogenases (HSD family) and cytochrome P450 oxidases (CYP family) (Figure 
1.2)(Cain and Cidlowski 2017, Desmet and De Bosscher 2017, Clayton, Jones et al. 
2018). Although local GC production has been reported in other tissue, including the 
thymus, intestine and skin, the major site of glucocorticoid steroidogenesis is in the 
cortex region of the adrenal glands (Cain and Cidlowski 2017, Clayton, Jones et al. 
2018). Cortisol is the main endogenous human GC and corticosterone the main rodent 
GC, since rodents lack the adrenal 17α-hydroxylase enzyme. Corticosterone is also 
   
Cortisol /                                 Corticosterone                       Dexamethasone   
Hydrocortisone             
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present in humans, although it circulates at levels 10-30 times lower than cortisol 
(Nixon, Upreti et al. 2012). The synthesis and release of endogenous GC is controlled 
in a circadian and ultradian manner by the hypothalamic-pituitary-adrenal (HPA) axis 
(Figure 1.3) (Cain and Cidlowski 2017, Desmet and De Bosscher 2017, Clayton, Jones 
et al. 2018). The HPA axis can also be activated to produce GCs in response to various 
stressors (such as psychological distress, physical strain, tissue trauma and 
inflammatory cytokines) (Cain and Cidlowski 2017). In health, GCs can then act via 
negative feedback and limit their own production through suppression of the HPA axis 












Figure 1.2: Glucocorticoid biosynthetic pathways occurring in the adrenal cortex. 
Glucocorticoids are synthesised from cholesterol through a series of reactions as shown.  HSD 
= hydroxysteroid dehydrogenase. 
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Figure 1.3: Glucocorticoid regulation by the hypothalamic-pituitary-adrenal (HPA) axis. 
In response to circadian cues, stress, or inflammatory cytokines, the hypothalamus produces 
corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP), which then act on the 
anterior pituitary gland, causing it to synthesise and secrete adrenocorticotropin hormone 
(ACTH). When ACTH binds receptors on adrenocortical cells, steroidogenesis is stimulated 
and GC produced (Kadmiel and Cidlowski 2013, Cain and Cidlowski 2017). Image adapted 
from reference (Cain and Cidlowski 2017) and ‘Psychology’ book, ‘Stress, lifestyle and health’ 










Once released into the circulation from the adrenal cortex, ~90% endogenous 
GC becomes bound to plasma proteins, mainly the plasma protein corticosteroid-
binding globulin (CBG) whereas 10% remains unbound. CBG-bound GR is protected 
from metabolic degradation. Since GCs are small hydrophobic molecules the unbound 
fraction can readily diffuse across membranes and exert their biological effects (Nixon, 
Andrew et al. 2013), or are themselves metabolised in the liver and then excreted from 
either the kidney (95%) or gut (5%)(Schacke, Docke et al. 2002). However there is 
also evidence of selective active transport of glucocorticoids out of tissues. For 
example, the ATP (adenosine 5’ –triphosphate)-binding cassette (ABC) transporters 
have been described which differentially transport cortisol and corticosterone out of 
target cells, providing further control over their availability (Nixon, Mackenzie et al. 
2016). Although active systemic GC levels are controlled by the HPA axis, CBG 
protein in serum, and ABC transporters in cells, GC availability in tissues and cells 
can be further controlled enzymatically through the action of metabolic enzymes, best 
exemplified by 11β-hydroxysteroid dehydrogenases (11β HSDs). 11βHSD2 is able to 
convert the active GC (cortisol in human, corticosterone in rodent) into its inactive 
form (cortisone in human, 11-dehydrocorticosterone in rodent), whilst 11βHSD1 
predominantly catalyses the reverse reaction (Draper and Stewart 2005, Walker 2007, 
Tiganescu, Walker et al. 2011, Chapman, Holmes et al. 2013). Differences in 
11βHSD1 and 11βHSD2 abundance and activities, therefore, provide an extra control 
to determine GC sensitivity at a cell and tissue specific level. More recently my 
supervisor’s group has shown that the enzyme 5-reductase 1 (5αR1) also modulates 
GC activity (Livingstone, Di Rollo et al. 2014, Livingstone, Di Rollo et al. 2017). The 
5α-reductases convert GCs into their 5α-reduced forms and are involved in GC 
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clearance in the liver as the first step of increasing polarity to promote excretion. Aside 
from the liver, 5αR1 is also expressed in other metabolic tissues such as adipose and 
skeletal muscle (Russell and Wilson 1994, Upreti, Hughes et al. 2014). The loss or 
inhibition of 5αR1 has been linked to an adverse metabolic phenotype in humans and 
rodents including development of a fatty liver, decreased insulin sensitivity, increased 
weight gain, as well as HPA suppression, all of which are consistent with the effects 
of GC excess (Livingstone, Di Rollo et al. 2014, Livingstone, Barat et al. 2015). 
Once inside a target cell, GCs exert their main effects through binding to the 
glucocorticoid receptor (GR; unified nuclear receptor nomenclature NR3C1) which is 
expressed in almost all cells and tissues (De Bosscher 2010, Kadmiel and Cidlowski 
2013). Endogenous GCs can also bind to the Mineralocorticoid receptor (MR, NR3C2) 
with a 10 fold higher affinity than they do to the GR (Schacke, Docke et al. 2002, 
Vandevyver, Dejager et al. 2013). However, although GC binding to MR is important 
for some physiological effects, GC selectivity for GR is achieved in most cellular 
contexts due to the more limited/ tissue specific expression of MR, and also as a result 
of the activity of the 11βHSD2 isozyme which is often co-expressed with MR. Hence, 
11βHSD2 provides a barrier against GC binding to MR, achieving GR selectivity 
(Nixon, Andrew et al. 2013).  Many synthetic glucocorticoids (such as dexamethasone) 
also exist which, in contrast, often do not bind MR since they were designed to be 






1.2. The Glucocorticoid Receptor  
The glucocorticoid receptor is a 94 kD modular protein. It is a member of the 
nuclear receptor superfamily of transcription factors which includes the progesterone 
receptor (PR), androgen receptor (AR), estrogen receptor (ER) and mineralocorticoid 
receptor (MR) (Kadmiel and Cidlowski 2013, Nixon, Andrew et al. 2013, De 
Bosscher, Beck et al. 2016). GR is activated through ligand binding, with different 
ligands resulting in distinct conformational changes and, hence, a different spectrum 
of effects. Encoded by the NR3C1 gene, GR consists of 9 exons (Kino 2000, Cain and 
Cidlowski 2017). Exon 1 is an untranslated region, exon 2 encodes an N-terminal 
transactivation domain (NTD), exons 3 and 4 encode a DNA-binding domain (DBD), 
and exons 5-9 encode a ligand binding domain (LBD) as well as a hinge region which 
separates the DBD and LBD (Kino 2000). Like the other nuclear receptors, GR is 
therefore composed of three major functional domains: The NTD, DBD and LBD 
(Figure 1.4)(Kadmiel and Cidlowski 2013, Cain and Cidlowski 2017). 
 
Figure 1.4: Domain structure of the Glucocorticoid Receptor (GR). GR is composed of an 
N-terminal domain (NTD) including the AF1 transactivation region; a central DNA binding 
domain (DBD) region containing ‘zinc fingers’ responsible for binding DNA; and a C terminal 
domain (CTD) separated from the DBD by a hinge region. The C terminal domain contains 
another transactivation region AF2 , and also interacts with various stabilising proteins (for 
example Heat shock proteins (HSP) 90, 56 and 70, p23 and Src) as well as folding to form a 
ligand binding domain (LBD) where ligand becomes bound. Figure adapted from reference 




1.2.1. Functional domains of GR 
The NTD (residues 1-417) is the least conserved domain of GR (Kadmiel and 
Cidlowski 2013). This contains a transcriptional activation function (AF1) which 
mediates binding to diverse molecules necessary for the initiation of transcription, such 
as coactivators, chromatin modulators, and transcriptional machinery (Kino 2000, 
Kadmiel and Cidlowski 2013). Whereas in its basal state AF1 is relatively unfolded, it 
adopts a more complex helical structure in response to binding of cofactors (Kino 
2000). It also contains several serine residues (S203, S211 and S226) capable of being 
phosphorylated to modulate GR function (Nixon, Andrew et al. 2013). 
The central DBD (residues 418-487) is the most conserved region throughout the 
nuclear receptor superfamily (Kino 2000, Kadmiel and Cidlowski 2013). It contains 
two zinc finger motifs, each composed of a zinc ion held between four cysteine 
residues and followed by an α-helix (Kino 2000). The zinc finger motifs mediate 
genomic interaction with specific DNA sequences called glucocorticoid responsive 
elements (Kino 2000, Kadmiel and Cidlowski 2013, Cain and Cidlowski 2017). The 
DBD also contains a nuclear localisation function, a dimerisation interface, and has 
additional roles in transcription factor interaction (Schacke, Rehwinkel et al. 2006, De 
Bosscher 2010, Yang, Ray et al. 2012, Vandevyver, Dejager et al. 2013). 
Finally, the well conserved C terminal LBD is comprised of 11 α-helices and 4 
small β-sheets that fold to form a hydrophobic pocket for high affinity binding to 
specific ligands (Kino 2000, Kadmiel and Cidlowski 2013, Cain and Cidlowski 2017). 
The LBD also contains a transcriptional activation function (AF2) to recruit 
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coactivators in a ligand dependent manner (Yang, Ray et al. 2012). Like the DBD, the 
LBD is also involved in nuclear localisation and dimer formation (De Bosscher 2010). 
 
1.2.2. ‘Classical’ genomic signalling by GC 
Many mechanisms exist by which GC exert their effects. These mechanisms 
are complex and depend on the ligand structure. The ‘classical’ GC signalling 
mechanism involves its binding to GR, followed by translocation of GR into the 
nucleus, where GR either binds to DNA or to other transcription factors, resulting in 
direct or indirect gene regulation, respectively. These components of ‘classical GC 
signalling’ are described in sections 1.2.2.1 – 1.2.2.3. However, it is now known that 
signalling by GC is much more complex, and additional mechanisms are described in 
1.2.3. 
1.2.2.1.  GR binding and nuclear translocation 
In the absence of ligand, GR is reported to constantly shuttle through the 
nuclear pore channel between the nucleus and cytoplasm but to reside predominantly 
in the cytoplasm (De Bosscher 2010, Yang, Ray et al. 2012, Vandevyver, Dejager et 
al. 2013). In the cytoplasm, GR exists as part of a multiprotein complex (Cain and 
Cidlowski 2017, Scheschowitsch, Leite et al. 2017, Vandewalle, Luypaert et al. 2018) 
consisting of GR interacting with two molecules of HSP90, additional heat shock 
proteins (HSP70, HSP56), members of the Mitogen-activated protein kinase (MAPK) 
family, and other chaperones and co-chaperones (p23, p60, Src, hop) (Stahn, 
Lowenberg et al. 2007, De Bosscher, Beck et al. 2010, Yang, Ray et al. 2012, 
Chinenov, Gupte et al. 2013, Vandevyver, Dejager et al. 2013, Keenan, Lew et al. 
43 
 
2016, Scheschowitsch, Leite et al. 2017, Whirledge and DeFranco 2018). These 
interactions are required for efficient folding of GR into a stable conformation, 
preventing its degradation and enhancing its affinity for ligand (Kino 2000). The 
region of GR responsible for forming these stabilising interactions is demonstrated in 
figure 1.4 and is close to the ligand binding domain (Stahn, Lowenberg et al. 2007, De 
Bosscher, Beck et al. 2010, Yang, Ray et al. 2012, Chinenov, Gupte et al. 2013, 
Vandevyver, Dejager et al. 2013). Additionally the complex contains an 
immunophilin, which is either FK506 binding protein 51 (FKBP4) or FK506 binding 
protein 52 (FKBP5)(Bekhbat, Rowson et al. 2017). FKBP4 and FKBP5 compete with 
each other for binding to HSP90 (Bekhbat, Rowson et al. 2017). Whereas interaction 
with FKBP4 stimulates GR nuclear translocation, this movement is inhibited by 
FKBP5, which is reported to have a reduced interaction with dynein and also to mask 
nuclear localisation signals (NLS) (Bekhbat, Rowson et al. 2017, Clayton, Jones et al. 
2018). 
Upon ligand binding to the GR LBD, a conformational change takes place in 
the receptor, resulting in partial dissociation of the complex, and in FKBP5 
replacement with FKBP4 (Keenan, Lew et al. 2016, Cain and Cidlowski 2017, Desmet 
and De Bosscher 2017, Clayton, Jones et al. 2018, Vandewalle, Luypaert et al. 2018). 
This conformational change exposes NLS and results in GR now favouring nuclear 
import over nuclear export, as the NLS interacts with dynein (a motor protein) and 
dynein then associates with microtubules to transport the GR complex to the nuclear 
pore (Bekhbat, Rowson et al. 2017, Scheschowitsch, Leite et al. 2017). At the nuclear 
pore GR interacts with importins and nucleoporins, allowing it to enter the nucleus, 
dissociate from further chaperones and induce its genomic effects (Scheschowitsch, 
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Leite et al. 2017). The extent of GR nuclear translocation is, therefore, in part dictated 
by the balance of FKBP4 and FKBP5, as well as by exposure of NLS (of which there 
are two for GR: NL1 and NL2), which often depends on the ligand structure (Kino 
2000, Bekhbat, Rowson et al. 2017, Scheschowitsch, Leite et al. 2017). Once in the 
nucleus GR modulates gene transcription. The ligand receptor complex is then 
degraded, as GR dissociates from the ligand and is cleared from DNA (Kino 2000). 
GR is then recycled, slowly translocating back to the cytoplasm, reportedly mediated 
by the Ca2+ binding protein calreticulin, and finally the GR chaperone complex 
reforms (Kino 2000, Cain and Cidlowski 2017). 
1.2.2.2. Direct gene regulation by GR (Transactivation) 
One of the most widely reported mechanisms of gene regulation is the direct 
binding of GR, using the two zinc fingers contained within its DBD, to glucocorticoid 
response elements (GREs) in the promoter regions of target genes (Kino 2000). 
Classical GREs consist of inverted repeats of hexameric half sites separated by a 
sequence of three base pairs, with the consensus sequence GGAACAnnnTGTTCT, 
where ‘n’ is any base (Cain and Cidlowski 2017). Each half site binds one GR 
molecule, and these two bound GR molecules form multiple contacts and subsequently 
dimerise (Kino 2000); although it is still under debate whether the dimerisation occurs 
prior to DNA binding and in which subcellular compartment (Scheschowitsch, Leite 
et al. 2017). GR binding and dimerisation results in a conformational change 
(Scheschowitsch, Leite et al. 2017) and leads to the recruitment of coactivator proteins 
via the GR activation functions AF-1 and AF-2 (Kino 2000, Keenan, Lew et al. 2016, 
Whirledge and DeFranco 2018). Examples of these coactivator proteins are the steroid 
receptor coactivator 1 (SRC1, also known as NCOA1), glucocorticoid receptor- 
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interacting protein 1 (GRIP1, also known as NCOA2), and p300/CBP (Keenan, Lew 
et al. 2016, Cain and Cidlowski 2017). The recruitment of coactivator proteins induces 
chromatin remodelling, subsequently allowing the pre-initiation complex to form 
(including the recruitment of RNA polymerase II) and resulting in the activation of 
gene transcription (Keenan, Lew et al. 2016, Cain and Cidlowski 2017). Variation in 
GRE sequences, such as the 3 non-specific spacer nucleotides, influences the 3D 
structure of the bound GR dimer, leading to variations in its surface conformation 
(Kino 2000, Scheschowitsch, Leite et al. 2017). This in turn determines which 
transcriptional co-activators and chromatin-remodelling complexes are recruited, and 
modulates the transcriptional output of GR (Kino 2000, Scheschowitsch, Leite et al. 
2017). The DNA GRE sequence itself is, therefore, described to be critical in 
determining GR transcriptional activity (Kino 2000, Cohen and Steger 2017, 
Scheschowitsch, Leite et al. 2017), although other mechanisms are also involved in 
directing GR to these sites (Desmet and De Bosscher 2017).  This mechanism of 
action, demonstrated in figure 1.5a, is known as transactivation (TA) and these dimeric 
GRE sites are mainly associated with an increase in gene expression (Cohen and Steger 
2017). 
1.2.2.3. Indirect gene regulation by GR (Transrepression) 
GR can also indirectly regulate gene transcription, and the main mechanism 
through which it does this is by targeting transcription factors. This alternative mode 
of GR-mediated gene regulation occurs when GR monomers (Scheschowitsch, Leite 
et al. 2017) physically interact with, or ‘tether’, to another transcription factor without 
contacting DNA, although the TF may or may not be bound to DNA itself (Cain and 
Cidlowski 2017, Desmet and De Bosscher 2017, Scheschowitsch, Leite et al. 2017, 
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Vandewalle, Luypaert et al. 2018). This protein-protein interaction, demonstrated in 
figure 1.5d, alters the ability of both GR and the tethered transcription factor to 
influence gene transcription, such as by modulating their ability to bind DNA or to 
recruit co regulators and the transcriptional machinery (Kino 2000, Cain and 
Cidlowski 2017). The process has been termed transrepression (TR) and is usually 
associated with gene down-regulation (Desmet and De Bosscher 2017). It is reported 
to be particularly important for the suppression of inflammatory and immune 
responses by glucocorticoids (Kino 2000, Cain and Cidlowski 2017).  
1.2.3. Additional ‘non-classical’ genomic GC signalling 
Increases and decreases in gene expression were originally assumed to largely 
depend on transactivation (1.2.2.2) and transrepression (1.2.2.3) mechanisms, 
respectively. However, the situation is now known to be more complex. Direct GR 
binding to DNA can also result in suppression of gene expression, whereby GR 
interacts with repressive DNA motifs, termed negative GREs (nGREs)(figure 
1.5b)(Kino 2000, Cain and Cidlowski 2017, Cohen and Steger 2017, Scheschowitsch, 
Leite et al. 2017). nGREs consist of an inverted palindrome separated by 0-2 
nucleotide pairs, with the consensus sequence CTCC(n)0-2GGAGA (Kino 2000, Cain 
and Cidlowski 2017). Two monomers bind to nGREs with inverted polarity compared 
to how they bind GREs (Bekhbat, Rowson et al. 2017). Whereas at GRE the GR 
monomers bind on the same side of the DNA strand in a head to head fashion, at a 
nGRE they bind in a head to tail fashion on opposite sides of DNA (Kino 2000, 
Bekhbat, Rowson et al. 2017, Vandewalle, Luypaert et al. 2018). This orientation 
prevents GR dimerization (Bekhbat, Rowson et al. 2017, Scheschowitsch, Leite et al. 
2017), ensuring that two single monomers are bound to nGREs (Scheschowitsch, Leite 
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et al. 2017), and leading to the formation of a repressing complex through the 
recruitment of histone deacetylases and of co-repressors such as nuclear receptor co-
repressor 1 (NCOR1) and silencing mediator of retinoid and thyroid hormone 
receptors (SMRT) (Keenan, Lew et al. 2016, Cain and Cidlowski 2017, Vandewalle, 
Luypaert et al. 2018). This results in the suppression of gene transcription (Keenan, 
Lew et al. 2016, Scheschowitsch, Leite et al. 2017). In addition to GREs and nGREs, 
half site GREs are now also known to exist (figure 1.5c). These consist of only half of 
the classic GRE binding sequence (Desmet and De Bosscher 2017). GR binds to half 
site GREs as a monomer (Cohen and Steger 2017, Desmet and De Bosscher 2017, 
Scheschowitsch, Leite et al. 2017, Clayton, Jones et al. 2018), and has already been 
shown to drive transcription in both liver and primary macrophages in this way 
(Scheschowitsch, Leite et al. 2017). Interestingly, it was demonstrated in mouse liver 
that, under physiological conditions, GR monomer binding to half site motifs occurs 
more frequently than GR dimer binding to GREs (De Bosscher, Beck et al. 2016, 
Scheschowitsch, Leite et al. 2017), whilst administration of exogenous GCs causes a 
preference for GR homodimer binding at GRE sites, which occurs at the cost of 
monomer binding to half site GREs (De Bosscher, Beck et al. 2016, Vandewalle, 
Luypaert et al. 2018). It has, therefore, been suggested that GR monomers are more 
important for the physiological roles of GCs, and GR dimers for the pharmaceutical 
and stress functions (Vandewalle, Luypaert et al. 2018). Another layer of complexity 
is added by the fact that GR has also recently been reported to form heterodimers with 
MR and regulate gene expression this way (Trapp, Rupprecht et al. 1994, Liu, Wang 
et al. 1995, Savory, Prefontaine et al. 2001, Mifsud and Reul 2016). Furthermore, as 
well as translocating into the cell nucleus (Kino 2000) the ligand bound GR is also 
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reported to translocate into mitochondria and bind to mitochondrial DNA, stimulating 
gene expression and mediating apoptosis (Cain and Cidlowski 2017). 
Additionally, indirect methods of gene regulation other than transrepression 
exist. GR may compete with other TFs for essential co-activators, preventing TF 
activity (Cain and Cidlowski 2017).  Furthermore, in a slight variation of the TR 
mechanism, GR may interact with transcription factors whilst itself bound to DNA. 
This typically occurs at DNA sites containing both a responsive element for a distinct 
transcription factor as well as a half site GRE (Figure 1.5e) (Kino 2000, Cain and 
Cidlowski 2017, Whirledge and DeFranco 2018). This type of site is known as a 
‘composite element’ (Kino 2000, Cain and Cidlowski 2017, Vandewalle, Luypaert et 
al. 2018) and monomer binding at these sites has also been suggested to stabilise the 
interaction between monomer and nearby TFs in a process known as ‘half site 
facilitated tethering’ (Cohen and Steger 2017, Desmet and De Bosscher 2017). 
Binding at composite elements can lead to gene repression due to an interruption in 
TF-DNA binding, as described for the TR mechanism. However, it can also lead to 
gene activation in some cases, and this has been explained in terms of the bound TFs 
acting as pioneer factors in order to facilitate access of GR to the GRE half site. This 
mechanism is known as ‘assisted loading’ and alternatively (depending on the binding 
site composition and local chromatin conditions) may involve GR acting as the pioneer 
factor to aid TF binding to its response element (Kino 2000). Whether gene induction 
or suppression occurs at a composite element often depends on the TF subunit 
composition, with both directions of GR regulation being described for various STAT 
family members as well as for AP1 depending on the context (Cain and Cidlowski 
















Figure 1.5: Genomic signalling mechanisms of the Glucocorticoid Receptor (GR): Glucocorticoids (GC) diffuse through cell membrane and bind 
to GR, causing it to dissociate from a stabilising complex and translocate into the nucleus to exert its effects. In a mechanism known as Transactivation 
(a) GR may bind as a homodimer to glucocorticoid response elements (GRE) in the promoter region of target genes, which is usually associated with 
gene activation. It may also bind negative GRE (nGRE) as two GR monomers (b), usually associated with gene down regulation, or may bind as a 
monomer to a half-site GRE (c). Alternatively, GR monomers may tether to and suppress the activity of transcription factors (TF)(d) which are either 
unbound or bound to TF response elements (TFRE) on target genes. They may also bind at a ‘composite element’ € which has both a GRE for a GR 
monomer, and a TFRE for a TF. DNA helices are modified from the following source:  http://www.funkidslive.com/events/its-dnas-60th-birthday/#
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1.2.4. Non-genomic signalling of GCs 
Aside from genomic mechanisms which target DNA or transcription factors to 
regulate transcription/translation, non-genomic GC signalling is also known to occur 
and is thought to be particularly important for rapid GC effects. Whereas genomic GC 
effects usually occur within a few hours, more rapid GC actions have been 
demonstrated which, in contrast, occur within minutes. Non-genomic effects are 
reported to clearly contribute to the physiological and pharmaceutical effects of GCs, 
including the suppression of inflammation, as described in detail in section 1.3. GC 
modulation of brain function and behaviour is known to involve non-genomic 
mechanisms (Haller, Mikics et al. 2008) as is HPA axis regulation (Song and 
Buttgereit 2006). The mechanisms underpinning these non-genomic effects are diverse 
and vary according to the cell, tissue, species and steroid. However, they do appear to 
overlap and share some common signalling pathways; for example often involving 
calcium ions, protein kinase C (PKC), phospholipase C (PLC), cyclic adenosine 
monophosphate (cAMP), mitogen-activated protein kinases (MAPK), and tyrosine 
kinases (Wehling 1997, Falkenstein, Tillmann et al. 2000, Losel and Wehling 2003). 
Although a crossover between non-genomic and genomic mechanisms is known to 
exist it has not been widely explored (Haller, Mikics et al. 2008), and the genomic 
effects later arising from non-genomic signalling may be very important for function. 
(Losel and Wehling 2003).  
One non-genomic mechanism involves non-specific interactions with cell 
membranes, during which steroids intercalate into cell and mitochondrial membranes, 
thus influencing their physiochemical properties, although very high concentrations of 
GC are often required for this (Stahn, Lowenberg et al. 2007, Strehl and Buttgereit 
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2013). However, non-genomic GC effects may alternatively involve GC binding to the 
cytoplasmic GR (cGR) or to a membrane bound receptor (Buttgereit and Scheffold 
2002, Buttgereit, Straub et al. 2004, Song and Buttgereit 2006, Stahn, Lowenberg et 
al. 2007, Haller, Mikics et al. 2008, Strehl and Buttgereit 2013). cGR-mediated non-
genomic effects are based on the fact that GC binding causes the stabilised GR-multi 
protein complex to dissociate (Strehl and Buttgereit 2013). This promotes the release 
of cofactors (including of Src, HSPs, kinases such as MAPKs, and immunophilins) 
which mediate non-genomic intra-cellular signalling (Buttgereit and Scheffold 2002, 
Buttgereit, Straub et al. 2004, Stahn, Lowenberg et al. 2007, Haller, Mikics et al. 2008, 
Strehl and Buttgereit 2013). Alternatively, specific non-genomic effects of GCs can 
also occur through binding to receptors other than the classical GR. One example is 
the membrane variant of this receptor termed membrane GR (mGR)(Stahn, 
Lowenberg et al. 2007). mGR originates from the same gene as cGR but is suggested 
to vary through differential splicing, promoter switching or post translational editing 
(Stahn, Lowenberg et al. 2007). mGR was originally only known to exist in amphibian 
neuronal membranes, lymphoma and leukaemia cells (Buttgereit and Scheffold 2002, 
Buttgereit, Straub et al. 2004, Song and Buttgereit 2006, Stahn, Lowenberg et al. 
2007). It was later identified in PBMCs (monocytes and B lymphocytes) with the use 
of a high sensitivity immunofluorescence technique (Buttgereit, Straub et al. 2004, 
Stahn, Lowenberg et al. 2007). mGR exerts rapid effects through phosphorylation and 
dephosphorylation processes (Strehl and Buttgereit 2013). cGR and mGR have a 
similar capacity for binding to HSP and DNA binding, and they also possess similar 
phosphorylation patterns (Mitre-Aguilar, Cabrera-Quintero et al. 2015). However, 
there are also differences between mGR and cGR (as well as the difference in location) 
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such as different molecular weights and, interestingly, different ligand binding 
specificities. An example is that, whereas mGR was reported to bind dexamethasone 
and aldosterone but not hydrocortisone, cGR is known to bind hydrocortisone (Powell, 
Watson et al. 1999, Mitre-Aguilar, Cabrera-Quintero et al. 2015).  
A receptor other than the classical GR and mGR, through which non-genomic 
effects have been proposed to be mediated, is a 63 kDa acidic glycoprotein (Mitre-
Aguilar, Cabrera-Quintero et al. 2015), possessing completely different 
pharmacological characteristics from mGR, and originally described to share 
similarities with opioid receptors (Losel and Wehling 2003). Interestingly, cortisol and 
corticosterone bind to this receptor with high affinity and specificity, but other 
classical GR ligands such as dexamethasone and aldosterone do not (Rose and Moore 
1999, Falkenstein, Tillmann et al. 2000, Mitre-Aguilar, Cabrera-Quintero et al. 2015). 
However, a whole series of membrane proteins capable of GC binding appear to exist 
not just on the plasma membrane but also on other membranes such as the endoplasmic 
reticulum, intra cytoplasmic vesicles and mitochondria (Haller, Mikics et al. 2008). 
Glucocorticoid effects are also known to be mediated through allosteric actions at 
receptors for other hormones, and this has been reported for the GABA receptor 
(Tasker, Di et al. 2006). GABA receptors are proteins with allosteric binding sites not 
just for GABA neurotransmitters but also for benzodiazepines and barbiturates 
(Falkenstein, Tillmann et al. 2000). 3α,5α-tetrahydroprogesterone (3α5αTHP) and 
3α,5α-tetrahydrodeoxycorticosterone (3α,5αTHDOC) were the first steroids 
demonstrated to modulate neuronal excitability through interaction with GABA 
(Falkenstein, Tillmann et al. 2000) and a 3α OH group in the steroid A ring seems to 
allow the positive allosteric interaction.  
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1.4.  Achieving cell- and tissue-specific regulation by GR 
Despite ubiquitous expression of GR, and the fact that all cells have the same 
set of genes, the effects of GR are cell, tissue, context, and ligand specific (Cohen and 
Steger 2017, Vandewalle, Luypaert et al. 2018). This is because multiple factors 
determine responsiveness to GCs, hence leading to this specificity in GR 
transcriptional regulation.  
1.4.1. Chromatin Accessibility 
Chromatin accessibility is one factor contributing to cell and tissue specificity 
of GC effects. Section 1.2.3 described the various types of GR binding sites on DNA, 
however the accessibility of the binding sites for GR and TF depends on the local 
chromatin structure (Cohen and Steger 2017, Scheschowitsch, Leite et al. 2017, 
Clayton, Jones et al. 2018). In eukaryotic cells, DNA associates with various nuclear 
proteins such as histones and chromatin modifying factors. It wraps 1.67 turns around 
a histone octamer to form the smallest structural unit called a ‘nucleosome’, which 
then compacts further into a higher order chromatin (Kino 2000). It has been shown 
that up to 95% of GR occupancy occurs in pre-existing regions of accessible 
chromatin. However, this takes up only a subset of the existing binding sites, as the 
rest are inaccessible due to being buried in repressive chromatin structures (Cohen and 
Steger 2017, Vandewalle, Luypaert et al. 2018). Chromatin structure is organised 
differently depending on the tissue and cell type, and this is one reason why GR binds 
and regulates different genes in a cell specific manner (Cohen and Steger 2017, 
Scheschowitsch, Leite et al. 2017, Vandewalle, Luypaert et al. 2018). In vivo work 
suggests that GR on its own cannot remodel chromatin in order to access DNA in 
nucleosomes (Cohen and Steger 2017). However once bound to DNA it can further 
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remodel chromatin and, therefore, stimulate binding of other TFs (or vice versa) in a 
mechanism known as ‘assisted loading’ described to occur at ‘composite elements’ in 
section 1.2.3.2 (Cohen and Steger 2017). 
1.4.2. GR Isoforms 
Alternative splicing and transcription initiation of the NR3C1 gene gives rise 
to a variety of mRNA species. This and a further variety in translation initiation sites 
mean that many heterogeneous GR isoforms are produced, perhaps contributing to 
tissue specific functions (Kino 2000, Bekhbat, Rowson et al. 2017, Cain and Cidlowski 
2017, Cohen and Steger 2017, Desmet and De Bosscher 2017, Clayton, Jones et al. 
2018). 
The human GR gene contains 9 exons, and alternative splicing of the terminal 
exon (exon 9) generates the two major and most widely studied isoforms, the classic 
GRα and the non-ligand binding GRβ, with molecular weights of 97 and 94 kilo-
Daltons, respectively (Kino 2000, De Bosscher, Beck et al. 2016, Bekhbat, Rowson et 
al. 2017, Vandewalle, Luypaert et al. 2018). GRα and GRβ are both ubiquitously 
expressed and are highly homologous. They differ only after amino acid 727, after 
which GRα has an additional 50 amino acids in its C terminal region, whereas GRβ 
has an additional-non homologous 15 amino acids (Kino 2000). 
GRα is the traditional receptor isoform (Kino 2000) which acts as a transcription factor 
to influence gene expression and accounts for the classical functions of GR (Kino 
2000, Bekhbat, Rowson et al. 2017, Scheschowitsch, Leite et al. 2017, Vandewalle, 
Luypaert et al. 2018). In contrast, the GRβ isoform, does not bind glucocorticoid and 
cannot induce gene transcription in response to GC (Kino 2000, De Bosscher, Beck et 
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al. 2016, Bekhbat, Rowson et al. 2017, Vandewalle, Luypaert et al. 2018). This is 
because, whereas the NTD and DBD are the same in both isoforms, their LBD are 
different (Kino 2000). Specifically, helix 11 and 12 are disrupted in the LBD of GRβ, 
and these helices are crucial for forming the ligand binding pocket (Kino 2000, Cohen 
and Steger 2017). GRβ is able to interact with GREs in the nucleus using its DBD, and 
it is thought to negatively regulate the activity of the GRα isoform (De Bosscher, Beck 
et al. 2016, Bekhbat, Rowson et al. 2017, Cohen and Steger 2017, Scheschowitsch, 
Leite et al. 2017). Consistent with this, GRβ attenuated GRα-mediated transrepression 
of IL6 and TNFα genes (Kino 2000) and was also shown to have a negative effect on 
GRE-mediated transactivation by GCs, such as of the MKP-1 and PEPCK genes (Kino 
2000). Clinical studies have also provided evidence that GRβ inhibits GRα activity, 
and increased GRβ expression is thought to be a mechanism of glucocorticoid 
resistance in inflammatory disease (Bekhbat, Rowson et al. 2017). Cytokine signalling 
increases expression of GRβ relative to GRα, and increased GRβ expression is 
associated with reduced sensitivity to GCs in patients with various inflammatory and 
immune system diseases (Kino 2000, Cohen and Steger 2017, Vandewalle, Luypaert 
et al. 2018). GRβ has been proposed to act as an inhibitor through several mechanisms. 
This includes competing with GRα for GRE sites, binding directly to GRα to prevent 
its activity, or by using its AF1 domain to compete for co-activator proteins (Kino 
2000). However, due to the low expression of GRβ in comparison to GRα, its 
inhibitory effect has been doubted by some and is not universally accepted (Bekhbat, 
Rowson et al. 2017). Interestingly, it was recently shown that GRβ has intrinsic 
transcriptional activity, independent of its effects to inhibit GRα-activity (Kino 2000, 
Keenan, Lew et al. 2016, Cain and Cidlowski 2017, Scheschowitsch, Leite et al. 2017). 
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For example, GRβ has been shown to stimulate STAT1 expression through GREs, and 
was shown to modulate gene expression both in GRα-dependent and -independent 
manners in the liver (Kino 2000). However, the physiological role of this activity is 
not yet known (Kino 2000). Furthermore, although currently there are no known 
endogenous ligands for GRβ, it has recently been demonstrated that it can bind the GR 
antagonist mifepristone (RU486) in the same ligand binding pocket and orientation as 
GRα (Lewis-Tuffin, Jewell et al. 2007, Ligr, Li et al. 2012, Min, Perera et al. 2018). 
Although GRβ is located predominantly in the nucleus (Bekhbat, Rowson et al. 2017, 
Cohen and Steger 2017, Vandewalle, Luypaert et al. 2018), RU486 also stimulates 
cytoplasmic GRβ to undergo nuclear translocation and to regulate gene expression in 
an antagonistic manner (Lewis-Tuffin, Jewell et al. 2007, Min, Perera et al. 2018). This 
is because despite the lack of helix 12, the GRβ/ RU486 complex preferentially 
interacts with a co-repressor, but not with a coactivator, with an affinity similar to that 
of the GRα/RU486 complex (Min, Perera et al. 2018). 
As well as alternative splicing, further GR isoforms are produced due to the 
presence of 8 different translation initiation sites, beginning at amino acids 1 (GRα-
A), 27 (GRα-B), 86 (GRα-C1), 90 (GRα-C2), 98 (GRα-C3), 316 (GRα-D1), 331 
(GRα-D2) and 336 (GRα-D3). Since all initiation sites are present on the NTD, both 
GRα and GRβ are thought to give rise to a similar amount of isoforms (Kino 2000). 
With regard to the GRα isoforms, whilst all are capable of nuclear translocation in 
response to ligand, in the absence of ligand they have different cytoplasmic and nuclear 
distribution patterns (Kino 2000). Furthermore, the isoforms vary in their ability to 
transactivate and transrepress genes, reported to be in part due to distinct chromatin 
modulatory activity (Kino 2000, Bekhbat, Rowson et al. 2017). Differences in 
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expression of these diverse isoforms could partly explain the cell-specific responses to 
GCs (Cain and Cidlowski 2017, Vandewalle, Luypaert et al. 2018). 
















Figure 1.6. Glucocorticoid Receptor (GR) Isoforms: Alternative splicing and translation 
initiation of a single GR primary transcript give rise to diverse GR isoforms. Five splice variants 
(GRα, GRβ, GRγ, GR-A, and GR-P) have been identified, each with 8 potential translational 






1.4.3. Post Translational Modifications 
Post translational modifications (PTM) of GR also contribute to the diversity 
of glucocorticoid signalling, by regulating GR activity (Keenan, Lew et al. 2016). 
Aspects of GR activity which are influenced by PTM include nuclear translocation, 
effects on gene transcription, protein interactions and receptor degradation (Cain and 
Cidlowski 2017, Whirledge and DeFranco 2018). 
Phosphorylation is a commonly reported post-translational modification. The 
NTD of GR is extensively phosphorylated, and contains at least 5 phosphorylation 
sites (Kino 2000, Cohen and Steger 2017, Clayton, Jones et al. 2018) whereby a serine 
residue can be phosphorylated in response to GC (Bekhbat, Rowson et al. 2017). 
Several kinases phosphorylate GR, including mitogen activated protein kinases 
(MAPKs), cyclin-dependent kinases (CDKs), and glycogen synthase kinase 3 
(GSK3)(Kino 2000, Cohen and Steger 2017). Phosphorylation can alter GR 
transcriptional activity either globally or in a gene specific manner, by influencing GR 
recruitment to target genes (Bekhbat, Rowson et al. 2017, Clayton, Jones et al. 2018). 
As mentioned in section 1.2.1, many serine residues located inside the AF1 domain of 
GR can be phosphorylated, which alters its interaction with cofactors and its 
subsequent transcriptional regulation (Kino 2000). GR phosphorylation at certain 
residues is often ligand selective, and has been shown to correlate with GR 
transcriptional activity (Keenan, Lew et al. 2016). Various GR phosphorylation sites 
have been functionally characterised (Clayton, Jones et al. 2018). GR Serine211 
residue can be phosphorylated by p38 MAPK and this is associated with increased 
nuclear translocation, cofactor recruitment and an enhancement of transcriptional 
activity (Kino 2000, Grose, Werner et al. 2002, Bekhbat, Rowson et al. 2017, Cohen 
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and Steger 2017). Adenosine 5’monophosphate-activated protein kinase (AMPK) 
activates p38 MAPK, and is therefore able to indirectly phosphorylate GR (Kino 
2000). In contrast, phosphorylation of the GR Serine226 residue by c-Jun N-terminal 
kinases (JNKs) suppresses transcriptional activity, and this is reported to be due to its 
increased nuclear export (Kino 2000, Cohen and Steger 2017). 
1.4.4. Micro RNAs 
Further GR regulation appears to be mediated by microRNAs (miRNAs) which 
are short single stranded RNAs, around 19-22 nucleotide bases long (Kino 2000, 
Clayton, Jones et al. 2018). miRNAs are transcribed mainly by RNA polymerase II 
either from miRNA clusters or from within protein-coding or non-coding genes (Kino 
2000, Clayton, Jones et al. 2018). They can interact with mRNA causing its 
degradation, or can inhibit transcriptional initiation, both resulting in post-
transcriptional down-regulation of protein expression (Clayton, Jones et al. 2018). It 
is estimated that miRNAs can regulate as much as 60% of the mammalian 
transcriptome, and although individual mRNAs only have subtle effects on gene 
expression, the cumulative effects of several miRNAs on a biological process may be 
much more profound (Clayton, Jones et al. 2018). miRNAs are known to negatively 
regulate steroidogenesis, and to also influence GC availability through modulating 
11βHSD enzyme expression (Clayton, Jones et al. 2018). Furthermore, it is reported 
that several miRNAs regulate inflammatory and immune responses, some of which are 
induced by GCs (De Bosscher, Beck et al. 2016, Clayton, Jones et al. 2018). mRNAs 
may, therefore, influence GR signalling through effects on its ligand, or alternatively 
by associating with GR itself to influence signalling (De Bosscher, Beck et al. 2016). 
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1.4.5. Ligand Selectivity 
Crucially, the spectra of effects which result from GR activation depend on the 
ligand structure. Different ligands can activate distinct GR-regulated genes and 
signalling pathways, resulting in different pharmacological outcomes (De Bosscher, 
Beck et al. 2016, Keenan, Lew et al. 2016). This results from the fact that GR exhibits 
a high level of flexibility, and, therefore, the conformational change which results from 
their activation is highly ligand-dependent (De Bosscher, Beck et al. 2016, 
Vandewalle, Luypaert et al. 2018). Consequently, different ligands lead to varying 
patterns of GR co-factor recruitment, dimerization, nuclear translocation and 
transcriptional activity (De Bosscher, Beck et al. 2016, Scheschowitsch, Leite et al. 
2017). This raises the possibility of designing ligands which selectively activate some 
GR effects over others, in order to improve the safety and effectiveness of GCs 
(Keenan, Lew et al. 2016). This theme is discussed further in sections 1.6 onwards, 
since the focus of this thesis is a particular compound which provides promise as a 
selective GR ligand to treat inflammatory diseases. 
1.4.  Pharmaceutical use of GCs to treat inflammation 
1.4.1. Introduction to inflammation 
Inflammation is fundamental to the immune system’s response to infection, 
irritation or injury. It is normally initiated with the binding of a foreign molecule 
(which may be a protein, nucleic acid or an endotoxin such as LPS) to a specific pattern 
recognition receptor (PRR) such as a Toll like receptor (TLR) on the surface of 
immune and neighbouring cells. Binding to these receptors activates signalling 
cascades which ultimately lead to activation of key inflammatory transcription factors 
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such NFκB, AP1, IRF and STAT. Activation of pro-inflammatory transcription factors 
is a crucial step during an inflammatory response as it leads to increased expression of 
many key anti-inflammatory molecules, such as the IL6, IFNα and TNFα cytokines. 
These inflammatory mediators then induce changes in, for example, vascular 
permeability and immune cell recruitment, which ultimately lead to the successful 
clearance of infection (Chinenov, Gupte et al. 2013). 
1.4.2. History of anti-inflammatory GC use 
          Hench and co-workers, in 1948, were the first to demonstrate the therapeutic use 
of glucocorticoids to suppress inflammation, when they used cortisone in the treatment 
of rheumatoid arthritis (Hench 1950). For this work they later won a Nobel Prize, and 
since then it has become commonplace to use GCs for the treatment of a wide range 
of acute and chronic inflammatory and immune diseases (Schacke, Schottelius et al. 
2004, Yang, Ray et al. 2012). Cortisol is now regularly administered under the name 
of ‘hydrocortisone’ which was first introduced in the early 1950s (Schacke, Docke et 
al. 2002). However, since GR signalling underpins many processes other than just 
inflammation, any exogenously administered GC not only targets inflammatory cells 
but all others in which GCs are active, hence resulting in the detrimental side effects. 
Consequently, the long term use of GCs is associated with increased risk of death from 
cardiovascular disease (Souverein, Berard et al. 2004, Wei, MacDonald et al. 2004) 
with phenotypes strongly resembling those in patients with Cushing’s syndrome in 
whom endogenous GC levels are high (Nixon, Upreti et al. 2012). In addition to these 
increased disease risks, long term administration of GCs is also known to suppress the 
HPA axis, in turn resulting in maladaptive behaviour and increased susceptibility to 
future inflammatory insult (Stahn, Lowenberg et al. 2007). It is, therefore, clear that 
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new drugs, which retain anti-inflammatory ability but do not cause these side-effects, 
or at least have a reduced side-effect profile, are urgently required. Many synthetic 
glucocorticoids have been developed over the years, a common one being 
dexamethasone (Figure 1.1). Synthetic GCs generally possess a similar steroid 
scaffold but have structural modifications to improve potency as well as specificity for 
the GR over MR since 11βHSD2 often does not metabolise synthetic GCs in the same 
way as endogenous GCs. Importantly, some synthetic GCs are even predominantly 
reduced by 11βHSD2 rather than oxidised. As a result the co expression of 11βHSD2 
with MR is often not sufficient for synthetic GCs to achieve GR selectivity  (Best, 
Nelson et al. 1997, Wamil, Andrew et al. 2008, Nixon, Upreti et al. 2012, Kadmiel and 
Cidlowski 2013). Additional attention has also been paid to the pharmacokinetics of 
drugs in order to reduce side-effects and improve the therapeutic index (Schacke, 
Schottelius et al. 2004, Schacke, Rehwinkel et al. 2006). A big improvement in 
synthetic topical GC use was marked by the development of drugs which are less stable 
and can be delivered directly to the site of inflammation, therefore undergoing 
degradation before they can exert systemic effects (Schacke, Rehwinkel et al. 2006, 
Stahn, Lowenberg et al. 2007). Especially in the context of skin inflammatory 
conditions such as eczema, the therapeutic index has been greatly improved in drugs 
such as mometasone furoate (MF) and methylprednisolone aceponate (MPA) which 
rarely have systemic effects. However local side effects such as skin atrophy and 
decreased wound healing still exist and cannot be ignored (Schacke, Zollner et al. 
2009). Improvements based on drug design principles have almost reached their limit 
and the remaining problems now appear to lie within the molecular mechanism of 
these drugs, namely the fact that they stimulate a wide range of GR mediated processes 
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other than just the desired anti-inflammatory effects. Understanding this phenomenon 
may open doors to new strategies for drug design. 
1.4.3. Dissociating between GR mechanisms 
For decades, an attractive idea has been that the anti-inflammatory effects of GCs 
are mainly a consequence of GR tethering to transcription factors (TR), whereas the 
side-effects arise because of an increase in gene expression due to direct binding of 
GR to GREs (TA)(Cain and Cidlowski 2017, Vandewalle, Luypaert et al. 2018). This 
was because the GR is known to suppress the activity of pro-inflammatory 
transcription factors via the TR mechanism, leading to downregulation of pro-
inflammatory genes such as intracellular adhesion molecule (ICAM1), interleukin 6 
(IL6), monocyte chemoattractant protein 1 (MCP1), and tumour necrosis factor α 
(TNFα)(De Bosscher, Beck et al. 2016, Keenan, Lew et al. 2016). In contrast, genes 
up-regulated as a consequence of the TA mechanism included those involved in 
carbohydrate, protein and fat metabolism (which lead to the common GC side-effects), 
such as tyrosine amino transferase (TAT), phosphoenolpyruvate carboxykinase 
(PEPCK), and fatty acid synthase (Grose, Werner et al. 2002, De Bosscher, Beck et al. 
2010, De Bosscher, Beck et al. 2016, Vandewalle, Luypaert et al. 2018). From this 
idea arose the hypothesis that the anti-inflammatory effects of GCs could be separated 
from the adverse effects, by selectively targeting TR, and avoiding TA mechanisms 
(De Bosscher, Beck et al. 2016). The concept of an improved ‘dissociated steroid’ has 
therefore arisen. A dissociated steroid would bind to GR to induce its TR effects, but 
without affecting the TA mechanism. Since TA is assumed to rely on GR dimers and 
TR on monomers, a skewing towards GR monomers has been the avenue explored in 
order to create a ‘dissociated steroid’. This idea was explored with the help of a GR 
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dimerisation defective mouse (GRdim). The GRdim mouse model was generated by 
an A458T (alanine-to-threonine) single point mutation introduced by gene targeting 
using the Cre/loxP system (Reichardt, Kaestner et al. 1998). This mutation is in the 
second zinc finger of the DBD (De Bosscher, Beck et al. 2016, Scheschowitsch, Leite 
et al. 2017, Vandewalle, Luypaert et al. 2018). Dimer binding to a typical GRE is 
reported to be stabilised by protein-protein interactions of two GR monomers through 
a dimerization interface within the second zinc finger of the DBD (Adams, Meijer et 
al. 2003). The A458T mutation therefore compromises the ability of GR to form 
homodimers, and impairs any process dependent on homodimerisation, such as GRE 
driven TA (De Bosscher, Beck et al. 2016, Vandewalle, Luypaert et al. 2018).  Indeed, 
the authors reported a loss of TA and impaired DNA binding of GR in GRdim mice, 
however the mutated GR was still able to repress the activity of other transcription 
factors such as AP1 (Reichardt, Kaestner et al. 1998). The GRdim mouse model 
therefore demonstrated that TA and TR activities could be separated in vivo, and that 
any action of GCs remaining in these mice were independent of GR binding to DNA 
(Reichardt, Kaestner et al. 1998). The authors also concluded that DNA binding of GR 
is not essential for survival, since unlike GR-/- mice which die shortly after birth due 
to atelectasis of the lungs, GRdim mice are viable (Reichardt, Kaestner et al. 1998). 
Further studies have since been performed using the GRdim mouse model, confirming 
that TR functions mediated by GR tethering to TFs remain intact in GRdim mice 
(Vandewalle, Luypaert et al. 2018). In both wild and mutant animals, TR mechanisms 
mediated through AP1 and NFκB were retained, and cytokines under the control of 
these transcription factors, such as IL6 and TNFα, were suppressed to the same extent 
after LPS stimulation in macrophages (Schacke, Docke et al. 2002, Nixon, Andrew et 
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al. 2013). However whilst retaining anti-inflammatory ability, the DNA interaction 
and transcriptional activity of the mutated GR appears to be impaired at classical GRE 
binding sites (Vandewalle, Luypaert et al. 2018). Indeed, the GRdim mice have 
demonstrated an impaired ability to upregulate certain GRE containing genes such as 
TAT, glutathione-3-peroxidase and PEPCK, in comparison with wild type mice 
(Schacke, Rehwinkel et al. 2006, Nixon, Andrew et al. 2013, Vandevyver, Dejager et 
al. 2013). Furthermore, in the GRdim mice, in contrast to wild types, after exogenous 
GC treatment there was an enrichment of GR at half site GRE motifs due to a lack of 
GR redistribution from monomeric to dimeric GRE sites (De Bosscher, Beck et al. 
2016, Vandewalle, Luypaert et al. 2018). This is consistent with impaired gene 
regulation in GRdim mice. These studies, therefore, provided strong evidence that the 
anti-inflammatory effects of GCs were strongly dependent on the TR mechanism, and 
were capable of occurring in the absence of direct DNA interaction with GR dimers. 
The search for improved GR ligands has, hence, moved in recent years to focus on 
dissociating between different mechanisms of the GR, and this idealised type of ligand 
has been given the term a Selective Glucocorticoid Receptor Agonist (SEGRA). 
However, a ligand which dissociates TA and TR is an oversimplification of what 
needs to be achieved. Indeed, the GRdim model itself has been criticised. Evidence 
has suggested the requirement of other residues for dimerization, and it has been 
questioned whether the single point mutation is sufficient to eliminate GR dimerization 
and TA. It has been suggested that, independent of the DBD dimer interface, other 
‘alternative’ types of dimer can form in GRdim mice and that these can bind DNA but 
in a reduced manner dependent on the cell type and gene promoter. Examples given 
have included multimers or even GR/MR dimers (Nixon, Andrew et al. 2013, 
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Vandevyver, Dejager et al. 2013). Indeed whilst the A458T point mutation (contained 
within the GR of the GRdim mouse) prevents GR binding at a single GRE, it is now 
suggested that on some GR responsive promoters GR can form distinct multimers 
independently of the DBD dimer interface (Adams, Meijer et al. 2003). The PNMT 
gene promoter for example contains five regions where GR could bind (in contrast to 
TAT which contains a single GRE). Furthermore a dimerization defective GR was 
reported to bind to the PNMT promoter and in fact stimulated its transcription more 
strongly than wild type GR in vitro. This report demonstrated that typical GR dimer 
binding to GRE is not essential for regulation of PNMT. The authors of this latter paper 
therefore proposed that in fact, DNA binding of GR might be essential for survival 
(Adams, Meijer et al. 2003) 
Furthermore, although the separation of GRE-dependent TA and protein-protein 
interaction-dependent TR initially provided considerable optimism (De Bosscher, 
Beck et al. 2016), understanding of GR mechanisms and their complexity has now 
improved (Keenan, Lew et al. 2016) and achieving a dissociation of the side-effects 
and anti-inflammatory effects of GCs in this way is now considered unrealistic 
(Vandewalle, Luypaert et al. 2018). For example, GR is able to enhance, rather than 
repress, transcriptional activity through interaction with some transcriptional factors, 
such as with members of the signal transducer and activator of transcription (STAT) 
family (Keenan, Lew et al. 2016). Likewise, recent observations suggest that GR 
bound to canonical GREs can lead to negative regulation of genes in some cases, rather 
than cause TA (Keenan, Lew et al. 2016). Importantly, many genes up-regulated by 
the TA mechanism encode anti-inflammatory proteins, such as glucocorticoid induced 
leucine zipper (GILZ), inhibitor of NFκB (IκBα), interleukin 10 (IL10), MAP kinase 
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phosphatase 1 (MKP-1) and lipocortin 1(De Bosscher, Beck et al. 2016, Keenan, Lew 
et al. 2016, Cain and Cidlowski 2017, Desmet and De Bosscher 2017). These are often 
essential, particularly in acute inflammatory conditions, to completely resolve 
inflammation (De Bosscher, Beck et al. 2016, Vandewalle, Luypaert et al. 2018), 
making GR dimerization a requirement in some conditions for responding to 
exogenous GCs and suppressing inflammation (Vandewalle, Luypaert et al. 2018). In 
fact, GRdim mice are significantly more susceptible to several models of acute 
inflammation (such as septic shock induced by LPS, and TNF lethality) than wild type 
mice (Desmet and De Bosscher 2017, Vandewalle, Luypaert et al. 2018). Whereas 
wild type mice are well-protected by exogenous GCs in acute inflammation, GRdim 
mice are not (Vandewalle, Luypaert et al. 2018). Interestingly, this is in contrast to 
chronic models (such as irritative skin inflammation) in which wild type and GRdim 
mice are equally protected by exogenous GCs (Schacke, Schottelius et al. 2004). It 
has, therefore, been suggested by De Bosscher et al. (2016) that for chronic conditions, 
where long term treatment is required and GR dimers are most likely to result in side-
effects, skewing the balance towards GR monomers would be of benefit (De Bosscher, 
Beck et al. 2016, Desmet and De Bosscher 2017); whereas a skewing towards GR 
dimers over monomers may be beneficial to treat acute inflammatory diseases for 
which the long term effects are less of a consideration due to the short term and 
lifesaving nature of the treatment (De Bosscher, Beck et al. 2016, Vandewalle, 
Luypaert et al. 2018). De Bosscher et al. have proposed that new compounds that 
maximally stimulate GR dimerization could be designed for acute conditions, whereas 
compounds which selectively form monomers could be used for chronic conditions. 
They have termed these compounds SEDIGRAMs (selective dimerising GR agonists 
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or modulators) versus SEMOGRAMs (selective monomerising GR agonists or 
modulators) (De Bosscher, Beck et al. 2016, Vandewalle, Luypaert et al. 2018). 
However, this approach may also be overly simplistic. An alternative approach may 
be based on designing ligands which when bound to GR, result in a modified GR-
ligand structure, in turn affecting interaction of the GR-ligand complex with cofactors 
and, hence, influencing gene expression. Indeed, upon GR binding, the agonist 
dexamethasone induces a conformational change within helix-11, leading to 
interaction with TIF2 coactivator. Binding of the GR antagonist RU486, however, 
caused helix-11 to adopt an alternative conformation with co-repressor NCoR instead 
being recruited (Nixon, Andrew et al. 2013). It may, therefore, be that SEGRAs bind 
to GR and cause differences in gene transcription through distinct cofactor recruitment. 
1.4.4. The development of a Selective Glucocorticoid Receptor Agonist 
(SEGRA) 
          In recent years there has been an immense effort in both pharmaceutical and 
academic settings to develop a SEGRA. This is a compound capable of binding to GR 
and activating its anti-inflammatory mechanisms (which are thought to largely depend 
on TR by GR monomers) whilst not affecting mechanisms underpinning the side 
effects (many of which involve TA by GR dimers). The first compounds which 
appeared to be able to ‘dissociate’ between these two mechanisms of GR activity were 
the RU compounds (RU24782, RU24858 and RU40066) (Schacke, Rehwinkel et al. 
2006, Stahn, Lowenberg et al. 2007). The RU compounds, which were developed by 
Roussel Uclaf (now Sanofi Aventis, Paris, France) have a steroidal core and 
demonstrate strong GR binding affinity (Figure 1.7) (Schacke, Rehwinkel et al. 2006, 
McMaster and Ray 2007). In contrast to conventional GCs, the RU compounds showed 
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a reduced in vitro ability to cause TA of target genes and, hence, were thought to 
distinguish between TA and TR mechanisms (McMaster and Ray 2007). However, 
while these data were tantalising in vitro,  when tested in vivo it was evident that this 
was not the case, since the same side effects arose as with conventional GCs, with no 
therapeutic advantage (Rosen and Miner 2005, McMaster and Ray 2007). 
          Since the RU compounds, various other SEGRAs, both steroidal and non-
steroidal, have been proposed. Examples of non-steroidal candidates are AL-438 and 
Compound A (Figure 1.7). AL-438 is a quinolone-based compound which binds 
strongly to GR and which was synthesised by modification of the progestin scaffold 
(McMaster and Ray 2007, Reeves, Rayavarapu et al. 2012). Developed by Ligand 
Pharmaceuticals (San Diego, CA, USA) and Abbott Laboratories (Abbott Park, IL, 
USA) this compound demonstrated anti inflammatory effects with a reduced side 
effect profile, especially in relation to glucose metabolism and bone reabsorption. This 
was evident in vivo as well as in vitro (Schacke, Rehwinkel et al. 2006, Reeves, 
Rayavarapu et al. 2012). Rather than completely dissociating TA from TR 
mechanisms, AL-438 is reported to reduce the interaction between GR and 
coactivators involved in the development of certain side effects (Schacke, Rehwinkel 
et al. 2006). 
Compound A was the first proposed SEGRA to be derived from a natural 
source (Reeves, Rayavarapu et al. 2012). It is a synthetic analog of a non-steroidal 
compound identified from the Namibian shrub Salsola tuberculatiformmis 
Botschantev, by Haegman and colleages (De Bosscher, Vanden Berghe et al. 2005, 
Reeves, Rayavarapu et al. 2012). Compound A is a high affinity GR ligand and can 
induce GR nuclear translocation (De Bosscher, Vanden Berghe et al. 2005, Reeves, 
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Rayavarapu et al. 2012, Reuter, Grunwitz et al. 2012). It has been reported to favour a 
monomeric GR conformation and also did not appear to increase Ser-211 
phosphorylation in a similar way to Dex as described in sections 1.2.1. and 1.2.4.3 (De 
Bosscher, Vanden Berghe et al. 2005, Reeves, Rayavarapu et al. 2012). It, therefore,  
appeared to have low TA potential and, indeed, this was demonstrated in comparison 
to conventional GCs in vitro and in vivo (De Bosscher, Vanden Berghe et al. 2005, 
Reeves, Rayavarapu et al. 2012). However, at high doses of compound A, toxic 
aziridine breakdown products are formed, resulting in apoptosis of various cell types, 
and death of mice (Reeves, Rayavarapu et al. 2012, Reuter, Loitsch et al. 2012).  
Another series of promising SEGRA compounds are the ZK compounds by 
Bayer Schering Pharma AG (Berlin). Of special interest has been compound 
ZK216348 which is a non-steroidal compound synthesised from dihydrobenzofurane 
(Schacke, Rehwinkel et al. 2006, Reeves, Rayavarapu et al. 2012). This compound 
was identified as the (+) enantiomer of a racemic compound (ZK 209614) during a 
screening process specifically for selective glucocorticoid modulators. Although the (-
) enantiomer did not bind GR, ZK216348 was found to be a high affinity GR agonist 
(Schacke, Schottelius et al. 2004). In addition to binding GR, ZK 216348 was also able 
to induce GR nuclear translocation (Reuter, Loitsch et al. 2012) and exert anti-
inflammatory effects both in vitro and in vivo (Schacke, Schottelius et al. 2004). 
Furthermore, this compound has demonstrated a reduced side-effect profile compared 
to conventional GCs, especially in relation to dermal applications (Reuter, Loitsch et 
al. 2012). ZK216348 reduced skin thickness and skin breaking strength significantly 
less than prednisolone in vivo (Schacke, Schottelius et al. 2004). In vitro, ZK216348 
did not inhibit the closure of wounds made in a non-transformed rat small intestine 
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epithelial cell line (IEC-6), nor in HaCaT cells (a skin-derived keratinocyte cell line), 
whereas dexamethasone significantly reduced migration of cells in comparison to 
control (Reuter, Loitsch et al. 2012). However ZK216348 also binds to the MR and to 
PR which may limit its use due to unwanted effects. Another compound in this series, 
Compound ZK245186, is currently in phase 2 clinical trials for atopic dermatitis 
(Reeves, Rayavarapu et al. 2012). 
          It seems that the SEGRA quest is moving forward since the focus has been put 
on finding drugs which dissect between different GR signalling mechanisms. These 
synthetic drugs have real promise for dramatically reducing side-effects. However, 
although much focus has been paid to synthesising these dissociative compounds, it 
may now appear that compounds like this, which were previously ignored, may already 
be in existence physiologically. Indeed, 5α-reduced glucocorticoids, which have been 









Figure 1.7: Structures of previously investigated Selective Glucocorticoid Receptor 
Analogues (SEGRAs). Image adapted from (Schacke, Rehwinkel et al. 2006). 
 
 
1.4.5. 5α reduced Glucocorticoids 
          5α reduced glucocorticoids are formed via a series of reductions that occur 
naturally in the liver as part of the elimination process for glucocorticoids. In the rate 
limiting step, 5α reductase enzymes catalyse reduction of the Δ4,5 double bond in the 
glucocorticoid A ring (Stahn, Lowenberg et al. 2007) to form a 5α dihydrometabolite.  
The 3-ketone group is then rapidly reduced either by 3α-hydroxysteroid 
dehydrogenase (3α-HSD) to give the major 3α,5α-tetrahydro-metabolite or by 3β-
hydroxysteroid dehydrogenase (3β-HSD) to give the minor 3β,5α-
tetrahydrometabolite (McInnes, Kenyon et al. 2004, Nixon, Upreti et al. 2012), as 
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shown in Figure 1.7. These reactions provide a GC clearance route since the polar end 
products can be more easily cleared by the kidneys (Nixon, Upreti et al. 2012). Since 
disruption of 5αR activity shares adverse effects with alterations in GC activity, it does 
appear that 5α reduced GCs may be physiologically relevant in tissues other than the 
liver (Livingstone, Barat et al. 2015), although the relative contributions of increased 
product and decreased substrate are hard to dissect.  
The 5α reductase enzymes are hydrophobic membrane bound enzymes 
identified in rodent work during the 1950s. They are expressed not only in the liver 
but also in other tissues such as the skin, lungs, GI tract, adipose tissue and 
reproductive tissue (McInnes, Kenyon et al. 2004, Nixon, Upreti et al. 2012). In 
addition to binding GCs, 5α reductase enzymes also bind a range of 3-oxo-4-ene 
steroids, including the androgens, progestogens, and mineralocorticoids. The 5α 
reduced metabolites of these other steroids are known to have biological activity 
(Yang, Nixon et al. 2011, Nixon, Upreti et al. 2012). For example, 5α reduced 
androgens (such as dihydrotestosterone) bind the AR with greater affinity than the 
parent androgens. 5α reduced progesterones, which bind PR and are suggested to be 
neurosteroids, are actually the main progestogen in some species. Although with 
weaker activity, 5α reduced aldosterone metabolites also bind the MR (Nixon, Upreti 
et al. 2012). In contrast, 5α reduced GCs were assumed inert metabolites since they 
only very weakly activated metabolic gene transcription (such as TAT) which was 
known to be an important effect of the parent GCs. They were thus deemed a 
‘suboptimal inducer’ and remained largely ignored (Nixon, Upreti et al. 2012). 
However, recently there has been renewed interest in 5α reduced GCs since they have 
been shown to possess some previously unexplored anti-inflammatory activity. If able 
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to be used as an anti-inflammatory treatment, the fact that 5α reduced GCs only weakly 
activate metabolic gene expression is actually highly desired in order to prevent side 
effects. Due to our better understanding of GR mediated mechanisms, we can now 
postulate that 5α reduced GCs may be SEGRAs, capable of activating TR processes 
with limited effects on TA. This could be explained in terms of the more planar Δ4,5 
trans double bond of parent GCs which is likely to interact with GR in a different 
manner to the reduced forms with all single bonds. This may therefore affect the final 
conformation of the ligand bound GR, and hence its ability to induce downstream 
processes (Nixon, Upreti et al. 2012). 
1.4.6. 5α Tetrahydrocorticosterone (5αTHB) 
Of particular interest, is the 5α reduced metabolite of corticosterone (the main 
rodent GC), 5alpha tetrahydrocorticosterone (5αTHB) (Figure 1.8 iii). 5αTHB has a 
reduced side-effect profile in vitro and in vivo in comparison to its parent GC 
corticosterone, alongside its anti-inflammatory effects. Accumulating evidence 
suggests that the mechanisms of action of 5αTHB are different from those of 
conventional GCs. 
 
Figure 1.8:  Metabolism of natural rodent glucocorticoid corticosterone (B) to produce 
5α-tetrahydrocorticosterone (5αTHB).  The conversion of B (i) to 5αTHB occurs naturally in 
the liver to increase polarity and, therefore, enable easier excretion. In the rate-limiting step, 
B is reduced by the 5α-reductase enzyme (5αR) to form the dihydrometabolite 5αDHB 
(ii)(McInnes, Kenyon et al. 2004, Nixon, Upreti et al. 2012). Further reduction by 3α-
hydroxysteroid dehydrogenases (3αHSDs) then follows rapidly to form 5αTHB (iii) (McInnes, 
Kenyon et al. 2004, Yang, Nixon et al. 2011, Nixon, Upreti et al. 2012). 
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          Evidence of 5αTHB having anti-inflammatory effects in vitro and in vivo has 
been collated. In LPS-stimulated mouse bone marrow-derived macrophages (BMDM), 
5αTHB suppressed IL6 and TNFα cytokine release although to a lower extent than 
dexamethasone and corticosterone (Yang, Nixon et al. 2011). Dose-dependent effects 
of 5αTHB to suppress cytokine release were also demonstrated in RAW264.7 
macrophages (Nixon, 2011), again with a weaker suppressive effect than 
corticosterone. This work also provided evidence that the cytokine suppression is due 
to direct effects of 5αTHB on transcription factors by demonstrating that both 5αTHB 
and corticosterone suppressed phosphorylation of JNK and p38; two MAPK family 
members which once phosphorylated, lead to AP1 and NFкB activation. Unlike 
corticosterone, 5αTHB did not have a significant effect on the amount of IKβα, which 
could be suggestive of effects mediated by 5αTHB solely through the MAPK family. 
Anti-inflammatory effects to suppress IL6 and TNFa cytokine release in vivo were 
confirmed in mouse whole blood, and in peritoneal lavage fluid from a mouse model 
of thioglycollate-induced peritonitis 5αTHB suppressed IL6 and MCP1 (TNFα was 
not tested)(Yang, Nixon et al. 2011). Furthermore, in the latter model inflammatory 
cell infiltration into the peritoneum was also measured, and 5αTHB suppressed 
neutrophil and inflammatory monocyte cell infiltration. However, recent work 
suggests interesting modes of action (Gastaldello, Livingstone et al. 2017). In a mouse 
model of dermatitis (induced with croton oil) 5αTHB appeared to mediate anti-
inflammatory effects in a different manner to corticosterone. Whereas the anti-
inflammatory effects of corticosterone (decreased cell infiltration, ear swelling and 
neutrophil activity) were evident after 6 hours, 5αTHB demonstrated (at 
concentrations 5 fold higher than corticosterone) a different time course of action with 
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these effects only evident after 24 hours. In addition to this difference in time course, 
Gastaldello (2014) demonstrated that 5αTHB increased transcripts of the anti-
inflammatory Dusp1 (also known as Mkp-1) in two different mouse models, whereas 
interestingly corticosterone did not. This is strongly suggestive of 5αTHB acting to 
suppress inflammation through different mechanisms to those of conventional GCs. 
Further evidence to suggest differences exerted by 5αTHB is that when HE293 cells 
were co-transfected with GR, 5αTHB actually increased NFкB and AP1 mediated 
luciferase activity (Nixon, 2011). This is contrary to the effects of corticosterone and 
5αDHB and to what would be expected if 5αTHB suppressed inflammation through 
the conventional TR mechanism. 
          It, therefore, appears that 5αTHB is anti-inflammatory but with different 
mechanisms of actions and reduced adverse metabolic effects in comparison to 
conventional GCs. The in vivo anti-inflammatory effects of 5αTHB were first 
demonstrated in a murine model of thioglycollate-induced peritonitis, in which 5αTHB 
suppressed neutrophil infiltration with a similar efficacy to corticosterone (McInnes, 
Kenyon et al. 2004).  In this model the drugs had to be administered subcutaneously, 
since 5αTHB was rapidly cleared from the circulation when infused systemically, 
indicative of poor systemic bioavailability and difficulty in maintaining an effective 
dose. This, therefore, suggested that 5αTHB would not be suitable for oral use and 
instead should be developed as a topical treatment. For topical use, the rapid clearance 
is actually a positive feature, reducing the likelihood of systemic side effects occurring. 
Evidence that 5αTHB could suppress inflammation when applied topically was 
subsequently tested. Indeed, in a murine croton oil ear model of dermal inflammation, 
5αTHB reduced swelling and cell infiltration to a similar extent to corticosterone, 
78 
 
without inducing systemic side-effects (42)(Dawn Livingstone, personal 
communication). 5αTHB is now being investigated as a safer topical glucocorticoid 
and, therefore, its adverse effects locally on the skin (e.g. impaired wound healing) 
need to be explored.  
1.4.7. 5αTHB as a SEGRA with decreased adverse effects on wound 
healing 
With eczema estimated to affect 230 million people worldwide, inflammatory 
skin diseases are highly prevalent and are most commonly treated with topical GCs. 
Absorption of these drugs into the circulation leads to the systemic side effects 
previously described. This is a particular problem for babies with a low body volume 
to skin ratio. Therefore, in the context of topical treatments, the high clearance rate of 
5αTHB may actually be an advantage, reducing the potential for systemic effects. 
However topical GC treatments are additionally plagued by local adverse effects of 
delayed wound healing and skin atrophy. For patients with a skin barrier which is 
already delicate and compromised, such as in the elderly or in diabetic patients who 
are more likely to experience chronic non healing wounds, this is a particular concern 
(Brandt, Grunler et al. 2015, Briquez, Hubbell et al. 2015, Holmes, Plichta et al. 2015, 
Rosique, Rosique et al. 2015). Therefore, more needs to be known about the effects of 
5αTHBs on wound repair. Delayed wound healing as a result of GC exposure is not 
only a problem for skin treatments but also for systemic use, where GCs may delay 
internal wound healing (for example in vascular repair processes). The wound repair 
process is surprisingly similar in different tissues and after various insults, with 
internal repair mechanisms (occurring after, for example myocardial infarction, 
reperfusion injury or tissue ischaemia) strongly resembling those following skin 
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wounding (Gurtner, Werner et al. 2008). The skin, hence, provides a very useful model 
for studying effects on wound healing processes in general, and 5αTHB could not only 
provide a safer topical anti-inflammatory treatment, but through an understanding of 
its mechanisms may also help to provide a prototype for a safer drug which could 
regulate internal inflammation at sites of vascular injury and repair, without some of 
the adverse effects.  
1.10.  Mechanisms of wound repair in the skin 
The skin is the largest organ of the body, composed of two main layers (Bayo, 
Sanchis et al. 2008, Hopkinson, Hamill et al. 2014, Holmes, Plichta et al. 2015, 
Rosique, Rosique et al. 2015). The inner layer is the dermis consisting mainly of 
fibroblasts and connective tissue. The outer layer, the epidermis, is a stratified 
squamous epithelium containing multilayers of keratinocytes (Hopkinson, Hamill et 
al. 2014). The dermis and epidermis are joined together through a basement membrane 
of many extracellular matrix (ECM) proteins (Hopkinson, Hamill et al. 2014). Due to 
the skin’s crucial function as a protective barrier, it is very important that when a 
wound is formed and this barrier is broken, that the healing process occurs as quickly 
as possible.  
The wound healing process involves many cell types, pathways, proteins, 
growth factors, and ECM components (Eming, Brachvogel et al. 2007, Jiang, Zhang 
et al. 2013, Sinno and Prakash 2013, Ding and Tredget 2015). It can be divided into 
four main phases of haemostasis, inflammation, new tissue formation, and tissue 
remodelling (Eming, Brachvogel et al. 2007, Giusti, Rughetti et al. 2013, Sinno and 
Prakash 2013, Johnson and Wilgus 2014, Martinez, Smith et al. 2015, Portou, Baker 
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et al. 2015, Rosique, Rosique et al. 2015). Haemostasis initiates the wound healing 
process (Ding and Tredget 2015, Portou, Baker et al. 2015, Rosique, Rosique et al. 
2015). Platelets released from damaged vessels form a ‘haemostatic plug’ in the 
wound, and release biomolecules important for later stages of tissue repair (Giusti, 
Rughetti et al. 2013, Sinno and Prakash 2013, Hopkinson, Hamill et al. 2014, Ding 
and Tredget 2015, Martinez, Smith et al. 2015, Rosique, Rosique et al. 2015). The 
haemostatic plug provides a protective barrier, prevents haemorrhage and serves as a 
temporary matrix for early cell migration (Sinno and Prakash 2013, Hopkinson, Hamill 
et al. 2014, Briquez, Hubbell et al. 2015, Ding and Tredget 2015).  Inflammation is 
then activated whereby increased vascular permeability, capillary dilation, and 
expression of endothelial adhesion molecules, result in leucocyte recruitment (Sinno 
and Prakash 2013, Ding and Tredget 2015).  Neutrophils arrive first, followed by 
macrophages after a few days and later T lymphocytes (Eming, Brachvogel et al. 2007, 
Barrientos, Stojadinovic et al. 2008). The immune cells clean the wound of foreign 
material and provide further growth factors and cytokines for later stages of wound 
repair (Portou, Baker et al. 2015). The proliferative stage of wound healing involves 
the migration and proliferation of many cell types including fibroblasts, keratinocytes 
and endothelial cells. Fibroblasts migrate to the wound site and differentiate into 
myofibroblasts, which contract to help close the wound and secrete ECM components 
such as collagen (Barrientos, Stojadinovic et al. 2008, Briquez, Hubbell et al. 2015, 
Rosique, Rosique et al. 2015) (Eming, Brachvogel et al. 2007, Portou, Baker et al. 
2015, Rosique, Rosique et al. 2015). In a process called reepithelialisation 
keratinocytes from the side of the wound migrate, proliferate and differentiate in order 
to cover the wound site and restore the epidermis (Martinez-Mora, Mrowiec et al. 
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2012, Jiang, Zhang et al. 2013, Hopkinson, Hamill et al. 2014, Portou, Baker et al. 
2015). Finally, angiogenesis occurs. This is the formation of new blood vessels from 
the pre-existing vasculature and is vital for wound repair to give a temporary increase 
in blood vessels, providing oxygen and nutrients at the injury site (Eming, Brachvogel 
et al. 2007, Sinno and Prakash 2013, Johnson and Wilgus 2014, Martinez, Smith et al. 
2015). During angiogenesis the vessel basement membrane degrades, and the vessel 
dilates and becomes more permeable to allow proliferation and migration of 
endothelial cells, leading to the sprouting of new vessels (Hwang and Heath 2010, 
Johnson and Wilgus 2014, Lee, Lin et al. 2015). The final stage in wound repair, which 
overlaps with the end of the proliferative phase, is the remodelling phase during which 
the ECM is remodelled into a more permanent scar tissue (Sinno and Prakash 2013). 






Figure 1.9: Skin structure and the wound repair process. The skin consists of the epidermis (mainly keratinocytes) and the dermis (fibroblasts, 
blood capillaries and connective tissue). When a wound is formed the repair process involves: the formation of a haemostatic plug by platelets (P); 
dilation and increased permeability of blood vessels, and the subsequent infiltration of neutrophil (N) and monocyte (M) inflammatory cells; the growth 
of new blood vessels (angiogenesis) into the wound to supply it with oxygen and nutrients; and finally, the migration of fibroblasts and keratinocytes 
for wound contraction, connective tissue formation, and epithelialisation. 
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1.6.  Mechanism of angiogenesis 
Angiogenesis is the formation of new blood vessels from the pre-existing 
vasculature (Johnson and Wilgus 2014). Since oxygen can only diffuse up to 200μM 
through tissues this process is vital for wound repair to give a temporary increase in 
blood vessels at the injury site and, hence, provide nutrients and oxygen for granulation 
tissue formation (Eming, Brachvogel et al. 2007, Logie, Ali et al. 2010, Sinno and 
Prakash 2013, Johnson and Wilgus 2014, Martinez, Smith et al. 2015). 
Blood vessels in healthy tissue exist in a quiescent state, with tight cell-cell 
adhesions between endothelial cells, and surrounded by a basement membrane which 
is important for stabilisation as well as for endothelial cell function. Mature vessels 
are further stabilised due to the pericytes and smooth muscle cells surrounding them 
(Johnson and Wilgus 2014). The blood vessels are held in this quiescent state in adult 
tissues, due to production of more inhibitors of angiogenesis than activators in the 
microenvironment (Johnson and Wilgus 2014). However, during wound repair, many 
proangiogenic molecules are released, such as from platelets and macrophages 
(Martinez, Smith et al. 2015). This tips the balance in favour of angiogenic activation, 
and the point at which the proangiogenic factors dominate is known as the ‘angiogenic 
switch’ (8, 11, 18, 19). Angiogenesis then proceeds through several stages, 
demonstrated in figure 1.9. The existing vessel first dilates and becomes more 
permeable - Pericytes and SMCs detach from the vessel and endothelial cell-cell 
contacts loosen, transforming them from their quiescent state into proliferative and 
migratory cells (Hwang and Heath 2010, Zhu, Yao et al. 2015).  Degradation of the 
basement membrane and surrounding ECM by matrix metalloproteinases (MMPs) and 
serine and cysteine proteases then provides a gap for migration of ECs to occur and 
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form a sprout (Johnson and Wilgus 2014) (Hwang and Heath 2010, Lee, Lin et al. 
2015). Proliferation and migration of cells within the sprout, and subsequent 
remodelling, forms a ‘lumen’ or ‘tube’. Finally, maturation of the vascular network 
occurs. Whilst excessive blood vessels regress in a process known as ‘vessel pruning’ 
(Korn and Augustin 2015), other vessels are stabilised through formation of a new 
basement membrane, and for larger vessels, also the reattachment of smooth muscle 
cells and pericytes (Eming, Brachvogel et al. 2007). 
 
 
Figure 1.10: Mechanisms involved in the initiation of angiogenesis. Angiogenesis is 
initiated by an alteration in the presence of angiogenic signalling molecules. These signals 
stimulate degradation of the basement membrane, and also activate endothelial cells to loosen 
their cell-cell contacts, in preparation for cell migration through the gap in the basement 





1.7. Glucocorticoid-mediated effects on wound repair and 
angiogenesis 
Glucocorticoids impair wound healing through effects on both the epidermal 
and dermal skin layers, as well as causing a flattening of the junction between these 
two layers (Schoepe, Schacke et al. 2006, Tiganescu, Walker et al. 2011, Tiganescu, 
Tahrani et al. 2013). Keratinocytes and fibroblasts are both targets of GCs, with growth 
factor signalling and cross-talk between the two cell types also being affected 
(Schoepe, Schacke et al. 2006, Tiganescu, Hupe et al. 2014). With regard to 
keratinocytes, their migration and proliferation is inhibited by GCs (Schoepe, Schacke 
et al. 2006, Tiganescu, Walker et al. 2011, Jozic, Vukelic et al. 2017, Tiganescu, Hupe 
et al. 2018). Their size is also decreased, assumed to be mediated by reduced synthesis 
of macromolecules (Schoepe, Schacke et al. 2006). There is also a reduced synthesis 
of epidermal lipids. The consequences of these effects are epidermal thinning, 
impaired epithelialisation, with increased permeability and water loss (Schoepe, 
Schacke et al. 2006, Schoepe, Schacke et al. 2010, Tiganescu, Hupe et al. 2014) 
resulting in disrupted barrier function of the skin (Schoepe, Schacke et al. 2006). 
Fibroblasts are also affected by GCs due to a reduction in proliferation (Schoepe, 
Schacke et al. 2006, Guo and Dipietro 2010) and in particular their synthesis of ECM 
proteins is inhibited by GCs (Schoepe, Schacke et al. 2006, Guo and Dipietro 2010) 
GCs have direct effects on gene expression involved in collagen turnover (Tiganescu, 
Tahrani et al. 2013) and reduce both major skin collagens – type 1 (making up around 
80% of skin collagen) and type III (10-15%) (Schoepe, Schacke et al. 2006, Terao, 
Tani et al. 2014, Terao and Katayama 2016). Other ECM proteins, such as elastin, are 
also affected by GCs (Guo and Dipietro 2010). This results in a thinning of the dermis, 
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with decreased tensile strength and elasticity (Schoepe, Schacke et al. 2006). The 
combined effects of GC on the epidermis and dermis results in skin with a reduced 
barrier function and reduced structural integrity (Tiganescu, Walker et al. 2011). It is 
thinner, dryer, and has a reduced ability to heal. Wound healing is further impaired by 
GCs due to a suppression of angiogenesis (Gastaldello, Livingstone et al. 2017).  
 GCs are well known to inhibit angiogenesis, both at physiological 
concentrations and in chronic excess (Small, Hadoke et al. 2005, Logie, Ali et al. 2010, 
Morgan, Keen et al. 2018). This has been demonstrated in vitro, in vivo and during 
wound repair, and is reported to be mediated via GR (Small, Hadoke et al. 2005, Logie, 
Ali et al. 2010, Morgan, Keen et al. 2018). Pharmacological inhibition of GCs has been 
suggested as a possible treatment to enhance angiogenesis and improve healing during 
both topical and internal wound repair (Logie, Ali et al. 2010, McSweeney, Hadoke et 
al. 2010). The mechanisms through which GCs affect vascular function are diverse 
and are still not completely understood, but they appear to act at multiple stages of the 
angiogenesis process (Small, Hadoke et al. 2005, Logie, Ali et al. 2010, Morgan, Keen 
et al. 2018). It is well known that GCs suppress inflammation, and this itself is 
detrimental to angiogenesis due to the pro-angiogenic cytokines released from 
inflammatory cells (McSweeney, Hadoke et al. 2010). GCs also modify secretion of 
angiogenic factors from other cell types. For example, they are suggested to inhibit 
VEGF transcription and nitric oxide production by endothelial cells themselves 
(Small, Hadoke et al. 2005). Furthermore, in a recent study they modified the secretion 
of factors from myofibroblasts, which caused an indirect suppression of angiogenesis 
and also prevented endothelial cell migration and ability to form tube like structures 
(Drebert, MacAskill et al. 2017). Another indirect mode in which GCs can suppress 
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angiogenesis is through effects on the basement membrane. GCs can cause degradation 
of the ECM, and this can affect cell behaviour such as to inhibit endothelial cell 
migration and proliferation (Drebert, MacAskill et al. 2017, Morgan, Keen et al. 2018). 
The ECM is often reported as the key component in the effects of GCs on angiogenesis. 
Next generation RNA sequencing analysis recently assessed gene expression changes 
in the mouse aorta in response to cortisol. Of 13 enriched KEGG pathways for with 
genes downregulated in cortisol-treated aorta, 9 were associated with inflammatory 
responses and 4 were associated with ECM or cytoskeletal function (Morgan, Keen et 
al. 2018). Aside from indirect effects, there is also evidence that GCs exert direct 
effects on endothelial cells themselves. This is perhaps expected since endothelial cells 
express both GR and MR (Logie, Ali et al. 2010). Indeed, GCs have been shown to 
directly inhibit TLS formation by cultured isolated endothelial cells. This TLS 
formation was inhibited in a concentration- and time-dependent manner, and was 
prevented by the GR antagonist RU486. It was demonstrated that the GCs achieved 
this by reducing the formation of cell-cell contacts rather than increasing the 
degradation of existing tubes. Furthermore, the GCs did not impair endothelial cell 
proliferation, migration or viability but instead caused alterations in the cytoskeletal 
structure of the endothelial cells, hence interfering with their morphology and ability 
to form cell-cell connections (Logie, Ali et al. 2010). Finally, GCs are also reported to 
act on vascular smooth muscle cells which surround the vessels. For example they can 
inhibit production of matrix metalloproteinases, and also prevent their migration and 





1.8. Introduction Summary 
 In summary, glucocorticoids (GCs) thin the skin and prevent wound repair. 
Along with adverse metabolic effects, these are the major side effects associated with 
the use of GCs topically to treat inflammatory skin disease. The GC metabolite 5αTHB 
may reduce inflammation with fewer side effects than GCs. However the mechanisms 
of action of 5αTHB are unknown. This thesis will compare the effects of 5αTHB and 
the topical GC hydrocortisone to prevent wound repair. It will also investigate the 
mechanisms of action of 5αTHB, in particular whether its effects are mediated through 
the glucocorticoid receptor. This work may bring us closer to the development of a 













1.11. Hypotheses and Aims 
          Our group is interested in developing 5αTHB as a topical anti-inflammatory 
agent, necessitating studies of the effects of 5αTHB on wound repair processes. 
Further studies are also required to decipher its mechanism of action which appears 
different from that of conventional GCs.  
The hypotheses explored in this thesis are: 
1. 5αTHB is suitable for use as a safer topical anti-inflammatory treatment. 
2. 5αTHB acts through GR. 
3. 5αTHB is a SEGRA, dissociating between different GR- mediated molecular 
mechanisms. 
The corresponding aims are: 
1. To assess whether 5αTHB is less detrimental to wound repair processes than 
conventional GCs. 
2. To investigate whether the anti-inflammatory effects of 5αTHB are GR-
dependent. 




























2. Materials and Methods 
2.1 Materials and reagents 
Room temperature is abbreviated as RT. Overnight is abbreviated as O/N. 
2.1.1. Source and maintenance of animals 
Male C57Bl/6 mice, 8-12 weeks old, were purchased from Harlan Laboratories Ltd. 
(Bicester, UK). They were allowed to acclimatise for one week after arrival prior to 
being used for experiments. Mice were maintained under controlled conditions of 
temperature (18-22⁰C) and light (lights on between 0700-1900 hours). They were 
allowed free access to standard chow (RMI 801002; Special Diet Services, Witham, 
UK) and drinking water. All experiments were approved by Veterinary Services at the 
University of Edinburgh and performed under the guidelines of the UK Home Office, 
and the following project licences: PW Hadoke, PPL No: 60/4523 and KE Chapman, 
PPL No: 60/7874. Animals were killed by asphyxiation with CO2. 
2.1.2. Outsourced reagents and chemicals 
All cell culture reagents, including for washing cells and for the preparation of media, 
were from Lonza (Berkshire, UK) unless otherwise stated. All laboratory chemicals 
and reagents are from Sigma Aldrich (Dorset, UK) unless otherwise stated. Steroids, 
including the GR antagonist RU486, were from Steraloids (Newport, RI, USA). 
2.1.3. Sources of cultured cells 
2.1.3.1. Cell lines 
hTERT immortalised human dermal fibroblasts were a gift from Andrew Campell, 
Beatson Institute for Cancer Research (Glasgow, UK); The human keratinocyte cell 
line HaCaT was from, and is considered proprietary to, the German Cancer Research 
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Centre (DKFZ, Heidelberg, Germany). The HaCaTs were formed by spontaneous 
transformation to immortality of a long term primary culture of human adult skin 
keratinocytes, originally obtained from a male skin melanoma specimen (Boukamp, 
Petrussevska et al. 1988). Human umbilical vein endothelial cells (HUVECs) were 
from PromoCell GmbH (Heidelberg, Germany). Each batch had been pooled from 
multiple donors from the supplier, and cells were used between passage number 2 and 
6 in all experiments. A549 cells were from the European Collection of Cell Cultures 
(ECACC, distributor Sigma-Aldrich) and are transformed human type II alveolar 
epithelial cells, initiated from the lung carcinoma of a 58 year old Caucasian male 
(Lieber, Smith et al. 1976). L292 cells were also obtained from ECACC (distributor 
Sigma- Aldrich) and are transformed fibroblast cells derived from normal 
subcutaneous areolar and adipose tissue of a 100 day old male C3H/An mouse. 
2.1.3.2. Murine bone marrow-derived macrophages (BMDM) 
Primary BMDMs were freshly isolated from murine tibia and femur according to a 
published protocol (Weischenfeldt and Porse 2008), using mice which had been 
maintained and culled as described in (2.1.1.), as follows: 
2.1.3.2.1. Removal of femur and tibia bones: 
Hip joints were dislocated from culled mice which had previously been partially 
dissected for the aortic ring assay described in (2.2.3). Posterior limbs were removed 
and cleared of skin and soft tissues to reveal the bones. Femur and tibia bones were 
then detached, immersed in sterile ice cold PBS and stored at 4ºC for a maximum of 
24 hours, until required, since the cells do not loose viability in this time period 
(personal communication from Professor Karen Chapman). 
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2.1.3.2.2. BMDM cell isolation, plating, and differentiation 
Femur and tibia bone ends were removed with a scalpel (Swann-Morton, Sheffield, 
UK) to expose the marrow. Holding the bone at one end with sterile forceps, the 
marrow was flushed out into a Falcon tube (Falcon, Fischer Scientific, Loughborough, 
UK) with a syringe (Medisave, Dorset, UK) containing normal serum medium for 
BMDM (2.1.4.1.1, 5 mL), attached to a needle (22 G; Medisave, Dorset, UK). The cell 
suspension, resulting from the contents of all 4 bones of the mouse, was passed gently 
ten times through a larger needle (18 G; Medisave, Dorset, UK) to break cell clumps, 
and then filtered through a 40 µM FalconTM cell strainer to remove bone fragments 
and debris. The suspension was then adjusted to 20 mL with medium, and transferred 
to a T25 ultra low-attachment flask (Corning, Flintshire, UK) which was incubated (37 
°C, 7 days) to allow for monocyte-macrophage differentiation. Every 2 days, 1/3rd of 
the medium was replaced, and one week after plating the cells, they were detached 
from the bottom of the flask by firmly hitting it from the side. The resulting cell 
suspension was transferred into a 50 mL Falcon tube, and the flask washed with PBS 
(no calcium, no magnesium)(4°C 20 mL)(Thermo Fisher Scientific, Paisley, UK) and 
subjected to another round of firm hitting on its side to remove any remaining cells. 
The PBS containing the remaining cells was added to the suspension in the 50 mL 
tube, which was centrifuged (400 G, 5 min, RT) to collect the cells as a pellet. The cell 
pellet was then resuspended in serum free medium. Cells were then plated 5x105 
cells/mL per well in 12 well plates (Corning, Flintshire, UK) and left to settle at 37 °C 
for 24 hours before treatment.  
2.1.4. Preparation of reagents and solutions 
2.1.4.1. Cell culture medium 
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2.1.4.1.1. Normal serum medium:  
Normal serum medium for murine bone marrow derived macrophage (BMDM) cells 
consisted of DMEM/Nutrient mixture F-12 (DMEM F-12) supplemented with 
penicillin (100 IU/mL), streptomycin (100 µg/ mL), L-glutamine, FBS (10% v/v) and 
L929 cell cultured medium described in 2.1.4.2 (15%). L929 cells were cultured in 
DMEM/F-12 supplemented with HI-FBS (10% v/v), penicillin (100 IU/mL) and 
streptomycin (100 µg /mL). For HaCaTs, Fibroblasts, and A549 cells normal serum 
medium consisted of Dulbecco’s modified Eagle’s medium supplemented with a high 
concentration of glucose (4.5 g/L, glucose), HI-Foetal Bovine Serum (HI-FBS, 10% 
v/v), penicillin (100 IU/ml), streptomycin (100 µg/mL) and L-glutamine (2 mM). For 
HUVECs normal serum medium consisted of endothelial basal medium-2 (EBM-2) 
with all the supplements and growth factors added from the ECM-2 SingleQuot kit.  
2.1.4.1.2. Serum free medium: 
Serum free medium for BMDM consisted of normal serum medium in the absence of 
FBS and L929 cultured medium.  
2.1.4.1.3. Stripped serum medium: 
For HaCaTs and fibroblasts, stripped serum medium consisted of normal serum 
medium with the same volume of charcoal stripped FBS (Sigma Aldrich) in place of 
HI-FBS. For HUVECs, stripped serum medium consisted of normal serum medium 
minus the addition of the hydrocortisone aliquot from the ECM-2 SingleQuot kit. 
2.1.4.2. L929 fibroblast-conditioned medium for BMDMs.  
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L929 cells were cultured until confluent and then left for 10 days without the medium 
being changed. The medium was then collected, sterilised by filtration (0.22 µM, 
Millipore, Hertfordshire, UK) and frozen (-20 °C) for subsequent use during the 
culture of BMDMs. 
2.1.4.3. Freezing medium 
This was composed of 10% dimethyl sulphoxide (DMSO; Sigma Aldrich) in FBS. 
2.1.4.4. Steroid solutions 
Steroids were dissolved in ethanol to obtain stock solutions 1000 times more concentrated 
than required. 1 μL of these stock steroid solutions was added for every 1 mL of medium, 
at the time of treatment, minimising the amount of ethanol which was present in the final 
solution (and hence exposed to cells) to 0.1%.  
 
2.1.5. Cell culture 
2.1.5.1. Cell thawing 
Aliquots of cells were stored frozen in liquid nitrogen. Frozen cells were thawed in a 
water bath maintained at 37 °C and then transferred to a 15 mL Falcon tube (Falcon, 
Fisher Scientific, Loughborough, UK) containing normal serum medium (2.1.3.1.1) 
and collected as a pellet by centrifugation (1000xg, 5 min, RT). The cell pellet was 
resuspended in normal serum medium and plated in 75 cm3 flasks (Corning, Flintshire, 
UK). The flasks used for HUVECs were coated in gelatin (as described in 2.1.5.4.) 
representing an adjustment of the standard protocol.  
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2.1.5.2. Maintenance and passaging of cells 
The thawed cells were maintained at 37 °C in a 5% CO2 incubator, and were passaged 
when confluent. To passage cells, they were first washed with phosphate buffered 
saline (PBS) and detached from the flask by treatment with trypsin (5 mL, 5 min, 37 
°C)(Gibco by Life Technologies, Thermo Fisher Scientific, Paisley, UK). For HaCaT 
cells which adhere strongly to cell culture plates, the trypsin was replaced with TrypLE 
Express Enzyme (1X) phenol red (gibco, life technologies, Thermo fisher scientific, 
Paisley, UK) and incubated for 10, instead of 5, minutes. Once the cells had detached, 
an equal volume of medium was added in order to inactivate the trypsin, followed by 
centrifugation (1000xg, 5 min, RT) to collect the cells as a pellet. The pellet was re 
suspended in medium and separated into 5 - 10 new flasks, which already contained 
medium so that the final volume of medium in each flask was 12 mL. The cells were 
then returned to 37 °C.  
2.1.5.3. Cell freezing 
To freeze, cells were washed with sterile PBS and detached from the flask by treatment 
with trypsin (5 mL, 5 min, 37 °C) or TrypLE Express in the case of HaCaTs (5 mL, 
10 min, 37 °C). An equal volume of fresh culture medium was then added to counteract 
the trypsin, and the cells were collected as a pellet by centrifugation (1000xg, 5 min, 
RT). The cell pellet was re suspended in freezing medium and separated into 1 mL 
aliquots. Aliquots were gradually frozen, primarily at -80°C inside a polystyrene box 





2.1.5.4. Coating of culture flasks and plates 
Gelatin-coating: To coat the 75 cm2 cell culture flasks in gelatin (Sigma Aldrich, 
Dorset, UK), gelatin was first diluted in PBS to give a 0.1% solution, and 10 mL of 
this was added to the cell culture flask. The flask was incubated (37 °C, 0.5 hours) and 
then transferred to a sterile hood with the lid left ajar, for 3 hours. To coat 96 well 
plates with gelatin, 50 µL of the 0.1% gelatin solution was pipetted into each well, and 
the same protocol followed as for the flasks.  
Collagen-coating: To coat 96 well plates with collagen-type 1 (rat tail, Millipore, 
Hertfordshire, UK), collagen was diluted 1:4 in 70 % ethanol then vortexed until it had 
solubilised. 25 µl of this was then transferred to each well, and the plate gently shaken. 
The cell culture plate was then left ajar to allow airflow and prevent condensation, for 3 hours. 














2.2. Laboratory protocols 
2.2.1. RNA analysis 
2.2.1.1. Materials 
2.2.1.1.1. Tris-Borate-Ethylenediamine tetra acetic acid (TBE) 10X Buffer 
solution: 
1.0 M Tris, 0.9 M Boric acid, 0.01 M ethylenediamine tetra acetic acid (EDTA) 
2.2.1.1.2. TBE 0.5X Buffer Solution:  
10X Buffer Solution diluted 1/20 using de-ionised water. 
2.2.1.2. RNA extraction from aorta 
A protocol which had previously been used for RNA extraction (Morgan, Keen et al. 
2018) was adapted in order to obtain sufficient amounts of RNA at the desired 
concentration range (10-100 ng/µL) and of adequate quality. In comparison to the 
original protocol, tissue homogenisation was altered to be performed at the lowest 
speed (4000 x g) and for the shortest time (30 sec) possible, to avoid degradation. The 
modified protocol consisted of adding Qiazol lysis reagent (250 µL/well; Qiagen, 
Manchester, UK) to each well of a 96 well plate on ice, and using a pipette to mix this 
with the collagen, to release the aortic rings. The mixture of Qiazol, collagen and aortic 
rings was then transferred from the well to a 1.5 mL Eppendorf tube and stored frozen 
at -80°C. Four rings which had been treated in the same way, together with the collagen 
and QIAzol solution, were then pipetted into a MagNA lyser green beads tube (Roche 
Diagnostics, Mannheim, Germany) for tissue homogenization with Precellys 24 tissue 
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homogeniser (Bertin Technologies, Montigny le Bretonneux, France) (4000 x g, 30 
sec). Total RNA was extracted by using an RNeasy mini kit and its reagents (Qiagen). 
Briefly, chloroform (200 µL) was added to the MagNA lyser tubes, which were shaken 
and then incubated (2 min, RT). Centrifugation (21130 x g, 15 min, 4 °C) followed 
and the upper transparent layer containing the total RNA (approximately 700 µL) was 
transferred to an equal volume of ethanol (70%) in a new 2 mL Eppendorf tube.  After 
gentle mixing, the solution was transferred to an RNeasy Mini Spin Column, 
centrifuged (8000 x g, 30 sec, RT), and the flow-through discarded. The column was 
then sequentially washed with RWI buffer (700 µL), RPE buffer (500 µL), and finally 
ethanol (500 µL, 80 %), with centrifugation (8000 x g, 30 sec, RT) after each step, 
discarding the flow-through each time. A final centrifugation step (8000 x g, 1 min, 
RT) was then conducted in order to remove any residual ethanol, and the column was 
placed into a 1.5 mL Eppendorf tube.  Finally, RNase-free water (30 µL) was added 
to the column which was incubated (2 min, RT) and then centrifuged (8000 x g, 1 min, 
RT) in order to elute RNA. The RNA was then added again to the same column and 
centrifuged again (8000 x g, 1 min, RT) to maximise recovery of the RNA from the 
column.  
 
2.2.1.3. RNA quantification 
RNA Quantification was performed using the QubitTM RNA HS (High Sensitivity) 
Assay Kit (Invitrogen, Thermo Fisher Scientific) in order to obtain accurate 
quantification with the low concentrations of RNA. The QubitTM working solution was 
prepared by diluting the QubitTM RNA HS Reagent in QubitTM RNA HS Buffer 
(1:200). The two standards required by the assay were prepared by adding 190 µL of 
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the working solution and 10 µL of both QubitTM standard #1 and of QubitTM standard 
#2 in two separate 0.5 µL QubitTM assay tubes. The working solution was added to the 
individual assay tubes together with 2 µL of the samples so that the final volume in 
each tube was 200 µL. All the tubes were mixed by vortexing (2-3 sec) and allowed to 
incubate (2 min, RT). Standards were read using a QubitTM 2.0 Fluorometer 
(Invitrogen Life Technology, Thermo Fisher scientific, Paisley, UK) to calibrate the 
instrument. Then the sample concentrations were measured and reported by the 
instrument as ng/mL. RNA samples with concentrations equal or higher than 6.25 
ng/µL were accepted for real-time qPCR analysis. Four RNA samples were discarded 
since their RNA concentrations were lower than this. The excitation wavelength of the 
QubitTM 2.0 Fluorometer is 644 nm, and the emission wavelength of the fluorophore 
used by the QubitTM RNA HS Assay Kit is 673 nm. The fluorescence emission 
intensity is the indicator of the RNA concentration.  
 
2.2.1.4. Evaluation of RNA quality 
RNA quality and integrity were assessed, using gel electrophoresis, by the 
visibility of two bands, corresponding to 28S and 18S ribosomal RNA (rRNA). 
Agarose gel (1 %w/v) was prepared by dissolving agarose in TBE buffer solution 
(0.5X; section 2.2.1.1.2) followed by the addition of the Biotum GelRedTM Nucleic 
acid stain (Cambridge Bioscience, Cambridge, UK). When solidified, 2 µg RNA 
together with Loading Buffer Orange (VWR International Ltd, Leicestershire, UK) 
was loaded onto the gel and run in TBE buffer (0.5X) with an electrophoresis Power 
Supply POWER 350 (Fischer Scientific, Thermo Fisher Scientific) (200 V, 1 h, RT). 
The gel was imaged under Ultra-Violet (UV) radiation (306 nm) using UVDOC HD6 
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(UVITEC, Cambridge, UK) with the band for the 28S rRNA being approximately 
twice as intense as the band for the 18S rRNA. Samples that separated into two visible 
bands in a 2:1 ratio (figure 2.1) were deemed acceptable. This was the case for all 





Figure 2.1: RNA band visualisation under UV light. RNA was extracted from mouse aortic 
rings and assessed for quality and integrity using gel electrophoresis. The 28S and 18S 
ribosomal RNA bands were clearly visible in approximately a 2:1 ratio, indicating the total RNA 
samples were intact. Representative from images of all samples. 
 
2.2.1.5. Reverse Transcription 
RNA samples were diluted to a concentration of 6.25 ng/μL using nuclease free water. 
Reverse transcription of these RNA samples to give complementary DNA (cDNA) 
was performed with an applied biosystems High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific, Paisley, UK) using the kit reagents and 
protocol. Briefly, 75 ng of each RNA sample was added to RNAse Inhibitor (1 μL) to 
prevent RNA degradation, 10X RT buffer (2 µL) to maintain a favourable reaction pH 
and ionic strength, 25X deoxyribonucleotide triphosphate (dNTP) Mix (100 mM, 0.8 
µL), 10X RT Random Primers (2 µL), MultiscribeTM Reverse Transcriptase (1 µL) and 
nuclease free water (1.2 µL). Two negative controls were also prepared: one consisted 
of adding nuclease free water in place of the MultiscribeTM Reverse Transcriptase, in 
order to identify contamination with genomic DNA. The other consisted of replacing 
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the RNA sample with nuclease free water, to identify any contamination with RNA. 
Reverse transcription was performed using a thermal cycler (Techne, Staffordshire, 
UK) which involved incubating the samples at 25 °C for 10 min first to allow the 
primers to anneal, then at 37 °C for 2 h for DNA polymerisation to occur, followed by 
85 °C for 5 min for enzyme deactivation. Finally, temperature was reduced to 4 °C and 
samples were stored at -20 °C until needed.  
 
2.2.1.6. Real-time qPCR 
For quantification of genes by real-time PCR, a LightCycler® 480 (Roche 
Diagnostics, Mannheim, Germany) was used. Primers (Table 2.1) were designed to 
match intron-spanning probes with the Roche Universal Probe Library (UPL) using 
the online software Universal ProbeLibrary Assay Design Center 
(https://lifescience.roche.com/en_gb/brands/universal-probe-library.html#assay-
design-center, 2017). Primers were stored at concentrations of 100 pmol/ µL in Tris-
EDTA buffer solution for stability (100 µM) and diluted in nuclease free water to 20 
µM for use. The primer concentrations required by the assay was of 200 nM, therefore 
0.1 µL of each 20 µM primer was used in 10 µL of reaction. Each newly made cDNA 
was diluted 1/20 in nuclease free water for analysis.  In parallel, for each gene tested, 
a standard curve was generated: representative cDNA samples from each group were 
pooled and diluted 1/5 to give a starting solution, from which serial dilutions were 
prepared until 1/320 standard was achieved. Assay mix for each gene of interested was 
prepared as follows: each well contained LightCycler® 480 Probes Master (5 µL), 
primers (0.1 µL forward primer and 0.1 µL reverse primer), the corresponding UPL 
probe (0.1 µL) and nuclease free water (2.7 µL). Standards (2 µL) or samples (2 µL) 
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were mixed with the 8 µL of the master mix in the 384-well qPCR plate. A negative 
control to assess for potential contamination of reagents was prepared by using 
nuclease free water instead of sample. Samples were heated for initial denaturation (95 
°C, 30 sec), followed by 50 cycles of PCR amplification, consisting of denaturation 
(95 °C, 10 sec), and annealing and extension (60 °C, 30 sec). Once the PCR 
programme was complete, samples were cooled (40 °C, 30 sec). All samples were 
analysed in triplicate and amplification curves plotted (x axis = cycle number, y axis 
= fluorescence). Crossing points (Cp) were determined by the LightCycler® software 
v1.5.3, using the maximum point of the second derivative of the amplification plot. 
Triplicates were accepted if the standard deviation of their crossing points (Cp) was 
lower or equal to 0.4 cycles. If the standard deviation was higher than 0.4 cycles then 
the replicates were checked for consistency and any outliers excluded. A standard 
curve was generated for each gene (x axis = log concentration, y axis = crossing point), 
fitted with a straight line of best fit and accepted if reaction efficiency was between 
1.7 and 2.1. Negative controls were accepted as negative if there was no amplification 
for at least 10 cycles after the most dilute point on the standard curve. There were no 
statistical differences in transcript abundance of the housekeeping genes Actβ or Tbp 
between treatment groups. This was the case both for their individual transcript 
abundances measured alone (P=0.139 and P=0.226 respectively), and for the mean of 
their transcript abundances (P=0.122). This confirmed that the mean transcript 
abundance of these two genes was an appropriate reference in order for normalisation 







Gene symbol, full name Primers sequence UPL 
Actβ (Actin, beta) 5’-accagaggcatacagggaca-3’ 64 
3’-ctaaggccaaccgtgaaaag-5’ 
Col4a1 (Collagen, type IV, alpha 1) 5’-agttggaggaatgggcttg-3’ 80 
3’-ccagggacaccctgtgag-5’ 
Col14a1 (Collagen, type XIV, alpha 1) 5’-atgtggattccggtctatgg-3’ 79 
3’-agagtcctgttcttctttgaggtc-5’ 
Cxcl5 (C-X-C motif chemokine ligand 5) 5’-cagtgggtttgagaacaccata-3’ 25 
3’-ctggaggctcattgtggac-5’ 
Dusp1 (Dual specificity phosphatase 1) 5’-tggttcaacgaggctattgac-3’ 89 
3’-ggcaatgaacaaacactctcc-5’ 
Fkbp51 (FK506 binding protein 5) 5’-ccttcttgctccgagcttt-3’ 69 
3’-tgttcaagaagttcgcagagc-5’ 
Hsd11b1 (Hydroxysteroid 11-beta dehydrogenase 1) 5’-tctacaaatgaagagttcagaccag-3’ 1 
3’-gccccagtgacaatcacttt-5’ 
Mcp1 (Chemokine (C-C motif) ligand 2) 5’-catccacgtgttggctca-3’ 62 
3’-gatcatcttgctggtgaatgagt-5’ 
Mmp9 (Matrix metallopeptidase 9) 5’-cagaggtaacccacgtcagc-3’ 7 
3’-gggatccaccttctgagactt-5’ 
iNOS (Nitric oxide synthase 2, inducible) 5’-ctttgccacggacgagac-3’ 13 
3’-tcattgtactctgagggctgac-5’ 
Pecam1 (Platelet/endothelial cell adhesion molecule 1) 5’-actcgacaggatggaaatcac-3’ 45 
3’-cggtgttcagcgagatcc-5’ 
Per1 (Period circadian clock 1) 5’-acagcagccacggttctc-3’ 71 
3’-ggacccaggagtgcacag-5’ 
Tbp (TATA-binding protein) 5’-gatgggaattccaggagtc-3’ 97 
3’-gggagaatcatggaccagaa-5’ 
Vcam1(Vascular cell adhesion molecule 1) 5’-tcttacctgtgcgctgtgac-3’ 47 
3’-gacctccacctgggttctct-5’ 





Table 2.1: Details of primers and probes for real-time PCR analysis of murine genes 
using Roche Universal Probe Library (UPL). The forward primer (5’ → 3’) for each gene is 
the upper sequence, the reverse primer (3’ → 5’) is the lower. Reference genes were beta-
Actin (Actβ) and TATA-binding protein (Tbp). Primers were designed to match the given intron-
spanning probes with the Roche Universal Probe Library UPL using the online software 
















2.2.2. Protein analysis 
2.2.2.1. Western blotting 
2.2.2.1.1. Materials and buffers 
Hypotonic buffer: Hepes (20 mM, pH 7.6), glycerol (20 %; BD Laboratory supplies, 
Nottingham, UK), NaCl (10 mM), MgCl2 (1.5 mM), EDTA (0.2 mM), Triton (0.1% 
in distilled water). The following reagents were added immediately before use: 
Pefabloc (1 mM) and aprotinine (10 μL/mL, Thermo Scientific). 
Hypertonic buffer: Hypotonic buffer + NaCl (5 M). 
Running buffer 1X:  Tris Base (1 M), Sodium dodecyl sulphate (SDS, 0.035 M), Hepes 
(1 M) in distilled water. 
Transfer Buffer 1X: 0.025 M Tris Base (0.025 M), 0.2 M glycine (0.2 M), methanol 
(10% v/v in distilled water). 
TBS-T: TBS prepared with Tris-HCl (50 mM) and NaCl (150 mM) plus Tween-20 
(0.1% v/v, in distilled water). 
2.2.2.1.2. Whole protein extraction 
To extract protein from the cells, the RIPA lysis buffer system (Santa Cruz 
biotechnology, Heidelberg, Germany) was prepared using kit reagents as follows: Per 
mL of 1x RIPA lysis buffer, 10 μL PMSF, 10 μL sodium orthovonadate solution and 
20 μL protease inhibitor cocktail solution was added. Media was removed from the 
flask and cells washed (12 mL cold PBS) before incubating with complete RIPA buffer 
(1 mL, cold, shaker, 5 min). With the flask tilted on ice, cells were scraped from the 
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surface of the flask and the RIPA buffer containing these cells was transferred into an 
Eppendorf, rotated (15 min) to complete the lysis, before subjecting to centrifugation 
(15 min, 13 x g, 4 °C) and transferring the supernatant (containing protein) to a fresh 
Eppendorf for concentration measurement.  
2.2.2.1.3. Protein extraction of separated nuclear and cytoplasmic components 
Cells in 6 well plates were washed (2x PBS) and allowed to swell on ice in hypotonic 
buffer (700 μL/ well, ice cold, 5 min). Cells were then detached from the well plate by 
scraping, and the cells from 3 separate wells were combined and transferred into 15 
mL Falcon tubes. These were then centrifuged (100 x g, 15 min, 4ºC) after which the 
supernatant (containing the cell cytoplasm) was transferred into an Amicon ultra- 2 
mL centrifugal filter (Millipore, Hertfordshire, UK) and spun (800 x g, 4 ºC, around 
30-60 min) until around 400 μL cytoplasmic protein solution was obtained. The cell 
pellets (containing the nuclear fraction) were resuspended in 5 x their volume of 
hypertonic buffer and transferred to Eppendorfs. They were then rotated (1 hour, 4ºC) 
and centrifuged (16000 x g, 5 min, 4 ºC) and the supernatant containing the nuclear 
protein was transferred into fresh Eppendorfs. Protein concentration measurements 
and Western blot were then performed on nuclear and cytoplasmic fractions. 
2.2.2.1.4. Protein quantification 
Protein was quantified using the Bio-rad DC Protein Assay kit according to 
manufacturer’s instructions (Bio-Rad Laboratories Ltd, Hertfordshire, UK). Bovine 
serum albumin (BSA, fraction V) at concentrations of 0.25, 0.5, 1 and 2 mg/mL, was 
used to generate the standard curve. Water was used as a blank (0 mg/mL). Samples 
and standards (5 µL) were added in duplicate to a 96 well plate before addition of Bio-
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Rad’s alkaline copper tartrate solution (25 µl), followed by Bio-Rad’s dilute Folin 
reagent (200 µl). The plate was gently agitated to mix the reagents and after 15 minutes 
the absorbance was measured at 750 nm using an OPTImax tunable microplate reader 
(Molecular Devices, Wokingham, UK). The standard curve was deemed acceptable if 
r2 >0.98. The samples were accepted if the standard deviation between values was less 
than 10 % of the mean. The concentration of each protein sample was calculated from 
its absorbance value, using the line of best fit from the standard curve. 
2.2.2.1.5. Western blot sample preparation 
Western blot samples were prepared by adding 20 µg protein to appropriate volumes 
of 4x NuPAGE LDS Sample buffer (Life Technologies, Paisley, UK) and 10x 
NuPAGE sample reducing agent (Life Technologies). These samples were frozen at - 
20°C until required. 
2.2.2.1.6. Gel electrophoresis and protein transfer to membrane 
Protein samples were denatured (95 °C, 5 min) and separated on 4-12 % w/v gradient 
gels (Thermo Fischer Scientific) in running buffer for 2 hours at 80 V. Separated 
protein was then transferred to 0.45 µm nitrocellulose blotting membrane (GE 
Healthcare, Buckinghamshire, UK) using transfer buffer (1.5 hours, 60 V, 4°C). 
Transfer was confirmed by visualising protein on the membrane using Ponceau S 
solution which was washed off using 0.1 M NaOH as described in the manufacturer’s 
instructions. Membranes were then blocked with 5% blotting-grade blocker (Bio-rad, 
Hertfordshire, UK) in TBS-T (1 h, 37 °C) before washing (TBS-T, 5 minX3) and 
incubation with primary antibody (4 °C, O/N unless otherwise stated) diluted in 5% 
BSA in TBS-T. Primary antibodies and the dilutions used are given in Table 2.2. 
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Membranes were again washed (TBS-T, 5 minX3) and incubated with secondary 
antibody (1h, RT) diluted in 5% blocking solution in TBS-T, and matched to the 
species in which the primary antibody was raised. Membranes were then washed again 
in the same way before being viewed. 
 
Protein detected Code of antibody used Antibody 
dilution 
Species 
GR Sc-1003, Santa Cruz 1/500 Rabbit 
GR Sc-1004, Santa Cruz 1/500 Rabbit 
GR Sc-8992, Santa Cruz 1/500 Rabbit 
β-Tubulin Sc-101527, Santa Cruz 1/500 Mouse 
GRB2 Sc-255, Santa Cruz 1/1000 Rabbit 
PARP 556494, BD Pharmingen 1/1000 Mouse 
 
Table 2.2. Details of primary antibodies used for protein detection by Western blot. 
Primary antibodies were for binding to the Glucocorticoid receptor (GR), β-Tubulin, Growth 










2.2.2.1.7. Visualisation and quantification of protein on membrane 
2.2.2.1.7.1. Fluorescence  
Secondary antibodies used in 2.2.2.1.6 when being visualised by the fluorescence 
method were those listed in Table 2.3. The membrane was scanned using an Odyssey 
Imaging System (LICOR Biosciences, Cambridgeshire, UK): the fluorescence 
intensity was measured at an emission wavelength of 795 nm (excitation wavelength 
778 nm), and the band intensity was then quantified using Image studio-lite software 
(Odyssey Imaging Systems, LI-COR Biosciences, Cambridgeshire, UK).  
Antibody Code of antibody Antibody dilution 
Goat anti-mouse IR Dye800 
CW 
926-32210, Licor Biosciences 1/10,000 
Goat anti-rabbit IR Dye800 
CW 
926-32211, Licor Biosciences 1/10,000 
Table 2.3. Secondary antibodies used for fluorescence detection of proteins by Western 
blot. 
 
2.2.2.1.7.2. Chemiluminescence  
Secondary antibodies used in 2.2.2.1.6 when being visualised by the 
chemiluminescence method were those listed in Table 2.4. Membranes were prepared 
for X-ray development using Immobilon Western Chemiluminescent Horse Radish 
Peroxidase (HRP) substrate kit (Millipore, Watford, UK) and its reagents. Briefly, the 
membrane was incubated (5 min, RT) in a mixture containing equal amounts of HRP substrate 
luminol and a HRP substrate peroxide solution. The membrane was then exposed to X ray film 
(CL-XPosureTM Film, 34088, Thermo Scientific)(5 min, RT) and film developed using an X 
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ray developer (Konica Minolta). The HRP-conjugated secondary antibody present on the 
protein of interest initiates luminol oxidation by peroxide, which then creates a signal on the 
film due to the emission of light as it decays to the ground state. 
Antibody Code of antibody Antibody dilution 
Anti-mouse IgG (whole molecule)- Peroxidase A5906, Sigma 1/10,000 
Anti-rabbit IgG (whole molecule)- Peroxidase A0545, Sigma 1/10,000 
Table 2.4. Secondary antibodies used for chemiluminescence detection of proteins by 
Western blot.  
 
2.2.2.2. Quantification of cytokines by ELISA 
IL6 and TNFα cytokines were measured in cell medium by following the 
manufacturer’s instructions and using kit reagents of the Mouse IL-6 and Mouse TNF 
alpha ELISA Ready-SET-Go! Kits (Invitrogen, Thermo Fischer Scientific, Paisley, 
UK). Briefly, the 96 well ELISA plate was prepared by shaking with capture antibody 
(100 µL/well, 4 °C, O/N). The plate was then washed three times by soaking it in wash 
buffer (>250 µL, 1 min) which consisted of 0.05 % Tween-20 in PBS. Wells were then 
blocked by shaking with assay diluent (200 µL/ well, RT, 1 hour). They were then 
washed (>250 µL wash buffer, 1 min, RT) and samples were loaded in duplicate (100 
µL/ well). Standard curve samples were prepared in diluent, and diluent was also used 
as a blank. The samples were shaken (4 °C, O/N) before washing 5 times with wash 
buffer as described above. Detection antibody (100 µL/ well) was added and incubated 
(1 hour, RT) then the plate washed 5 times as above. Then 100 µL / well Avidin-HRP 
enzyme was added (30 min, RT) and washed 7 times soaking for 2 minutes each time. 
Wells were incubated with TMB substrate solution (100 µL/ 15 min/ RT) and the 
reaction stopped with 1 M H2SO4 (50 µL/ well). The plates were analysed 
111 
 
spectrophotometrically using SoftMaxPro software (Molecular Devices, Berkshire, 
UK). The absorbance difference between 570 nM and 450 nM was measured, in order 
to correct for background. The standard curve, which was fitted according to 
manufacturer’s instructions, was accepted if r2 >0.98 and duplicates if the standard 
deviation was <10% of the mean. 
2.2.2.3. Visualisation of protein by immunofluorescence 
A549 cells were plated at 200,000 cells/4 ml/ well on glass coverslips in 6 well plates. 
After 24 hours the cells were washed (3 X PBS) and incubated in serum free medium 
for 24 hours. Treatments followed, and then treated cells were washed (2x PBS, RT) 
and fixed (2% v/v paraformaldehyde in PBS, 10 min, RT, 800 μL). Fixed cells were 
washed twice with PBS (RT) and then twice again with a solution of PBS containing 
0.1% v/v Triton X100). Excess liquid was subsequently removed from coverslips by 
holding their edges to tissue, and cells were permeabilised (ice cold methanol, 
Scientific laboratory supplies, Nottingham, UK) (3 min, wet ice) and left to air-dry (1-
3 min). Coverslips were blocked with 1% w/v heat-shock fraction BSA in PBS (4 
mL/well, 1 hour, RT), washed (2x PBS, RT), and incubated with primary antibody 
(100 µL, dark, ON, 4 °C). They were then washed (3x PBS + 0.05% v/v TritonX100) 
and incubated with secondary antibody (100 µL, dark, 2 hours, RT). After a further 
wash (3x PBS+0.05% TritonX100) coverslips were stained with DAPI (30 min, RT) 
then washed again (3x PBS+ 0.05% Triton, then 3x PBS) and placed on glass slides 
using mountant (Thermoscientific, Cheshire, UK). Slides were then air-dried in the 
dark and stored in the dark at 4 ºC until cells were visualised with fluorescence 
microscopy, using a Zeiss Axioskop microscope (HB050/HC, Germany) fitted with a 
microcolour liquid crystal tunable RGB filter and a photometrics Coolsnap camera. 5 
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images were taken randomly of each slide in blue (400-550nm), green (470-630nm) 
and red (550-700nm) channels, and then 10 cells were randomly chosen within each 
image to have their fluorescence quantified. Two approaches were taken for 
fluorescence quantification. A ‘scoring method’ required a qualitative measurement of 
the fluorescence in each cell according to the extents of fluorescence between the 
nucleus (N) and cytoplasm (C). Possible scores were 5 (N>>C), 4 (N>C), 3 (N=C), 2 
(N<C) and 1 (N<<C) and the mean score for each treatment were calculated. The other 
method of quantification was analysis using ‘ImageJ’ software, in which the corrected 
total cell fluorescence (CTCF) was quantified. The operator was blinded to treatment 
in all cases. 
2.2.3. Ex vivo aorta angiogenesis assay 
2.2.3.1. Aorta dissection from mouse 
The aortic ring assay was used to measure steroid effects on angiogenesis. Animals 
were maintained and killed as described in (2.1.1). The mouse was then pinned down 
by its paws, in the supine position, and cleaned with ethanol (70%, VWR Chemicals, 
Leicestershire, UK). The skin was cut along the ventral midline with sterile tweezers 
and scissors. The ribcage was cut open, and organs and tissues removed to expose the 
aorta. The aorta was subsequently cut at the distal end, and then cleared of blood by 
flushing serum free DMEM through it from the heart, using a syringe and 27G needle 
(BD Microlance, Medisave, Dorset, UK). The heart was subsequently removed, and 
the aorta isolated by detaching it from the surrounding upper and lower layer of 
adipose and connective tissue. Following dissection, the aorta was placed in DMEM 
and stored on ice for up to 4 hours until used. 
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2.2.3.2. Aortic ring plating and culture 
Aortas were cut into rings approximately 0.5 mm in length. Aortic rings were 
embedded one ring/well (96 well plate) in an ice cold solution of Collagen Type 1 (1 
mg/mL; Millipore, Hertfordshire, UK) in DMEM (ice cold, and adjusted with 0.1 M 
NaOH until the solution is pink, indicating a basic pH). Once embedded, the plate was 
left at RT (15 min) before transferring to 37ºC (1 hour). Opti-MEM (Life 
Technologies, Paisley, UK) was then added (150 μL/well) containing either no 
treatment, a growth stimulating treatment, or the growth stimulating treatment plus the 
appropriate steroid. The growth stimulating treatment consisted originally (day 0) of 
1% FCS and was then changed to 5 ng/mL Recombinant Murine Vascular Endothelial 
Growth Factor (VEGF) (PeproTech, London, UK) on days 3 and 5. In our laboratory 
this combination had previously been found to provide optimum conditions for vessel 
growth (personal communication from Dr Junxi Wu and Dr Robert Ogley). Medium 
was replaced on days 3 and 5.  
2.2.3.3. Quantification and analysis of angiogenesis 
Aortic rings were assessed, by light microscopy, for cells migrating out from the rings 
in response to FCS at day 3, and for vessel growth in response to VEGF at day 7. The 
rings that did not respond to the FCS and VEGF treatments, which lacked both a cell 
migration and vessel growth response, were assumed dead and were discarded (on 
average this was the case for one ring per two complete assays (of 20 rings each)). 
Angiogenesis was assessed by counting the new vessels which had grown from aortic 
rings, by direct light microscopy (x50). This vessel counting method is commonly used 
to quantify angiogenesis in the literature (Rohan et al. 2000, Nicosia & Ottinetti 1990). 
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Small (2005) had compared the accuracy and consistency of this method with a 
computer-assisted analysis method, which involved taking images of aortic rings from 
a live feed camera and then using the Microcomputer Imaging Device 
(MCID)(Imaging Research Inc, Canada) to measure the area of growth, maximum and 
average diameter of growth and vessel density. While measurement of vessel density 
proved to be unreliable and inconsistent, similar patterns of vessel growth were 
detected using the other 3 methods. However since they offered no major 
improvements Small et al. chose the counting method to quantify angiogenesis based 
on the fact that it is technically less demanding and requires only the use of light 
microscopy whilst still being reliable. The same decision was also made here, and 
vessels were counted originally both on days 5 and 7. Each segment sprouting from 
both the aortic ring and the new vessels, were considered as an individual vessel 
(Figure 2.2). Images of rings were captured on days 5 and 7 using an Axiovert 25 







Figure 2.2: Vessel counting from murine aortic rings under light microscopy. 
Representative example showing that each segment sprouting from both the aortic ring and 






2.2.4. In vitro cell migration assay 
Cell lines (Human dermal fibroblasts, HaCaTs, and HUVECs) were grown to 
confluence in normal serum medium, as detailed in 2.1.5. Cells were plated in stripped 
serum medium in specialised 96 well Image Lock Microplates (Essen bioscience, 
Hertforshire, UK). Cells were grown for 8-16 hours in a standard incubator. Scratches 
were then made using the Essen Bioscience 96 pin wound maker, which was specially 
developed to create precise and reproducible wounds. Medium was immediately 
removed and wells washed twice (100 µl PBS), to remove dead cells, before replacing 
with fresh stripped serum medium (100 µl/well) with or without treatment. The 
ImageLock plate was then placed in the Incucyte (Essen Bioscience, Hertfordshire, 
UK) and the proprietary software used to record images to monitor wound closure. 
The metric chosen for quantification of cell migration was Relative Wound Density 
(RWD, %). This metric relies on measuring the spatial cell density in the wound area 
relative to the spatial cell density outside the wound area, at every time point (therefore 
the RWD should be 0% at t=0, and 100% when the cell density inside the wound is 
the same as the cell density outside the initial wound).  Because of this it is self-
normalising for cell density changes occurring outside the wound due to cell 
proliferation and/or pharmacological effects, and is reported to be robust across 
multiple cell types (Incucyte ZOOM Scratch Wound Processing Overview Technical 
Note, Essen Bioscience).  
2.2.5. Measurement of co-regulator peptide recruitment to nuclear receptors 
This was performed in collaboration with Professor Onno Meijer (Leiden University 
Medical Centre) and René Houtman (PamGene International) using the PamGene 
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Microarray Assay for Real-time Coregulator Nuclear Receptor Interaction 
(MARCoNI). Steroids were first prepared in DMSO, and were then added to a buffered 
solution of the isolated GST-tagged ligand binding domain (LBD-GST, 10 nM, AB 
vector, San Diego, CA) of a human nuclear receptor (either GR or MR) and a 
fluorescent Anti-GST alexa 488 antibody (25 nM). Each assay mix was subsequently 
added to all wells of an individual PamChip array, where each well contained a 
different coregulator peptide immobilised in a porous microarray membrane. Binding 
of nuclear receptors to the coregulator peptides was visualised by detecting the 
fluorescence signal using a PamStation 12 processing platform. The changes in 
binding in response to steroid, relative to DMSO control, were made using Student’s 
unpaired t-tests. The experiment was repeated 3 times. 
2.2.6. Assessment of steroid ability to bind GR ligand binding domain 
This was performed by the Drug Discovery core (College of Medicine and 
Veterinary Medicine, University of Edinburgh) using a PolarScreen Glucocorticoid 
Receptor Competitor Assay kit (Fisher Scientific, Loughborough, UK). This kit is a 
displacement assay utilising a commercial fluorescent ligand, called Fluormone GS1. 
Since Fluormone GS1 is a specific ligand for the hGR LBD, it binds at this site to form 
a GS1/GR complex. However, an effective competitor may also bind to the hGR LBD 
and prevent this GS1/GR complex from forming. This results in a shift in the 
fluorescence polarisation value, and the extent of this shift is used to determine the 
relative affinity of test compounds for GR. The assay was performed in accordance 
with the manufacturer’s protocol. This involved adding the GR, fluormone GS1 and 
steroid to a micro well plate. The fluorescence polarisation (mP) was then measured 
at 535 nm and 590 nm using a TECAN infinite 1000 microplate reader (TECAN, 
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Reading, UK). Graphs were plotted using Graphpad 4, with the logIC curves plotted 
with a fitted four parameter equation. 
 
2.3. Data analysis 
Data analysis was performed using GraphPad Prism 6 (CA, USA) and was presented 
as mean ± SEM. Data were analysed using the statistical tests described in the legend 
of each figure. Statistical significance was taken at p<0.05, and when a trend is 
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Chapter 3: Is 5αTHB less detrimental during wound repair 
than current glucocorticoid administration? 
3.1. Introduction 
As mentioned in the introduction, 5α-Tetrahydrocorticosterone (5αTHB) is 
now being investigated as a safer topical anti-inflammatory treatment which is less 
detrimental during wound repair than current glucocorticoids (GCs). Wound repair is 
a complex process involving inflammatory signalling, formation of granulation tissue 
(composed largely of extracellular matrix proteins and myofibroblasts), angiogenesis, 
and epithelialisation (Eming, Brachvogel et al. 2007, Giusti, Rughetti et al. 2013, 
Sinno and Prakash 2013, Johnson and Wilgus 2014, Martinez, Smith et al. 2015, 
Portou, Baker et al. 2015, Rosique, Rosique et al. 2015). The process relies on the 
action of keratinocytes, fibroblasts, and endothelial cells. GCs are known to be 
detrimental to multiple stages occurring during wound repair (Schoepe, Schacke et al. 
2006, Tiganescu, Walker et al. 2011, Tiganescu, Tahrani et al. 2013). They are anti-
inflammatory, both by suppressing pro-inflammatory signalling and by remodelling 
the vasculature to prevent inflammatory cell recruitment to the wound site. They also 
cause decreased expression of many molecules involved in extracellular matrix (ECM) 
formation (such as collagen and matrix metalloproteinases (MMPs)), and inhibit the 
migration and proliferation of keratinocytes and fibroblasts (Small, Hadoke et al. 2005, 
Schoepe, Schacke et al. 2006, Tiganescu, Walker et al. 2011). Importantly, GCs inhibit 
angiogenesis (the formation of new blood vessels from the pre-existing vasculature) 
with defective angiogenesis being largely responsible for impaired wound healing in 
many cases (Johnson and Wilgus 2014).  
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Initial studies suggest that 5αTHB is less detrimental to angiogenesis and ECM 
component formation, than conventional GCs (Gastaldello, Livingstone et al. 2017). 
In a mouse subcutaneous sponge implantation model of angiogenesis, 5αTHB 
suppressed vessel growth only to a limited extent whereas growth was substantially 
decreased by corticosterone. Transcript analysis of mRNA from these sponges 
revealed that corticosterone decreased expression of many factors important during 
vessel formation, whereas 5αTHB reduced only a small subset. Furthermore, 5αTHB 
did not reduce deposition of collagen (an important ECM component of granulation 
tissue) in sponges whereas corticosterone did. This work provided initial evidence that 
5αTHB would have fewer adverse effects on wound healing processes than 














The hypothesis addressed in this chapter is that 5αTHB is suitable for use as a safer 
topical anti-inflammatory agent. It is less harmful to the skin than conventional GCs, 
with decreased effects on skin thinning and wound repair processes. In particular: 
1. 5αTHB has fewer adverse effects on migration of cells important during the 
wound repair process. 
2. 5αTHB is less angiostatic than conventional glucocorticoids. 
 
3.3. Aims 
1. To determine whether 5αTHB impairs migration of fibroblasts, keratinocytes 
and endothelial cells and compare its effects to those of dexamethasone and 
hydrocortisone. 
2. To assess the effects of 5αTHB on the vasculature using a mouse ex vivo aortic 
ring assay, and to compare with the effects of dexamethasone and 
hydrocortisone. The model will be used to: 
I. Compare steroid effects on vessel growth. 
II. Compare steroid effects on gene expression in the aorta. 








3.4.1. Investigating the effects of 5αTHB on cell migration in vitro  
3.4.1.1. Choice of cells 
HaCaT cells were chosen as the human keratinocyte cell model since they were known 
from the literature to be GC responsive, since dexamethasone impaired cell migration 
in an in vitro scratch wound assay (Reuter, Loitsch et al. 2012). Human umbilical vein 
endothelial cells (HUVECs) were used as the endothelial cell model since 
glucocorticoids had previously inhibited tube-like structure formation in these cells 
(Logie, Ali et al. 2010). Finally, hTERT immortalised human dermal fibroblasts were 
chosen as a relevant skin fibroblast model since they are taken from the skin and so 
are likely to be appropriate for studying effects on wound repair mechanisms; 
however, there was no literature available on steroid responsiveness of this particular 
cell line.  
3.4.1.2. Assessment of GR protein in cell lines 
The presence of GR protein was assessed in HaCaT, HUVEC, and dermal fibroblast 
cells. Cells were grown to confluence and complete protein extracted as described in 
2.2.2.1.2. Protein was subsequently quantified (2.2.2.1.4) and visualised as a band 
using Western blot (2.2.2.1.5 – 2.2.2.1.6). Primary antibodies used were GR (sc-1003, 
rabbit polycloncal IgG) and β-tubulin (sc-101527, mouse monoclonal IgG) (both 1:500 
dilution and from Santa Cruz, Heidelberg, Germany). Secondary antibodies used were 
goat anti-rabbit IR Dye 800 CW (926-32211) and goat anti-mouse IR Dye 800 CW 
(926-32210) (both 1:10000 dilution and from Licor Biosciences, Cambridge, UK) 
matched to the species of the primary antibody. The blots were developed and band 
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intensity quantified with the fluorescence method (2.2.2.1.7.1) using an Odyssey® 
Imaging Systems and ImageStudioLite software (both LI-COR Biosciences, Cambridge, 
UK). 
3.4.1.3. Essen bioscience cell migration scratch assay 
3.4.1.3.1. Method development 
The scratch assay was utilised as described in (2.2.4) in order to compare steroid 
effects on HUVEC, HaCaT or dermal fibroblast migration. Initial assays were 
performed in the absence of steroid treatment in order to find the optimum conditions 
required for confluent monolayers to have formed after 8-16 hours, from which 
reproducible scratches could be made. Seeding densities of between 10000 and 60000 
cells/ well were tested, and the effect of coating the plate with collagen type 1 or gelatin 
(protocols in 2.1.5.4) was also investigated in the case of fibroblasts and HUVECs, 
respectively, in order to increase adherence of cells to the plate surface. 
Pharmacological manipulation of the optimised assay was subsequently tested by 
treating HaCaT cells with epidermal growth factor (EGF, 25 ng/ml) as this had 
consistently been reported to increase HaCaT cell migration (Charvat, Chignol et al. 
1998, Tochio, Tanaka et al. 2010).  
3.4.1.3.2. Testing steroid effects 
Dexamethasone, hydrocortisone and 5αTHB concentration responses were performed 
in triplicate, and repeated on three independent cell preparations, using the following 
concentration range: 1 nM, 10 nM, 100 nM, 1 μM, and 10 μM, according to the method 
described in (2.2.4) with previously optimised conditions stated in table 3.2. The 
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negative control for all experiments consisted of the addition of ethanol as vehicle in 
the absence of steroid. 
3.4.2. Investigating the effects of 5αTHB in the vasculature ex vivo 
3.4.2.1. Comparing steroid effects on vessel growth 
Angiogenesis was examined using the mouse ex vivo aortic ring assay model 
(Baker, Robinson et al. 2012). As described in (2.2.3), vessel growth was stimulated 
from aortic rings, and the ability of steroids to suppress this was investigated. Day 7 
was determined  by Small et al. (Small, Hadoke et al. 2005) to be the optimal time-
point to assess effects on vessel growth. Small et al. (Small, Hadoke et al. 2005) 
reported that new vessel growth increased from days 3 to 7, then reached a plateau 
after day 7 (Small, G.R, 2005). In this thesis, vessel growth was stimulated with growth 
factors and it was therefore anticipated that a plateau of vessel growth may be reached 
in less than 7 days. For this reason the vessels were originally counted both on days 5 
and 7. However more vessels had grown on day 7 than on day 5, leading to an increased 
power to detect suppression of vessel growth at this later time point. Therefore, 
subsequent comparisons were made using day 7 data. Power calculations using PS: 
Power and Sample size calculation software (WD Dupont and WD Plummer, Jr) 
indicated that a sample size of n=8 was required in order to achieve sufficient power 
in this assay. Therefore n=8 was achieved in duplicate. Steroid concentration responses 
were performed, with treatments consisting of dexamethasone (1 nM, 3 nM, 10 nM, 
30 nM, 100 nM, 300 nM, and 1 μM), hydrocortisone (10 nM, 30 nM, 100 nM, 300 




3.4.2.2. Assessing GR dependence of the effects of 5αTHB on vessel growth 
Effects mediated via GR were also investigated using the GR antagonist RU486, 
initially using concentrations of 30 nM or 3 μM RU486 (equal to the doses used of 
dexamethasone and 5αTHB), either alone or in combination with dexamethasone (30 
nM) or 5αTHB (3 µM). Dexamethasone was chosen as the positive control due to its 
GR selectivity, and the concentrations used of dexamethasone (30 nM) and 5αTHB (3 
µM) were those previously calculated from their concentration response curves to be 
required for significant suppression of vessel growth. Subsequently, the effect of 
RU486 to shift the steroid concentration-response curves was investigated, by re-
performing the concentration response experiments described in (3.4.2.1) in the 
presence of 30 nM RU486. 
 
3.4.2.3. Comparing steroid effects on mRNA transcript expression in aortic 
rings 
After counting, on day 7, the new vessels that had grown from aortic rings used in the 
experiments described in (3.4.2.1) and (3.4.2.2), RNA was extracted from the rings 
and reverse transcribed for qPCR using the protocols described in (2.2.1.2 – 2.2.1.5). 
Four rings (of the same treatment group) were combined for RNA extraction to 
produce each RNA sample. Treatment groups consisted of unstimulated control, 
stimulated aortic ring (with FCS followed by VEGF as described in 2.2.3.2.), or aortic 
ring which had been stimulated and then treated with either 5αTHB (3 μM), 
dexamethasone (30 nM), hydrocortisone (1 μM), or RU486 (30 M or 3 M) either alone 
or in combination with 5αTHB (3 μM) or dexamethasone (30 nM). Table 3.1 
demonstrates these treatment combinations for clarification. The steroid doses were 
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chosen based on the results of the experiments described in (3.4.2.1). Since aortic rings 
were only treated with specific drug concentrations in order to achieve the 
concentration responses described in 3.4.2.1, it was not possible to compare EC50s of 
each steroid. Furthermore the EC50 of dexamethasone did not significantly suppress 
vessel growth. Consequently, the lowest concentrations of each steroid required to 
significantly suppress vessel growth were chosen to compare effects on gene 
expression in the aorta. At these concentrations vessel growth was suppressed to 
35±11%, 30±7% and 26±14% of stimulated controls by hydrocortisone, 
dexamethasone, and 5αTHB, respectively. RNA transcript abundance across the 
treatment groups was assessed by real-time qPCR (2.2.1.6). To ensure reliability of 
results, two reference genes (Tbp and Actβ) were used, and transcript abundance of 
each gene was normalised to the mean of the two for each sample, due to the lack of 
significant changes in the abundance of transcripts among groups. Next generation 
RNA sequencing analysis had recently been performed to identify gene expression 
changes in the murine aortic ring model in response to hydrocortisone, and genes of 
interest were selected from this study (Morgan, Keen et al. 2018), as well as from real-
time PCR analysis of transcripts in the sponge implantation model performed by 







 Unstimulated Stimulated 
Vehicle        √  
Vehicle  √ 
5αTHB  √ 
Hydrocortisone  √ 
Dexamethasone  √ 
RU486  √ 
RU486 + 5αTHB  √ 
RU486 + Hydrocortisone  √ 
RU486 + Dexamethasone  √ 
 
Table 3.1: Stimulation and treatment combinations for mouse aortic ring experiments, 
to investigate steroid effects on angiogenesis. 
 
3.4.2.4. Data and statistical analysis 
qPCR samples with RDS < 10 % different between analytical triplicates were deemed 
acceptable. All data were analysed using GraphPad Prism6 software and presented as 
mean with error bars representing the standard error of the mean (SEM). Data were 
analysed by one-way ANOVA and either Dunnett’s or Tukey’s multiple comparison 
test, depending on whether every mean was being compared with every other mean 
(Tukey’s test) or every mean was being compared to a control mean (Dunnett’s test). 
To fit the concentration response curves, a non-linear regression analysis was 
performed using the log (inhibitor) vs response (three parameters) equation and using 
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the least squares fitting method. Curves were fitted to the mean data and due to the 
inherent variability in the aortic ring assay, EC50 values were calculated from the mean 

























3.5.1. Assessing the effects of 5αTHB on cell migration 
3.5.1.1. Assessment of GR expression in cell types 
The presence of GR protein in the dermal fibroblast, HaCaT and HUVEC cell lines 
was assessed by Western blot. A similar intensity of bands for β-tubulin demonstrated 
equal loading of protein from each cell type and provided a control between slight 
deviations in sample loading. Bands were quantified and expressed relative to β-









Figure 3.1: Human Umbilical Vein Endothelial cells (HUVECs), HaCaTs and dermal 
fibroblasts all expressed GR. Whole protein was extracted from cells and visualised by 
Western blot with β-tubulin, the latter demonstrating equal loading of protein (a). GR band 
intensities were quantified and expressed relative to the band intensity of their β-tubulin 
loading control (b). GR protein was present in all cell types. Graph is mean ± SEM of n=3.  
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3.5.1.2. Optimisation of cell seeding conditions 
During initial preliminary assays with each cell type, the importance of 
selecting the correct seeding density became apparent. With too low a seeding density, 
cell monolayers were not completely formed due to the presence of gaps between cells. 
This meant that there was a lot of variability in the rate of wound closure between 
replicates, as cells often moved in other directions in order to fill the gaps, rather than 
to close the wounds. With too high a seeding density, cells would attach too tightly to 
each other, often forming clumps and detaching from the well surface. This prevented 
reproducible scratches from being formed, and also led to the presence of cell debris 
(which as well as blocking the pathway of migrating cells, also interfered with the 
computer’s ability to distinguish between ‘cell’ and ‘scratch’ areas). As an additional 
measure to prevent the formation of cell debris, it was also determined that both 
fibroblasts and HUVECs required a coating in order to increase their adherence to the 
surface of the well plates. This was achieved with collagen-1 and gelatin, respectively. 
Since collagen-1 is the major collagen in the skin (providing around 80% of skin 
collagen (Schoepe, Schacke et al. 2006)) this mimics well the granulation tissue 
present in the wound into which the fibroblasts migrate (Schoepe, Schacke et al. 2006, 
Terao, Tani et al. 2014, Terao and Katayama 2016).  In contrast, the basement 
membrane of blood vessels, which forms around the endothelial cells, is a dense 
polymeric sheet composed of ECM proteins but with a slightly different composition 
to the skin ECM (Eming, Brachvogel et al. 2007). The main collagen present is 
collagen IV, and this forms a scaffold together with separate polymers of laminin, held 
together by linker proteins such as nidogens and the heparin sulphate proteoglycan 
perlecan (Eming, Brachvogel et al. 2007, Briquez, Hubbell et al. 2015). Gelatin is a 
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heterogeneous mixture of water-soluble proteins present in collagen, and is extracted 
from skin, tendons, ligaments and bones. It is, therefore, often used mimic the 
basement membrane of blood vessels in order to test the mobility of endothelium cells 
in vitro 
(https://www.sigmaaldrich.com/catalog/product/sigma/g1393?lang=en&region=GB, 
last accessed 21/07/2018).  
Ultimately, the conditions which were deemed optimum in order to study cell 
migration in this assay for each cell type are given in table 3.2.  
 Seeding Density: Plates coated with: 
HaCaT 40000 Uncoated 
Fibroblast 15000 1 mg/mL collagen-type 1 
HUVEC 45000 0.1% gelatin 
 
Table 3.2: The optimum cell plating conditions chosen for use with the Essen 
Bioscience cell migration scratch wound assay. Human umbilical cord endothelial cells 
(HUVEC), HaCaTs, and dermal fibroblasts were plated in 96 well plates under the conditions 
in this table, 8-16 hours before scratch formation. 
 
 
3.5.1.3. Optimising assay analysis settings. 
After scratch formation, cell migration was continuously monitored and well-images 
taken every 2 hours by the Incucyte® analysis software package. From these images, 
cell migration was quantified using the relative wound density (RWD) metric 
previously described (2.2.4). To compute RWD the Incucyte® software relies on the 
formation of various masks – a ‘confluence mask’ covering the cells and a ‘wound 
mask’ covering the scratch area, demonstrated in figure 3.2, as compared to without 
the masks as seen in figure 3.3. It was therefore vital for these masks to be accurately 
applied and ‘processing definitions’ were made for each cell type, with various 
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parameters altered to optimise this as far as possible. Table 3.3 gives the optimised 







Figure 3.2: The Incucyte® analysis software package was used to apply ‘confluence’ (in 
orange) and ‘wound’ (in yellow) masks to cell migration images at each time point. From 
these masks, progress of the cells to migrate and cover the scratch area was computed by 
the software in terms of relative wound density (RWD). Image (a) is a representative original 
scratch at zero hours (0 hours) made by the Incucyte Wound maker tool in human umbilical 
vein endothelial cells (HUVECs). Cell migration to cover the scratch after 6 hours (the time at 
which vehicle-treated HUVECs had 40% RWD) can be visualised in image (b).  
 
  HaCaT Fibroblasts HUVEC 
Segmentation 
adjustment 
 1.2 1.3 2 
Clean up Hole fill (µm2) 500 4000 300 
Filters Minimum area 
(µm2) 
700 3500 900 
Table 3.3: The optimum analysis parameters chosen for ‘confluence’ and ‘wound’ 
masks to be accurately applied to images, using the Incucyte® analysis software 
package (Essen Bioscience). These parameters were optimised separately for each cell 
type, ensuring reliable mask formation and subsequent cell migration quantification. Only the 
settings listed in this table were applied. 
 
 






3.5.1.4. Model assessment and time point selection 
To assess whether the scratch wound model was suitable for studying pharmacological 
effects on cell migration, endothelial growth factor (EGF) was used, which is widely 
reported to stimulate HaCaT cell migration. Vehicle treatment did not influence cell 
migration in comparison to untreated control cells (figure 3.4). EGF treatment 
increased HaCaT cell migration as assessed visually and after RWD quantification 
(figures 3.3 and 3.4). For vehicle-treated scratches the average wound closure times 
were calculated as well as the time required for the scratch to reach 20, 40, 60 and 80% 
RWD.  RWDs of EGF-treated scratches were subsequently compared at each time 
point. EGF increased cell migration in comparison to vehicle-treated cells at time-
points when vehicle treated cells had 40, 60 and 80% RWD. This indicated that cell 
migration changes could be detected by the model and, hence, that it is suitable for 
assessing the effects of other compounds. The difference between vehicle- and EGF-
treated scratches became significant when vehicle-treated scratches had 40% RWD 
(occurring after 12 hours in HaCaTs). The time for vehicle-treated scratches to reach 




















Figure 3.3: Epidermal growth factor (EGF, 25ng/ml) increased migration of HaCaT cells 
in comparison to vehicle-treated cells. HaCaTs were plated in stripped serum medium and 
grown to confluence in 96 well ImageLock Microplates. A scratch was made and media 
replaced with either vehicle or EGF. Images (a) and (b) demonstrate original wounds zero 
hours (0h) after scratch formation. Cell migration occurred over time to cover the scratch area, 
and masks applied by the Incucyte® analysis software were used to compute relative wound 
density (RWD, %). After 12 hours RWD of vehicle-treated cells was 43% (c) whereas in EGF-
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Figure 3.4: Cell migration was successfully manipulated using the Incucyte® cell 
migration scratch assay, with differences between treatments becoming significant at 
the time point when vehicle treated scratches had 40% relative wound density (RWD). 
Scratches were made in confluent HaCaT monolayers and stripped serum media replaced 
either with no treatment (Control), with ethanol vehicle (V) or with epidermal growth factor 
(EGF, 25ng/ml). Wound closure was then monitored using Essen Bioscience Incucyte® 
analysis software. RWD was compared between the two treatment groups at the time when 
vehicle treated cells had 20, 40, 60 and 80% RWD.  Vehicle treatment did not influence wound 
closure in comparison to untreated control. EGF increased RWD of scratches in comparison 
to vehicle treatment, at the time points when vehicle treated scratches had 40, 60 and 80% 
RWD. Data from each time point were individually analysed by one-way ANOVA with 
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3.5.1.5. Assessing steroid effects on cell migration 
Cell seeding densities optimised as described in section 3.4.1.2 were successful in 
creating confluent monolayers from which reproducible wounds could be made. 
Processing definitions using the chosen parameters described in section 3.4.1.3 
allowed the Incucyte® software to distinguish clearly between open scratch areas and 
those containing cells for each cell type. The time taken for vehicle-treated scratches 
to close to 40% RWD occurred in a consistent manner, requiring 16 hours for 
fibroblasts, 12 hours for keratinocytes and 6 hours for HUVECs. Comparisons to 
assess steroid effects were subsequently made at these time points.   
The GR-selective glucocorticoid dexamethasone did not have a significant effect on 
fibroblast, HUVEC, or HaCaT migration, at any concentration tested from 1nM to 
10µM. This can be seen visually (appendices figures A1, A4 and A7) and was 
confirmed through quantification (figures 3.5a, 3.6a and 3.7a).  Hydrocortisone did not 
have any effect on fibroblast or HaCaT migration (figures 3.5b and 3.7b), but did 
suppress HUVEC migration (figure 3.6b), reaching significance at doses of 1 nM and 
10 nM. 5αTHB also did not affect cell migration of any cell type, at any dose tested 

























Figure 3.5: Dermal fibroblast cell migration was unaffected by dexamethasone (a), 
hydrocortisone (b) or 5α-tetrahydrocorticosterone (5αTHB)(c). Cell migration was 
assessed using the Incucyte® cell migration scratch assay (Essen Bioscience). Cells were 
plated in stripped serum medium. Scratches were made in confluent cell monolayers and 
media replaced containing vehicle (ethanol) or either dexamethasone, hydrocortisone or 
5αTHB concentrations ranging from 1 nM to 10 µM. Cell migration to cover the scratch area 
(or ‘wound’) was then assessed every 2 hours as the ‘relative wound density’ (RWD), a 
measurement of the spatial cell density in the wound area relative to the spatial cell density 
outside of the wound area at every time point. RWD was compared between treatments at the 
time when RWD of vehicle-treated cells was 40%. The steroids tested did not cause any 
difference in fibroblast cell migration in comparison to vehicle-treated control. Graphs are 
mean ± SEM, n=3. Data were analysed by one-way ANOVA. 









                                                    









                                                  
(c)  














































O v e ra ll o n e -w a y  A N O V A
p = 0 .9 8 4 1














































O v e ra ll o n e -w a y  A N O V A
p = 0 .9 6 3 9














































O v e ra ll o n e -w a y  A N O V A


























Figure 3.6: Human Umbilical Vein Endothelial Cell (HUVEC) migration was unaffected 
by dexamethasone (a) or 5α-tetrahydrocorticosterone (5αTHB)(c) but was inhibited by 
hydrocortisone (b). Cell migration was assessed using the Incucyte® cell migration scratch 
assay (Essen bioscience). Cells were plated in stripped serum medium. Scratches were made 
in confluent cell monolayers and media replaced containing vehicle (ethanol), or either 
dexamethasone, hydrocortisone or 5αTHB at concentrations ranging from 1 nM to 10 µM. Cell 
migration to cover the scratch area (or ‘wound’) was then assessed every 2 hours and the 
‘relative wound density’ (RWD) measured: the spatial cell density in the wound area relative 
to the spatial cell density outside the wound area at every time point. RWD was compared 
between treatments at the time when RWD of vehicle-treated cells was 40%. RWD of 
dexamethasone (a) and 5αTHB (c) treated wounds was unchanged relative to control. RWD 
was decreased by hydrocortisone (b) at doses of 1 nM and 10 nM, indicative of reduced 
HUVEC cell migration. Comparisons were made with Dunnett’s multiple comparisons test. 
Graphs are mean ± SEM, n=3. Data were analysed by one-way ANOVA. * = P<0.05, ** = 
P<0.01 vs control. 
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Figure 3.7: HaCaT cell migration was unaffected by dexamethasone (a), hydrocortisone 
(b) or 5α-tetrahydrocorticosterone (5αTHB) (c). Cell migration was assessed using the 
Incucyte® cell migration scratch assay (Essen bioscience). Cells were plated in stripped serum 
medium. Scratches were made in confluent cell monolayers and media replaced containing 
vehicle (ethanol) or either dexamethasone, hydrocortisone or 5αTHB concentrations ranging 
from 1 nM to 10 µM. Cell migration to cover the scratch area (or ‘wound’) was then assessed 
every 2 hours as the ‘relative wound density’ (RWD), a measurement of the spatial cell density 
in the wound area relative to the spatial cell density outside the wound area at every time point. 
RWD was compared between treatments at the time when RWD of vehicle-treated cells was 
40%. None of the drugs caused any difference in HaCaT cell migration in comparison to 
control, as analysed with Dunnett’s multiple comparisons test. Graphs are mean ± SEM, n=3. 
Data were analysed by one-way ANOVA
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3.5.2. The effects of steroids on angiogenesis 
3.5.2.1. Assessment of controls 
A growth stimulus (FCS followed by VEGF) increased the number of vessels that 
sprouted from aortic rings in comparison to unstimulated negative controls (figure 
3.8). This effect was significant after both 5 and 7 days (white panels in figures 3.9a 
and b, respectively). However, the magnitude of growth was greater at 7 days, 
justifying this as the correct time to assess the effects of steroids on vessel growth, as 
a greater suppression in the number of vessels could be possible at this time point. 
Dexamethasone (positive control) suppressed vessel growth in a concentration-
dependent manner (figures 3.9 and 3.11). There was a pattern indicating 
dexamethasone-induced suppression of growth at day 5 (figure 3.9a), with significant 
suppression achieved at 300 nM. However, this concentration-dependent suppression 
became more apparent at day 7, when several concentrations (30 nM, 100 nM, 300 nM 
and 1 µM) of dexamethasone significantly suppressed vessel growth. The EC50 dose 
for suppression of vessel growth by dexamethasone at day 7 was 7.66 nM. However 
suppression of vessel growth by 10 nM dexamethasone (just higher than the EC50 
dose) did not reach significance. Therefore a concentration of 100 nM was chosen as 
the positive control for future experiments; this was slightly higher than the first 
concentration required to reach significance (30 nM), in order to ensure demonstration 
of inhibition. 
Power calculations performed using PS: Power and Sample size calculation software 
(by WD Dupont and WD Plummer, Jr) supported day 7 as the best time point to 
robustly detect the observed suppression (by 69%) of vessel growth by 
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dexamethasone. In order to achieve power of 90%, a sample size of 8 was required 
when assessing vessel growth at day 7.  
The large error bars (particularly at lower concentrations of dexamethasone when the 
mean vessel numbers are high, and hence the standard deviations, are large) 
demonstrate an inherent variability in this assay. In an attempt to reduce this inter assay 
variability, the effect of normalising the data to the number of vessels which grew in 
response to the stimulus alone, was investigated. Curves were fitted to the mean raw 
data, and the mean data expressed as % stimulus (figure 3.10). However there was no 
major improvement in the parameters describing the quality of the curve fit by 
normalising the data to the stimulus. It was, therefore, decided to continue assessing 




Figure 3.8: Vessel growth was succesfully stimulated from murine aortic rings. Rings 
were plated in collagen and cultured in medium originally containing 1% Foetal calf serum 
(FCS, day 0). Medium was replaced on days 3 and 5, with the addition of vascular endothelial 
growth factor (VEGF, 5 ng/mL) in place of FCS. Rings treated with this stimulus treatment 
(FCS followed by VEGF) produced many more vessels than control rings, evident on days 5 
and 7. Images are representative of n=8.5X magnification. 
 













Figure 3.9: Dexamethasone (Dex) induced a concentration-dependent suppression of 
vessel growth from murine aortic rings. Aortic rings were maintained in medium containing 
vehicle (control), a stimulus for vessel growth, or a combination of the stimulus plus one of the 
following concentrations of dexamethasone: 1, 3, 10, 30, 100, 300 or 1000 nM (left to right on 
graphs). The stimulus consisted of foetal calf serum on day 0, followed by vascular endothelial 
growth factor on days 3 and 5. Vessels which had grown from aortic rings were counted on 
day 5 (graphs a and c) and on day 7 (b and d) after plating. The stimulus significantly increased 
vessel growth from aortic rings after 5 (a) and 7 (b) days, but more vessels had grown at the 
later time point. Dexamethasone induced a concentration-dependent suppression of this 
vessel growth, requiring a concentration of 300 nM to reach significance at day 5, and a lower 
concentration(30 nM) at day 7. Concentration- response curves were then plotted for data at 
both day 5 (c) and day 7 (d). From these the concentration of dexamethasone required to 
inhibit vessel growth by half (EC50) was found to be 11.1 nM at day 5, and 7.7 nM at day 7. 
EC50 values were calculated from mean data due to inherent variability in the aortic ring assay. 
Graphs show mean ± SEM of n=8. *=P<0.05, **=P<0.01 vs control as analysed by an unpaired 
t-test. #=P<0.05, ##=P<0.01 vs stimulus as analysed by one-way ANOVA, followed by 
Dunnett’s multiple comparisons test. 
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Figure 3.10: Aortic ring assay concentration-response curve fit was not improved 
through normalisation. Murine aortic rings were maintained in medium containing vehicle 
(control), a stimulus for vessel growth, or a combination of the stimulus plus dexamethasone 
(1, 3, 10, 30, 100, 300 or 1000 nM). After 7 days the vessels which had grown from the rings 
were counted and a concentration-response curve of these raw values was plotted (a). In 
addition, a concentration-response curve was also plotted of these vessel numbers normalised 
to the number of vessels which had grown from rings treated with the stimulus alone (set to 
100%)(b). The R2 value for the curve generated by normalising the data was not much 
different, since the shape stayed the same, so this does not control well for inter assay 
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Figure 3.11: Concentration-dependent suppression of vessel growth from aortic rings 
by dexamethasone (Dex). Aortic rings were plated in collagen and cultured in medium either 
alone, containing a stimulus (S) for vessel growth, or with a combination of the stimulus plus 
a dexamethasone concentration ranging from 1 nM to 1 µM. The stimulus increased the 
number of vessels which had sprouted from aortic rings after 7 days. Dexamethasone induced 
a concentration-dependent suppression of this vessel growth with 7.7 nM required for half-
maximal effect (EC50). The EC50 was calculated from mean data due to inherent variability 
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3.5.2.2.  Assessment of the effect of hydrocortisone in an ex vivo model 
of angiogenesis 
As demonstrated by the white panels in figure 3.12a, the stimulus (FCS followed by 
VEGF) was successful in stimulating the growth of vessels from murine aortic rings 
after 7 days of culture. This was consistent with the previous experiments given in 
figure 3.9, in which a similar number of vessels grew after treatment with the stimulus. 
This vessel growth was inhibited by the positive control, dexamethasone, once again 
demonstrating that angiogenesis can be manipulated in this assay and, hence, its 
appropriateness for assessing steroid effects.  
Further rings were treated with a combination of the stimulus and hydrocortisone. 
Hydrocortisone induced a concentration-dependent suppression of vessel growth from 
murine aortic rings. However, it was less potent than dexamethasone; the suppression 
of vessel growth became significant in comparison to stimulated controls (not treated 
with steroid) at a concentration of 1 µM (figure 3.12a) and the EC50 for suppression 




















Figure 3.12: Hydrocortisone (HC) induced a concentration-dependent suppression of 
vessel growth from murine aortic rings. Aortic rings were maintained in medium either 
containing vehicle (control), a stimulus for vessel growth, or a combination of the stimulus plus 
dexamethasone (Dex) positive control (100 nM) or a HC concentration of 10, 30, 100, 300, 
1000, 3000 or 10,000 nM (left to right on graphs). The stimulus consisted of foetal calf serum 
on day 0 followed by vascular endothelial growth factor on days 5 and 7. Vessels which had 
grown from aortic rings were counted 7 days after plating. By day 7, the stimulus had caused 
a significant increase in vessel growth from aortic rings (graph a). HC induced a concentration-
-dependent suppression of this vessel growth, with the effect becoming significant at 1 µM. A 
concentration-response curve (R2=0.2891) was plotted (b) and from this the concentration of 
HC required to inhibit vessel growth by half (EC50) was 867 nM. The EC50 was calculated 
from mean data due to inherent variability in the aortic ring assay. Graphs show mean ± SEM 
of n=8. ****=P<0.0001 vs control, ##=P<0.01, ###=P<0.001, ####=P<0.0001 vs stimulus as 
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Figure 3.13: Concentration-dependent suppression of vessel growth from aortic rings 
by hydrocortisone (HC). Aortic rings were plated in collagen and cultured in medium either 
alone, containing a stimulus (S) for vessel growth, or with a combination of the stimulus plus 
100 nM dexamethasone (Dex) or a HC concentration ranging from 10 nM to 10 µM. The 
stimulus increased the number of vessels which had sprouted from aortic rings after 7 days. 
Dexamethasone (positive control) suppressed this vessel growth. HC also induced a 
concentration-dependent suppression of vessel growth with 867 nM required for half-maximal 
effect (EC50). The EC50 was calculated from mean data due to inherent variability in the aortic 
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3.5.2.3. Assessment of the angiostatic effects of 5αTHB in an ex vivo 
model. 
As demonstrated in figure 3.14a, during experiments with 5αTHB the growth stimulus 
(FCS followed by VEGF) significantly increased the number of vessel outgrowths 
which had sprouted from mouse aortic rings after 7 days. This is consistent with the 
stimulus effect previously described (figures 3.9 and 3.12). Dexamethasone (positive 
control; 100 nM) significantly suppressed this vessel growth, demonstrating a 
functional and reliable assay.  
5αTHB also suppressed vessel growth from aortic rings. This suppression was evident 
at higher concentrations than required with the other steroids tested, reaching 
significance in comparison to stimulated control at 3 µM and 10 µM (figure 3.14a). 
However, at lower concentrations the effect of 5αTHB was less clear, and the 
concentration-response curve was flatter in comparison to those for dexamethasone 
and hydrocortisone. This is reflected in the higher EC50 of 2399 nM for suppression 



















Figure 3.14: 5αTHB induced a concentration-dependent suppression of vessel growth 
from murine aortic rings. Aortic rings were maintained in medium either containing vehicle 
(control), a stimulus for vessel growth, or a combination of the stimulus plus dexamethasone 
(Dex;  positive control) or 5αTHB at a concentration of 10, 30, 100, 300, 1000, 3000 or 10,000 
nM. The stimulus consisted of foetal calf serum on day 0 followed by vascular endothelial 
growth factor on days 5 and 7. Vessels which had grown from aortic rings were counted 7 
days after plating. At day 7, the stimulus had caused a significant increase in vessel growth 
from aortic rings. 5αTHB induced a concentration-dependent suppression of this vessel 
growth, with the effect becoming significant at 3 µM. A concentration-response curve (b) was 
subsequently plotted (R2=0.2512) and from this the concentration of 5αTHB required to inhibit 
vessel growth by half (EC50) was determined as 2399 nM. The EC50 was calculated from 
mean data due to inherent variability in the aortic ring assay. Graphs show mean ± SEM of 
n=8. ****=P<0.0001 vs control, #=P<0.05, ##=P<0.01, ###=P<0.001 vs stimulus as analysed 
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Figure 3.15: Concentration-dependent suppression of vessel growth from aortic rings 
by 5αTHB. Aortic rings were plated in collagen and cultured in medium either alone, containing 
a stimulus (S) for vessel growth, or with a combination of the stimulus plus 100 nM 
dexamethasone (Dex) as a positive control, or plus 5αTHB at a concentration ranging from 10 
nM to 10 µM. The stimulus increased the number of vessels which had sprouted from aortic 
rings after 7 days. Dexamethasone suppressed this vessel growth. 5αTHB induced a 
concentration-dependent suppression of vessel growth with 2399 nM required for half-
maximal effect (EC50). The EC50 was calculated from mean data due to inherent variability 
in the aortic ring assay. Images are representative of n=8.  5X magnification.
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3.5.2.4.  Summary of the effects of 5αTHB and hydrocortisone on 
angiogenesis in the aortic ring assay model. 
As evident from figures 3.12 and 3.14, hydrocortisone and 5αTHB both induced 
concentration- dependent suppression of vessel outgrowth from mouse aortic rings. 
Hydrocortisone did this with an EC50 of 867 nM and achieved a significant 
suppression with doses 1 µM and above. 5αTHB was less potent than hydrocortisone 
to suppress vessel growth. It had a higher EC50 of 2399 nM and required a larger dose 
of 3 µM in order for its suppression of vessel growth to reach significance. A summary 
of the angiostatic effects of the steroids tested in this model, including that of the 
positive control dexamethasone, is given in table 3.4. 
 
Steroid EC50 for 
angiostasis 
Lowest dose for significant angiostatic 
effect, and suppression achieved versus 
stimulated control. 
Dexamethasone 7.7 nM 30 nM, achieving 65±11% suppression. 
Hydrocortisone 867 nM 1 µM, achieving 70±7% suppression. 
5αTHB 2399 nM 3 µM, achieving 74±14% suppression. 
 
Table 3.4: A summary of the effects of steroids on angiogenesis in a murine aortic ring 
model after 7 days. Murine aortic rings were plated in collagen and cultured in medium with 
a stimulus for vessel growth plus either vehicle (ethanol, 1 µL per 1 mL), or dexamethasone, 
hydrocortisone or 5αTHB at concentrations ranging from 1 nM to 10 µM. All steroids induced 
concentration-dependent suppression of the stimulated vessel growth, with the half-maximal 
doses (EC50) given in the middle column. EC50 values were calculated from mean data due 
to the inherent variability in the aortic ring assay. The dose of each steroid required for the 
suppression of vessel growth to reach significance against stimulated controls (not treated 





3.5.3. Investigation of the involvement of GR in the angiostatic effects of 
5αTHB 
In section 3.4.2. it was determined that 5αTHB induced a concentration-
dependent suppression of angiogenesis in the murine aortic ring assay, albeit with a 
lower potency than either hydrocortisone or dexamethasone. To understand the 
underlying mechanism, the GR antagonist RU486 was used to determine whether this 
suppression of angiogenesis was mediated through GR. A GR-selective agonist, 
dexamethasone, was used as the positive control (hydrocortisone being a ligand for 
both MR and GR). 
3.5.3.1. Antagonism of the angiostatic effect of 5αTHB using equipotent doses 
of RU486 
N=12 was selected to increase power, since a concentration-response was no 
longer being performed. Equal concentrations of RU486 and steroid were used, since 
in previous preliminary work by McInnes (2003) this was sufficient for RU486 to 
antagonise the effect of 5αTHB in the same assay. The lowest concentrations required 
of dexamethasone and 5αTHB (as determined in sections 3.4.1.2 and 3.4.1.3) in order 
to significantly suppress vessel growth, were chosen in order to assess antagonism by 
RU486. At these doses it was anticipated that any antagonism would clearly be 
evident.  
Once again, aortic rings responded well to the stimulus with vessel growth 
successfully increased to an average of 98 sprouts per ring (figure 3.16). 
Dexamethasone (30 nM) suppressed this vessel growth (figure 3.16a) consistent with 
previous data. Low concentration (30 nM) RU486, in the absence of steroid, did not 
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alter vessel growth but the high concentration (3 µM) induced a significant suppression 
of growth. For this reason the combined effects of the steroids with this high 
concentration of RU486, could not be interpreted. Whereas dexamethasone (30 nM) 
suppressed vessel growth alone, in combination with the lower concentration of 
RU486 (30 nM, concentration equivalent to dexamethasone) it did not, suggesting 
some antagonism. Power calculations indicated that N=117 were required to detect 
(with 90% power) a significant difference between dexamethasone- mediated 
suppression of vessel growth in the presence of RU486, and in the absence of RU486. 
With regard to 5αTHB, in contrast to the previous concentration-response data, 
suppression of vessel growth by a concentration of 3 µM did not achieve significance 
(figure 3.16b). Power calculations based on this data demonstrated that N=41 would 

























Figure 3.16: Investigation of the involvement of the glucocorticoid receptor (GR) in 
5αTHB-mediated inhibition of angiogenesis. The GR antagonist RU486 was used to 
assess whether the suppression of vessel growth by (a) dexamethasone (Dex;  positive 
control), or (b) 5αTHB, is mediated via GR. Murine aortic rings were cultured in medium either 
with vehicle (control), with a stimulus for vessel growth, or with a combination of the stimulus 
plus either dexamethasone (30 nM) or 5αTHB alone or in combination with RU486 at low (30 
nM) or high (3 µM) concentrations. The stimulus increased the number of vessels which grew 
from aortic rings. High concentration RU486 alone suppressed this vessel growth, making its 
effects in combination with the steroids difficult to interpret. Graphs are mean ± SEM of n=12. 
****=P<0.0001 vs control as analysed by unpaired t-test, #=P<0.05, ##=P<0.01, 
###=P<0.001, ####=P<0.0001 vs stimulus, as analysed by one-way ANOVA followed by 
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3.5.3.2. Assessment of antagonism by a shift in the concentration-response 
curves. 
In section 3.5.3.1 single doses of steroid (30 nM of dexamethasone and 3 µM 
of 5αTHB) were used to suppress vessel growth, and antagonism of this suppression 
was assessed using RU486. However due to the inherent variability in the aortic ring 
assay, the sample sizes required to detect significant effects and gain definitive 
answers in this previous section would be very high, requiring many mice. In this 
current section, in order to better interpret the effects of RU486, the steroid 
concentration- responses were re performed in the presence of RU486 (30 nM). The 
EC50 values were then compared for steroid dose responses in the presence and 
absence of RU486, to assess whether the EC50 values were altered by RU486.                                                                                                                                                                                                                                                                                                               
3.5.3.2.1. Assessment of the effect of RU486 on the concentration-response 
to dexamethasone 
The stimulus significantly increased vessel growth from aortic rings in 
comparison to unstimulated controls (figure 3.17a). However there was less vessel 
outgrowth formation from rings in general in this assay compared to previous 
experiments. For example, during the original dexamethasone concentration-response 
(figure 3.9b) an average of 28 vessel outgrowths formed from unstimulated control 
rings, in comparison to an average of 15 vessel outgrowths in this experiment (figure 
3.17a). Likewise, an average of 71 vessel outgrowths formed from stimulated controls 
in the original dexamethasone concentration-response, compared to an average of 34 
in this experiment. Also in contrast, the suppression of vessel outgrowth formation by 
dexamethasone alone at 100 nM (positive control) in this current assay did not reach 
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significance (p=0.2). This is likely related to the assay variability as well as the lower 
number of vessel outgrowths, resulting in reduced sensitivity of the assay to allow 
detection of small effects. Power calculations revealed that a sample size of 47 would 
be required to detect a significant suppression of vessel growth by dexamethasone with 
90% power. This reflects problems with this experiment in comparison to the previous 
concentration-response experiment where n=8 was sufficient to achieve high power. 
An additional problem was that RU486 itself suppressed vessel growth, even at this 
lower dose of 30 nM, further complicating the interpretation of the experiment and 
indicating that further methods of answering the question should instead be sought.  In 
spite of these issues, in the presence of 30 nM RU486, dexamethasone still induced a 
concentration-dependent suppression of vessel growth in this experiment. A higher 
dose (1 µM) was required to reach significance in comparison to 30 nM required 
previously (figure 3.9b) in the absence of RU486. In addition the EC50 had increased 
to 287.7 nM (in comparison to 7.7 nM in the absence of RU486). A rightward shift 
was therefore induced in the dexamethasone concentration response curve by RU486. 
Raw vessel numbers were normalised to stimulated controls and concentration-
responses in the presence and absence of RU486 were superimposed on the same graph 
(figure 3.19a). Although the error bars do overlap at the lowest and highest doses of 
dexamethasone, they do not for the middle doses. Again this is suggestive of some 










Figure 3.17: Investigation of the effect of the glucocorticoid receptor antagonist RU486 
on the suppression of angiogenesis by dexamethasone. Murine aortic rings were cultured 
in medium either with vehicle (control), with a stimulus for vessel growth, or with a combination 
of the stimulus plus RU486 (30 nM) alone or together with one of the following concentrations 
of dexamethasone: 1, 3, 10, 30, 100, 300 or 1000 nM (left to right on graphs). After 7 days 
vessels which had grown from the rings were counted. The stimulus (foetal calf serum on day 
0, followed by vascular endothelial growth factor on days 3 and 5) increased the number of 
vessels which grew from aortic rings in comparison to control. RU486 when given alone 
suppressed this vessel growth, and dexamethasone had an additional effect, achieving 
significance in comparison to RU486 alone at a dose of 1 µM (a). In the presence of RU486 
the concentration of dexamethasone required to inhibit vessel growth by half (EC50) was 
287.7 nM (b). EC50 values were calculated from mean data.  Graphs show mean ± SEM of 
n=8. **=P<0.01 vs control, #=P<0.05, ##=P<0.01 vs Stimulus + RU486, $=P<0.05 vs Stimulus, 
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3.5.3.2.2. Assessment of the effect of RU486 on concentration response curve 
to 5αTHB 
The stimulus significantly increased vessel growth from aortic rings in comparison to 
unstimulated controls (figure 3.18a) from an average of 12 to an average of 32. Again, 
this assay has a lower power than the previous 5αTHB concentration response curve 
in the absence of RU486 (figure 3.14a) in which vessel growth was increased to an 
average of 56 from an average of 18. Just as in the dexamethasone concentration-
response curve in the presence of RU486 (figure 3.17a), the dexamethasone positive 
control did not suppress the stimulated vessel growth in this experiment (figure 3.18a). 
As suggested previously, this is likely to be a consequence of the low power of this 
experiment; indeed when the control data from both experiments are combined (to 
achieve n=16; figure 3.20) the suppression by dexamethasone becomes significant. 
Suppression of vessel growth by 5αTHB was also not statistically significant (figure 
3.18a). From the concentration-response curve (figure 3.18b) a higher EC50 of 3110 
nM was evident, in comparison to 2399 nM in the absence of RU486 (figure 3.14b). 
Again, this could be interpreted as a rightward shift of the concentration-response 
curve by RU486; however, when the normalised concentration-response curves in the 
presence and absence of RU486 were superimposed on the same graph (figure 3.19b) 
the error bars overlapped for all concentrations of 5αTHB. This suggests that RU486 
did not antagonise the effect of 5αTHB. However again due to the lack of power this 









Figure 3.18: Investigation of glucocorticoid receptor antagonist RU486 effect on the 
suppression of angiogenesis by 5αTHB. Murine aortic rings were cultured in medium either 
with vehicle (control), with a stimulus for vessel growth, or with a combination of the stimulus 
plus RU486 (30 nM) alone or together with one of the following concentrations of 5αTHB: 10, 
30, 100, 300, 1000, 3000 or 10000 nM (left to right on graphs). After 7 days, vessels which 
had grown from the rings were counted. The stimulus (foetal calf serum on day 0, followed by 
vascular endothelial growth factor on days 3 and 5) increased the number of vessels which 
grew from aortic rings in comparison to control. Suppression of this by dexamethasone (Dex) 
positive control did not achieve significance, demonstrating a lack of power in this assay and 
making further interpretation difficult. Graphs show mean ± SEM of n=8. **=P<0.01 vs control 
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Figure 3.19: The effect of the glucocorticoid receptor antagonist RU486 on the 
suppression of angiogenesis by dexamethasone (Dex) and 5αTHB. Steroid-induced 
suppression of vessel growth from mouse aortic rings was compared in the presence and 
absence of RU486 (30 nM). The number of vessels which grew from rings was normalised to 
stimulated controls, and normalised data were used to superimpose concentration-response 
curves in the presence and absence of RU486 for (a) dexamethasone, and (b) 5αTHB. 
Whereas RU486 appears to antagonise the effect of low concentrations of dexamethasone, it 
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Figure 3.20: Combined control data from concentration-response experiments for 
dexamethasone and 5αTHB in combination with RU486. Graphs show mean ± SEM of 16. 
****=P<0.0001 vs control, #=P<0.05 vs stimulus, as analysed by one-way ANOVA followed by 
Dunnett’s multiple comparisons test. 
 
3.5.4. The effect of steroids on gene expression in the mouse aorta 
In addition to investigating the mechanisms of 5αTHB by antagonism with RU486 
(section 1.4.3), in this section the effects of 5αTHB on gene expression in the aorta 
were compared to those of hydrocortisone and dexamethasone. 
3.5.4.1.  Retrieval of aortic rings and RNA extraction. 
In sections 1.4.2 and 1.4.3, aortic ring assays were performed, from which 
aortic rings were available for RNA extraction and subsequent gene expression 
analysis. Additional experiments were also performed to increase the availability of 
rings as they needed to be pooled. It was established, whilst using the protocol for 
RNA extraction described in section (2.2.1.2), that it was necessary to combine four 
aortic rings for RNA extraction in order to obtain sufficient RNA for analysis by 
qPCR. An initial power calculation revealed that a sample size of 5 was required in 
order to detect a 362% induction of Per1 by dexamethasone with 90% power. 
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number of RNA samples produced varied according to the aortic rings available, and 
were as follows: Stimulus only N=11, Dexamethasone N=8, Hydrocortisone N=5, 
5αTHB N=9, RU486 N=6, RU486 + Dex N=5, RU486 + 5αTHB N=5.  
3.5.4.2. Comparison of the effects of 5αTHB, dexamethasone, and 
hydrocortisone on gene expression in mouse aortic rings  
 
3.5.4.2.1. Genes involved in inflammation and signalling 
Exposure to dexamethasone decreased the abundance of transcripts for Cxcl5 (figure 
3.21a) and produced a trend (p=0.053) to increase transcripts for Dusp1 (figure 3.21b) 
in mouse aortic rings undergoing angiogenesis. Hydrocortisone decreased transcript 
abundance of Cxcl5 (figure 3.21a) and increased that of Dusp1 (figure 3.21b)(30). 
5αTHB did not affect transcript abundance of these genes. There was a trend (p=0.07) 
for 5αTHB to increase transcripts of Mcp1 versus control (figure 3.21c). Mcp1 
transcripts were significantly increased (P<0.01) by 5αTHB in comparison to aortic 
rings exposed to dexamethasone or hydrocortisone, both of which had no effect. 
Therefore the trend for 5αTHB to increase Mcp1 transcripts would likely become 
significant with increased power. iNOS expression was not altered by any treatment 
(figure 3.21d). 
3.5.4.2.2. Genes involved in remodelling of the extracellular matrix (ECM) 
The transcript abundance of Col4a1 was increased by hydrocortisone and there was a 
trend (p=0.0501) for an increase with dexamethasone (figure 3.21e). Both 
dexamethasone and hydrocortisone decreased abundance of Mmp9 transcripts (figure 
3.21f). There was a trend (p=0.09) for hydrocortisone to reduce the expression of 
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Col14a1 (figure 3.21g). 5αTHB did not alter abundance of any of these gene 
transcripts. 
3.5.4.2.3. Genes involved in remodelling the vasculature 
5αTHB decreased the abundance of Pecam1 transcripts, and hydrocortisone also 
exhibited a trend (p=0.07) to decrease them (figure 3.21h). Vcam1 expression was not 
altered by any treatment (figure 3.21i). 
3.5.4.2.4. Genes known to be directly associated with GR 
Dexamethasone and hydrocortisone both increased the abundance of Per1, Hsd11b1, 
and Fkbp51 transcripts (figures 3.21j, k, and l). 5αTHB only increased the abundance 
of Per1 transcripts; however this was to a lesser extent than hydrocortisone or 























Figure 3.21: Steroid effects on gene transcript abundance: RNA was extracted from stimulated mouse aortic ring sections treated with either 
vehicle (stimulus only), dexamethasone (Dex; 30 nM), hydrocortisone (HC; 1µM) or 5αTHB (3 µM). The RNA was reverse transcribed into cDNA and 
analysed by real-time PCR for expression of genes involved in inflammation and signalling ((a) Cxcl5, (b) Dusp1, (c) Mcp1, and (d) iNOS), extracellular 
matrix (ECM) remodelling ((e) Col4a1, (f) Mmp9, (g) Col14a1), vasculature remodelling ((h) Pecam1, (i) Vcam1) as well as typical GR responsive 
genes ((j) Per1, (k) Hsd11b1 and (l) Fkbp51)) . n=11 for stimulus- only treated group, n=8 for Dex, n=5 for HC, and n=9 for 5αTHB. Graphs (mean ± 
SEM) were analysed by one-way ANOVA followed by Tukey’s multiple comparison test, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 vs Stimulus; 
#=p<0.05, ##=p<0.01, ####=p<0.0001 vs HC; $=p<0.05, $$=p<0.01, $$$=p<0.001, $$$$=p<0.0001 vs Dex. 











































































































































































































































3.5.4.3.  Using RU486 to investigate the involvement of GR in the effects of 
steroids on gene expression in mouse aortic rings. 
In order to test the contribution of GR to transcript regulation by 5αTHB, the 
ability of RU486 to antagonise the effect was assessed. It should be kept in mind that 
this experiment is compromised by my demonstration that RU486 had a direct effect 
on vessel growth in this assay. Dexamethasone was used as a positive control in this 
experiment, since it is a selective GR agonist. Dexamethasone no longer caused 
differential expression of Cxcl5, Mmp9, and Hsd11b1 when co-administered with 
RU486 (figures 3.22a, b and d). RU486 also tended to antagonise dexamethasone-
induced up-regulation of Per1 (P=0.06) and Fkbp51 (P=0.08)(figures 3.22c and e). 
Interestingly, RU486 alone actually down-regulated Mmp9 (figure 3.22b). Whilst this 
makes interpretation difficult, it is interesting that rather than having an additive effect, 
dexamethasone no longer had an effect in the presence of RU486. 
In contrast to the genes influenced by dexamethasone, RU486 did not 
antagonise the effect of 5αTHB on Pecam1 and Per1 transcripts (figure 3.33a and b). 
RU486 did decrease Pecam1 transcript expression on its own, complicating the 
interpretation regarding this gene. However it did not alter transcript abundance of 



































Figure 3.22: RU486-mediated antagonism of dexamethasone-mediated changes in gene 
expression in the mouse aorta. RNA was extracted from mouse aortic ring sections, which 
had been treated with stimulus (1% FCS on day 0, followed by 5 ng/ mL VEGF on days 3 and 
5) in combination with either dexamethasone (Dex, 30 nM), the glucocorticoid receptor 
antagonist RU486 (RU, 30 nM), or a combination of the two (RU + Dex). The RNA was reverse 
transcribed into cDNA, and real-time PCR was used to measure transcript abundance of (a) 
Cxcl5, (b) Mmp9, (c) Per1, (d) Hsd11b and (e) Fkbp51. Dex altered transcript abundance of 
all the genes tested. When given in combination with RU486 it no longer altered transcript 
abundance of Cxcl5, Mmp9 and Hsd11b1. RU486 tended (0.05<P<0.1) to antagonise the 
effect of Dex on transcript abundance of Mmp9 (P=0.089), Per1 (P=0.058), Hsd11b1 
(P=0.063) and Fkbp51 (P=0.081). n=11 for stimulus-only treated group, n=8 for Dex, n=6 for 
RU, and n=5 for RU+Dex. Graphs (mean ± SEM) were analysed by one-way ANOVA followed 
by Tukey’s multiple comparisons test, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 vs 
stimulus, ##=p<0.01, ####=p<0.0001 vs Dex. 
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Figure 3.23: RU486-mediated antagonism of 5α-Tetrahydrocorticosterone (5αTHB)-
mediated changes in gene expression in the mouse aorta. RNA was extracted from mouse 
aortic ring sections, which had been treated with stimulus (1% FCS on day 0, followed by 5 
ng/ mL VEGF on days 3 and 5) in combination with either 5αTHB (3 µM), the glucocorticoid 
receptor antagonist RU486 (RU, 30 nM), or a combination of the two (RU + 5αTHB). The RNA 
and was reverse transcribed into cDNA, and real-time PCR was used to measure transcript 
abundance of (a) Pecam1 and (b) Per1. 5αTHB altered transcript abundance of both genes, 
both in the presence and absence of RU486. RU486 alone decreased expression of Pecam1, 
but had no effect on Per1. n=11 for stimulus-only treated group, n=9 for 5αTHB, n=6 for RU, 
and n=5 for RU+5αTHB. Graphs (mean ± SEM) were analysed by one-way ANOVA followed 
by Tukey’s multiple comparisons test, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 vs 






































































































The investigations described in this chapter were designed to assess the 
potential of 5αTHB as a potential novel topical anti-inflammatory treatment. 5αTHB 
had previously suppressed skin inflammation in vivo (Gastaldello, Livingstone et al. 
2017). However the local adverse effects of 5αTHB on the skin had not been fully 
investigated, and the effects of 5αTHB on wound repair were of particular interest. 
GCs are known to inhibit wound repair (Sevilla and Perez 2018). During wound repair 
the migration of keratinocytes, fibroblasts, and endothelial cells is important for 
epithelialisation, to secrete ECM/ close the wound, and for angiogenesis, respectively 
(Lee, Lin et al. 2015, Martin and Nunan 2015). Since each cell regulates a different 
stage of the wound healing process, steroid effects were compared on the migration of 
keratinocyte (HaCaT), fibroblast (dermal fibroblast), and endothelial (HUVEC) cell 
lines, hence providing a good overall broad model. However unexpectedly in this 
assay, migration of these cell lines was unaffected by the positive control 
dexamethasone, the topical glucocorticoid hydrocortisone, and by 5αTHB. One 
exception was a small effect on migration of the HUVEC endothelial cell line by low 
(but not high) doses of hydrocortisone which may be due to effects mediated via MR, 
or alternatively due to assay variability. Endothelial cells are known to express MR, 
and effects through MR may be dominant at lower doses when affinity for GR is low. 
Although MR expression was not tested here it has been reported in HUVECs 
(Oberleithner, Schneider et al. 2003, Yang and Zhang 2004, Logie, Ali et al. 2010). 
However, since the effect was lost at higher doses, and since the average RWD for 
vehicle -treated cells in this assay appears particularly high, the apparent effect is likely 
to result from small differences in the original scratch sizes and in the accuracy of 
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mask formation by the software. The effect could, hence, disappear with increasing 
sample size and could be tested in this way. 
Although migration of keratinocyte migration is described in the literature to 
be GC responsive (Lee, Vouthounis et al. 2005, Vukelic, Stojadinovic et al. 2010, 
Reuter, Loitsch et al. 2012), there are conflicting reports regarding the effect of GCs 
on endothelial cell and fibroblast migration (Huang, Liu et al. 2001, Eming, 
Brachvogel et al. 2007, Drebert, MacAskill et al. 2017). A lack of effect by 
dexamethasone on migration of this particular HUVEC endothelial cell line has been 
reported previously (Huang, Liu et al. 2001, Drebert, MacAskill et al. 2017) whereas 
GCs have inhibited migration of other types of endothelial cell such as porcine aortic 
endothelial cells and rat skeletal muscle microvascular endothelial cells (Fyfe, 
Rosenthal et al. 1995, Shikatani, Trifonova et al. 2012). The effect of GC on 
endothelial cell migration may, therefore, differ between species, due to species-
specific differences in GR. Indeed species differences are already known to exist 
regarding glucocorticoid effects on vascular smooth muscle cell (VSMC) migration, 
which dexamethasone is known to inhibit in rodent, but not in human cells (Pross, 
Farooq et al. 2002).  There are also known to be tissue specific differences in 
endothelial cells, and reports describing the limitations of using HUVECs as a model 
(Jaffe, Nachman et al. 1973, Alby and Auerbach 1984, Nolan, Ginsberg et al. 2013). 
If more time was available perhaps a more relevant cell model would be explored such 
as Human Dermal Microvascular Endothelial Cells (Markiewicz, Panneerselvam et al. 
2016). Interestingly in one of the previous studies in which dexamethasone did not 
suppress HUVEC migration, it did indirectly inhibit migration through a modification 
of the secreted factors from myofibroblasts (Drebert, MacAskill et al. 2017). Therefore 
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another likely reason for the lack of GC effects on endothelial cells in this chapter may, 
therefore, be because the cells were studied in isolation, when actually wound repair 
is a very complex process requiring communication between many cell types. The 
indirect effects of 5αTHB on HUVEC cell migration, may therefore be investigated in 
the future.  
Literature is sparse for the effects of GCs on fibroblast migration. In a previous 
study dexamethasone had no effect on migration of primary human normal dermal 
fibroblasts (Syed, Singh et al. 2013) but inhibited primary human keloid fibroblasts, 
which is interesting because keloids result from excessive fibrosis and are, thus, likely 
to contain more myofibroblasts (Eming, Brachvogel et al. 2007). As mentioned in 
section 1.9.2, fibroblasts differentiate into myofibroblasts during wound healing, 
therefore perhaps myofibroblasts would be a more relevant model. However unlike 
endothelial and fibroblast cells, keratinocyte cell migration is consistently inhibited by 
dexamethasone in the literature, including both the HaCaT cell line (Reuter, Loitsch 
et al. 2012) and primary human keratinocytes (Lee, Vouthounis et al. 2005, Vukelic, 
Stojadinovic et al. 2010). The lack of effect in this current work, therefore, is not in 
agreement with the literature in this case. It may be possible that the assay was not able 
to detect GC- mediated alterations in migration. However EGF positive control 
increased HaCaT migration in this assay consistent with the literature, demonstrating 
that the model was reliable for measuring pharmacological effects to upregulate cell 
migration (Charvat, Chignol et al. 1998, Tochio, Tanaka et al. 2010). Consistent 
positive controls to assess pharmacological manipulation of the fibroblast and 
endothelial cell lines could not be found, and ideally it would have been good to have 
a positive control for each cell type which is a critique I have of the work. Since the 
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cell migration assay was not responsive to even the conventional GCs, the effects of 
5αTHB could not be compared in this ‘broad’ model of wound healing. Instead the 
steroid effects were compared on angiogenesis; one particular stage of the wound 
repair process already known to be inhibited by GCs (Small, Hadoke et al. 2005) .  
Angiogenesis is crucial during wound repair. Since 1983 it has been known 
that GCs suppress angiogenesis (Folkman, Langer et al. 1983) and it is now known 
that even physiological GC concentrations can cause this inhibition (Small, Hadoke et 
al. 2005). The aortic ring assay model of angiogenesis was adopted here which had 
responded to GCs in past work (Small, Hadoke et al. 2005). Considerable intra-assay 
variability was noted in the data generated by this assay, caused by many factors such 
as variations in ring size, ring handling, and also the exact location of the aorta from 
which rings were taken from. However in spite of this variability, dose dependent 
suppression of vessel growth occurred in response to all three steroids 
(dexamethasone, hydrocortisone, and 5αTHB). Hydrocortisone required a 
concentration (1 µM) around 33x the concentration required of dexamethasone (30 
nM) in order to reduce vessel growth significantly. This is broadly consistent with a 
chick embryo chorioallantoic membrane bioassay performed in 1987, in which 
hydrocortisone was reported to be around 25x less angiostatic than dexamethasone 
(Folkman and Ingber 1987). In the current work, 5αTHB was less potent than 
hydrocortisone to suppress vessel growth, with a higher EC50 (2399 nM) in 
comparison to that of hydrocortisone (867 nM) and requiring a higher concentration 
(3 µM) in order for the suppression of vessel growth to reach significance. In a 
previous experiment using the aortic ring assay model, 5αTHB suppressed vessel 
growth at a lower dose than in the current work (1µM; McInnes 2003). However, in 
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that assay the vessel growth was not stimulated by growth factors whereas in my assay 
it was, which was important since during wound repair many growth factors are 
present and are known to initiate the process of angiogenesis. The results from this 
current study, therefore, suggest that 5αTHB is less detrimental to angiogenesis than 
hydrocortisone. In a mouse in vivo model of skin inflammation it has been 
demonstrated that 5αTHB has anti-inflammatory effects equipotent to those of 
hydrocortisone (Yang, Nixon et al. 2011). Combined with the results in this chapter, 
this suggests that 5αTHB would provide a safer topical anti-inflammatory treatment 
than GC, less detrimental to wound repair processes. However, it should be 
acknowledged that these were two separate models. Furthermore, since angiogenesis 
is just one stage of wound repair, additional processes involved in the healing process 
would need to be studied in order to make a definitive conclusion regarding the 
therapeutic profile of 5αTHB. In particular an in vivo mouse model of skin wound 
healing, which is known to be glucocorticoid responsive, would be a suitable approach 
(Duan, Patyna et al. 2006, Xie, Gao et al. 2009).  
In the recent in vivo sponge implantation model of angiogenesis 5αTHB was 
also less detrimental to vessel density than corticosterone, even at high doses 
(Gastaldello, Livingstone et al. 2017). During the wound healing process in vivo, 
inflammation precedes angiogenesis, and inflammatory cells such as neutrophils and 
macrophages are recruited into the wound site (Sinno and Prakash 2013). The growth 
factors and cytokines released from inflammatory cells, in particular from 
monocytes/macrophages, promote angiogenesis (Barrientos, Stojadinovic et al. 2008). 
However the aortic ring assay provides an excellent model for studying the effects of 
glucocorticoids directly on angiogenesis, whilst excluding their indirect effects on the 
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infiltration of inflammatory cells into the wound site. This current work using the 
aortic ring assay therefore expands on the findings of Gastaldello, by demonstrating 
that 5αTHB is also able to suppress angiogenesis through direct effects on the 
vasculature. Other steroids have been reported to suppress angiogenesis independent 
of their ability to reduce cytokine production, and are known as ‘angiostatic’ steroids 
(Hori, Hu et al. 1996). Indeed, in the literature the potencies of steroids in terms of 
their ability to suppress angiogenesis and inflammation do not necessarily appear 
correlated. It should not be ignored that, whilst less potent than hydrocortisone, 5αTHB 
still did induce a clear concentration-dependent suppression of angiogenesis, and this 
may be important physiologically. Importantly, in 1987, angiogenesis was inhibited 
by epicortisol (a stereoisomer of hydrocortisone)(Folkman and Ingber 1987) which 
lacks both GR and MR activity. This is particularly relevant here since there remains 
doubt over whether effects of 5αTHB are mediated through GR. Investigations into 
the mechanisms through which 5αTHB suppresses angiogenesis have been performed 
in this chapter, including mediation through GR. 
As described in 1.7.7.3, the mechanisms through which GCs affect vascular 
function are diverse and are still not completely understood (Small, Hadoke et al. 2005, 
Logie, Ali et al. 2010, Morgan, Keen et al. 2018). It is well known that GCs suppress 
inflammation, and thus indirectly suppress angiogenesis due to the proangiogenic 
cytokines released from inflammatory cells (McSweeney, Hadoke et al. 2010). 
Another indirect mode in which GCs can suppress angiogenesis is through effects on 
the vessel basement membrane, causing degradation of the ECM and affecting cell 
behaviour such as to inhibit endothelial cell migration and proliferation (Drebert, 
MacAskill et al. 2017, Morgan, Keen et al. 2018). Finally there is also evidence that 
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GCs exert direct effects on endothelial cells themselves, remodelling the vasculature 
by altering the ability of endothelial cells to form cell-cell connections (Logie, Ali et 
al. 2010). A functional analysis of next generation RNA sequencing data has recently 
been published to study the effect of hydrocortisone on gene expression changes in the 
mouse aorta. Of 13 KEGG pathways which were down-regulated in cortisol-treated 
aorta, 9 were associated with inflammatory responses and 4 were associated with ECM 
or cytoskeletal function (Morgan, Keen et al. 2018). It was concluded from this study 
that hydrocortisone mainly suppressed angiogenesis through effects on the basement 
membrane ECM (Morgan, Keen et al. 2018). In this chapter, the effects of steroids 
were compared on gene expression involved in ECM remodelling (Col4a1, Mmp9, 
and Col14a1) as well as in inflammatory signalling (Cxcl5, Dusp1, Mcp1, and iNOS), 
and vasculature remodelling (Pecam1, Vcam1). In relation to genes involved in 
inflammation and signalling, dexamethasone and hydrocortisone both caused down-
regulation of Cxcl5, and increased (hydrocortisone) or tended to increase 
(dexamethasone) expression of Dusp1. This is consistent with the effects of 
hydrocortisone on expression of these genes in the published next generation RNA 
sequencing analysis (Morgan, Keen et al. 2018). However, unlike dexamethasone and 
hydrocortisone, 5αTHB had no effect on expression of Cxcl5 and Dusp1 in this work. 
Instead it had a trend to increase Mcp1 expression, whereas dexamethasone and 
hydrocortisone had no effect.  
In relation to genes involved in ECM remodelling, while there was no effect 
on Col14a1, Mmp9 expression was decreased by both dexamethasone and 
hydrocortisone, whereas hydrocortisone increased, and dexamethasone tended to 
increase, Col4a1 expression.  Col4a1 encodes the α1 chain of collagen IV, the main 
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collagen present in the basement membrane surrounding endothelial and vascular 
smooth muscle cells (Vahedi and Alamowitch 2011). Likewise MMP9 (encoded by 
Mmp9) is one of the most commonly studied MMP proteins in blood vessels, where it 
degrades both collagens and gelatins, causing increased migration of vascular 
endothelial cells (Chen, Jin et al. 2013). A decrease in Mmp9 and increase in Col4a1 
is, therefore, consistent with a suppression of angiogenesis. The effects of 
hydrocortisone and dexamethasone here are consistent with the effects of 
hydrocortisone on expression of these genes in the RNA sequencing analysis 
previously published (Morgan, Keen et al. 2018). However, in contrast, 5αTHB had 
no effect on Col4a1 or Mmp9 expression in the mouse aorta in our current study.  
The work presented in this chapter is consistent with reports that 
hydrocortisone suppresses angiogenesis mainly through effects on the ECM and on 
inflammatory signalling (Folkman and Ingber 1987, Morgan, Keen et al. 2018). 
However, the results suggest that 5αTHB does not suppress angiogenesis through these 
same mechanisms. This is in agreement with previous in vivo work using the sponge 
implantation model of angiogenesis, where 5αTHB had more limited effects than 
corticosterone on altering transcript abundance involved in ECM homeostasis, and, in 
contrast to corticosterone, did not decrease collagen staining in sponges (Gastaldello, 
Livingstone et al. 2017). The increase in Mcp1 expression seen here in response to 
5αTHB is also in agreement with the sponge implantation model, where Mcp1 
expression was also increased by 5αTHB but not by corticosterone (Gastaldello, 
Livingstone et al. 2017). Mcp1 stimulates the recruitment of monocytes into tissues, 
and is described to have a key role in the development of an inflammatory response 
(Madrigal, Garcia-Bueno et al. 2010). Interestingly, in our current study 
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dexamethasone had no effect on expression of the genes investigated involved in 
vascular remodelling; whereas 5αTHB decreased, and hydrocortisone had a trend to 
decrease, expression of Pecam1. In the sponge implantation model Pecam1 expression 
was also suppressed by both corticosterone and 5αTHB. Pecam1, also known as CD31, 
is a cell adhesion molecule with pro-angiogenic and pro-inflammatory activity. A cell 
surface glycoprotein, it is expressed by endothelial cells and concentrated mainly at 
sites of cell-cell contact, where it has adhesive properties (Park, Sorenson et al. 2015). 
Pecam1 is also expressed to a lesser extent by platelets and leukocytes, and plays a 
role in the migration of leukocytes through junctions between adjacent endothelial 
cells (Woodfin, Voisin et al. 2007). A decrease in Pecam1 is consistent with reduced 
endothelial cell adhesion, and impaired TLS formation and angiogenesis. Since 
hydrocortisone also had a trend to decrease Pecam1, it could be that both 
hydrocortisone and 5αTHB have another mode of action which dexamethasone does 
not share. This may involve MR since hydrocortisone binds to both MR and GR, 
whereas dexamethasone is GR-specific. A decrease in Pecam1 may indicate that the 
suppression of angiogenesis is mediated by a decrease in endothelial cell adhesion in 
newly forming vessels. Alternatively it may suggest that the endothelial cells are being 
induced to undergo endothelial-to-mesenchymal transition, which is also associated 
with reduced angiogenesis.  
This suggestion that 5αTHB may act through different mechanisms to suppress 
angiogenesis is further supported by the fact that dexamethasone and hydrocortisone 
increased expression of all GR responsive genes tested (Per1, Hsd11b1, and Fkbp51) 
whereas 5αTHB only increased Per1 expression, which can also be increased by MR. 
The GR antagonist RU486 was used to further investigate whether the angiostatic 
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effects of 5αTHB were mediated through GR. RU486 is a competitive GR antagonist 
with a binding affinity for GR 3 times greater than that of dexamethasone, and 10 times 
that of hydrocortisone (Castinetti, Brue et al. 2012, Fleseriu, Biller et al. 2012, Nguyen 
and Mizne 2017). In addition, it also antagonises the progesterone receptor (binding 
affinity more than twice that of progesterone) and the androgen receptor (binding 
affinity less than one third that of testosterone)(Castinetti, Brue et al. 2012, Sun, Fang 
et al. 2014) but does not bind the MR or to the estrogen receptor (Castinetti, Brue et 
al. 2012, Fleseriu, Biller et al. 2012). Out of the two doses of RU486 originally tested 
in this work,  the higher concentration suppressed vessel growth alone, which was not 
entirely unexpected since RU486 also has some agonist activity (Peeters, Ruigt et al. 
2008). The lower RU486 concentration partially-blocked dexamethasone-induced 
suppression of angiogenesis, suggesting that dexamethasone was acting through GR. 
Furthermore when dexamethasone concentration-response curves in the presence and 
absence of RU486 were normalised and superimposed on the same graph, the error 
bars often did not overlap, again suggesting some antagonism, although it did not hold 
true for all data points. In contrast when 5αTHB concentration-response curves, in the 
presence and absence of RU486, were normalised and superimposed, the error bars 
overlapped for every concentration of 5αTHB. This suggests that RU486 did not shift 
the concentration-response curve of 5αTHB, and hence that the suppression of vessel 
growth by 5αTHB was independent of GR. However, these results should be 
interpreted with caution and no firm conclusions can be made as there was a lack of 
power in both the dexamethasone and 5αTHB concentration-response curves in the 
presence of RU486. This was due to poor vessel growth which may have resulted from 
the fact that, in comparison to previous assays, the experiments with RU486 were 
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performed around a year later than the original dose responses where vessel growth 
was much better. Although all medium was used prior to its expiration date, different 
batches may have caused variations in the extent of vessel growth from aortic rings. In 
line with this, the suppression of vessel growth by dexamethasone alone at 100 nM 
(positive control) did not reach significance for either of the 5αTHB or dexamethasone 
concentration–response curves in combination with RU486. This was due to the lack 
of power since when the 5αTHB and dexamethasone data were combined, the 
suppression by dexamethasone at this concentration reached significance. Power 
calculations indicated that this could only be resolved by using a high number of mice. 
Therefore the results from these experiments are only speculative and no firm 
conclusions can be made, both due to the lack of power and the fact that RU486 had 
an effect alone in this assay. Keeping the above limitations in mind, the low dose of 
RU486 (30 nM) was used to assess the role of GR on steroid-mediated alterations in 
gene expression in the mouse aortic rings. The effects on gene expression by 5αTHB 
were not blocked by RU486 and, therefore, may have been mediated through a 
receptor other than GR. This is in agreement with the previous concentration-response 
data.  
In summary, the work presented in this chapter provides further evidence that 
5αTHB is less detrimental to wound repair than current GCs. The work suggests that 
5αTHB is acting through alternative mechanisms than glucocorticoids to suppress 
angiogenesis, perhaps by preventing endothelial cell adhesion in newly forming 
vessels, or by inducing endothelial-to mesenchymal transition (EndMT). Both 
explanations are consistent with a decrease in angiogenesis. Future work will 
investigate whether 5αTHB is able to induce EndMT by assessing its effects on further 
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gene expression related to this process. Crucially, this work suggests that not only does 
5αTHB work through different signalling pathways but also via a distinct receptor. 
Since 5αTHB did influence Per1 transcripts one alternative receptor through which 
5αTHB may act through to suppress angiogenesis is the MR. Future work will address 
this by investigating whether the MR antagonist spironolactone antagonises the effects 






































4. Can 5αTHB act through GR? 
 
4.1. Introduction 
It has been demonstrated that 5αTHB has in vitro and in vivo effects to suppress 
inflammation, and now also to inhibit angiogenesis, although to a lesser extent than 
corticosterone and hydrocortisone (McInnes, Kenyon et al. 2004, Yang, Nixon et al. 
2011). However it has been difficult to determine whether or not these effects are 
mediated in the same way as for classical GCs.  
Of particular interest has been whether the effects of 5αTHB are mediated via 
GR. McInnes et al. showed that corticosterone and 5αTHB were similarly effective in 
displacing tritiated dexamethasone from binding sites in rat hepatocytes, with a Kd in 
the nM range (McInnes, Kenyon et al. 2004). However, it has been difficult to show 
that the anti-inflammatory actions of 5αTHB are GR dependent. In previous work, 
whereas the GR antagonist RU486 prevented 5THB-induced cytokine suppression 
in LPS-stimulated RAW264.7 cells (Nixon, M ,2011), it actually increased inhibition 
induced by 5αTHB in LPS-stimulated murine bone marrow-derived macrophages 
(BMDM)(Gastaldello, 2014; Yang, 2009). Later work revealed that RU486 alone 
suppressed cytokine release, making RU486 a poor tool for these studies (Gastaldello, 
2014). In vivo RU486 given systemically, antagonised the suppression of dermatitis 
by topical administration of corticosterone in mice but did not attenuate the anti-
inflammatory effects of 5THB (Gastaldello, Livingstone et al. 2017). Additional 
experiments are, therefore, required to address the question of whether the anti-
inflammatory effects of 5αTHB are GR mediated. 
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Although a simplified model, the classical mechanism by which GCs are 
reported to work is by binding to GR and stimulating its translocation into the nucleus, 
where ligand bound GR regulates the expression of target genes through direct DNA 
binding (mechanism a in figure 1.4). Ligand-dependent co-regulator proteins become 
recruited to GR during this process to assist with DNA binding. Alternatively GR may 
tether to other transcription factors and modulate their activity (mechanism d in figure 

















The conclusion in chapter 3 is that 5αTHB acts on the vasculature through different 
mechanisms from conventional glucocorticoids. It is thought that perhaps 5αTHB 
binds to GR to target alternative mechanisms to those targeted by the glucocorticoids 
currently in use. Therefore, the hypothesis tested by the work described in this chapter 
is that 5αTHB acts through GR but with alternative downstream effects. In particular, 
the sub-hypotheses tested here are that: 
1. 5αTHB is able to bind GR. 
2. 5αTHB can cause nuclear translocation of GR. 
3. 5αTHB can stimulate co-regulator peptide recruitment to GR. 
4. The anti-inflammatory effects of 5αTHB are dependent on GR. 
 
4.3. Aims 
The aim is to use model systems to investigate whether 5αTHB can stimulate the above 
GR mechanisms. The individual aims are to: 
1. Assess whether 5αTHB is able to displace selective GR ligands from the 
isolated human GR ligand binding domain (hGR LBD). 
2. To quantify nuclear translocation of human GR after treatment with 5αTHB in 
A549 cells. 
3. To compare effects of 5αTHB and dexamethasone on co-regulator peptide 
recruitment to the isolated hGR LBD. 
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4. Investigate whether GR knockdown prevents 5αTHB suppression of 





















4.4.1. Comparing steroid ability to bind GR 
Steroid binding to human GR ligand binding domain (hGR LBD) was 
measured using a PolarScreen Glucocorticoid Receptor Competitor Assay Kit (Fisher 
Scientific, Loughborough, UK) as described in 2.2.6. This was performed by the Drug 
Discovery core (College of Medicine and Veterinary Medicine, University of 
Edinburgh). For each steroid a concentration-response was performed, using 
concentrations of 0.5, 1, 5, 10, 50, 100, 500 and 1000 nM for dexamethasone, 0.5, 1, 
5, 10, 50, 100, 500, 1000, 5000 and 10000 nM for hydrocortisone, and 5, 10, 50, 100, 
500, 1000, 5000 and 10000 nM for 5αTHB.  
 
4.4.2. Assessment of 5αTHB ability to induce GR nuclear translocation 
A549 cells were chosen for the study of GR nuclear translocation due to the fact that 
they had also been used previously by Gastaldello (2014) to investigate whether 
5αTHB induces phosphorylation of the GR Serine 211 residue. Phosphorylation of GR 
at this residue is associated with GR nuclear translocation; therefore for completeness 
the work was performed in the same cell type. 
In order to investigate GR nuclear translocation, two alternative methods were 
evaluated: ‘Immunofluorescence’ and ‘Nuclear/Cytoplasmic (N/C) separation’. 
 
4.4.2.1. Immunofluorescence method 
The immunofluorescence protocol described in (2.2.2.3) was followed to visualise GR 
in A549 cells and to qualitatively and quantitatively assess the effects of steroids on 
GR nuclear translocation. Cells were treated in duplicate on days 3 (for 24 hour 
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treatment) and 4 (30 minute treatment) with dexamethasone (positive control; 100 nM) 
or 5αTHB (1, 3 or 10 μM).  The negative control consisted of either vehicle (ethanol, 
1 µL per 1 mL) or no treatment. The primary antibody was either GR sc-8992 or sc-
1003 (both 1/150 dilution in PBS) in combination with Goat-anti-rabbit 
AlexaFluor488 or AlexaFluor555 conjugate secondary antibody (Thermo scientific, 
1/800 dilution in PBS, 100μL, 2h, dark, RT). Negative controls were also performed 
with no primary antibody, no secondary antibody, or in the absence of both primary 
and secondary antibodies, as described in (4.4.3.1), to check for non-specific antibody 
binding and cell autofluorescence.  
 
4.4.2.2. Nuclear/Cytoplasmic separation method 
A549 cells were plated 350000 cells/ well in 6 well plates (day 1) and treated in 
triplicate on days 3 (24 hour treatment) and 4 (6 hours and 30 minute treatment). 
Treatment consisted of vehicle (ethanol, 1 µL per 1 mL; negative control), 
dexamethasone (positive control; 100 nM) or 5αTHB (1, 3 or 10 μM). Separate nuclear 
and cytoplasmic protein was then extracted from the cells and its concentration 
measured according to the protocols described in (2.2.2.1.3) and (2.2.2.1.4). The 
amount of GR was then quantified and compared between the two fractions using 
Western blot, as described in (2.2.2.1.5). The primary antibody for GR visualisation 
by Western blot was sc-1003; however, during optimisation sc-8992 and sc-1004 were 
also tested (all 1/500 dilution). Both sc-1003 and sc-8992 had previously been used 
my members of our group, and sc-1004 had been recommended to give clear GR bands 
by another group, although they were not using human tissue. Primary antibodies for 
GRB2 (sc-255) and PARP (BD Pharmingen, 556494) were used as nuclear and 
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cytoplasmic controls respectively (2 hours, RT, 1/1000 dilution) since they are only 
expressed in either the nucleus or cytoplasm respectively so could confirm the clear 
separation of the two fractions. Secondary antibodies used were either Goat Anti-rabbit 
(926-32211) or Goat Anti-mouse (926-32210)(both Licor Biosciences, 1/10000 
dilution) diluted in a milk solution (5% w/v in TBS-T). Finally, protein was detected 
on the membrane using fluorescence method as described in (2.2.2.1.7.1).  
 
4.4.3. Assessment of 5αTHB effects on coregulator peptide recruitment to GR. 
PamGene’s MARCoNI assay was used as described in (2.2.5) to compare the effects 
of dexamethasone (1 μM) or 5αTHB (1 μM) on co-regulator peptide recruitment to the 
isolated GR GST-tagged ligand binding domain (GR-LBD-GST, 10 nM, AB vector, 
San Diego, CA). Experiments were performed using  n=3. 
4.4.4. Comparing the effects of steroids on cytokine release from mouse bone 
marrow-derived macrophages 
Primary BMDM were freshly isolated from mouse tibia and femur bones, and 
then plated as described in section 2.1.4.2. Cells were treated 24 hours later with either 
hydrocortisone (at concentrations of 10, 30, 100, 300 or 1000 nM) or 5αTHB (at 
concentrations of 100, 300, 1000, 3000 or 10000 nM). Since there were not enough 
cells per mouse to treat in duplicate, cells were treated in singlicate. One hour after 
steroid treatment the cells were then stimulated with LPS (either 3 or 100 ng/mL; 
lipopolysaccharides from Escherichia coli, Sigma). A vehicle control was included 
which consisted of cells treated with ethanol and PBS in place of steroid and LPS, 
respectively. In addition, a stimulus control was performed which had ethanol (1 µL 
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per 1 mL) in place of steroid but was still stimulated by LPS (either 3 or 100 ng/mL). 
24 hours after LPS stimulation (or control treatment) medium was collected, and 
frozen at -20 °C for quantification of IL6 or TNFα cytokines by ELISA, performed as 
described in 2.2.2.2. ELISA standard curves were accepted with relative standard 
deviations (RSD) within 15%. 
 
4.4.5. Data analysis 
Data produced using methods 4.3.1 and 4.3.3.2 were analysed using GraphPad Prism6 
software and presented as mean with error bars representing the standard error of the 
mean (SEM). Data were analysed by one-way ANOVA and comparisons made using 
Dunnett’s multiple comparisons test. To fit the concentration-response curves, a non-
linear regression analysis was performed using the log (inhibitor) vs response (three 












4.5.1. Does 5αTHB displace selective GR ligands from the isolated GR ligand 
binding domain? 
A model GR expression system was used in order to assess whether 5αTHB is 
able to displace selective GR ligands from the isolated GR LBD (figure 4.1). 
Dexamethasone and hydrocortisone both decreased the fluorescence polarisation of 
the GR-selective ligand, with EC50 values of 0.00421 μM and 0.019 μM, respectively. 
5αTHB, however, only displaced the selective GR ligand to a very limited extent, and 












Figure 4.1: 5αTHB only competed for binding to the glucocorticoid receptor (GR) ligand 
binding domain (LBD) at high concentrations. A competitor assay was performed using 
the isolated GR LBD and a fluorescent ligand selective for the GR LBD. Dexamethasone and 
hydrocortisone both displaced the fluorescent ligand from GR, with EC50s of 0.00421 µM and 
0.019 µM, respectively. 5αTHB however did this only to a very small extent at high 
concentrations. Its EC50 was 480 µM. Data are mean ± SEM of n=3.  
 






4.5.2. Does 5αTHB translocate GR into the nucleus? 
In order to investigate nuclear translocation of GR two alternative methods, 
‘immunofluorescence’ and ‘Nuclear/Cytoplasmic (N/C) separation’, were evaluated 
to determine receptor localisation. 
4.5.2.1. Immunofluorescence method development 
As a preliminary screen, the immunofluorescence protocol and quantification 
procedure (described in 2.2.2.3) was performed in A549 cells either treated with 
ethanol vehicle, 5αTHB (1, 3 or 10 µM) or dexamethasone (positive control; 100 nM). 
Images of slides are given in figure 4.2 and graphs of quantification to assess nuclear 
translocation in figure 4.3. At all time-points (30 minutes, 6 hours and 24 hours) the 
quantification score for dexamethasone-treated cells was higher than for cells treated 
with vehicle, although only slightly and this was not significant. However, it is evident 
from the score, and also from visual inspection, that vehicle-treated cells already had 
high signal in the nucleus. This background signal created difficulties in measuring an 
increase in score after dexamethasone treatment, and, hence, the causes of this high 





























Figure 4.2: Representative images from a preliminary immunofluorescence screen of 
the effects of dexamethasone (dex, 100 nM) and 5αTHB (1µΜ, 3μM or 10μM) to cause 
GR nuclear translocation in serum-starved A549 cells. DAPI stain indicates cell nuclei, 
and GR is visualised by secondary detection of a GR antibody (in green). Additionally, overlay 
of the images is shown. White arrows highlight examples of nuclei with increased signal after 
dexamethasone treatment, indicating increased nuclear GR translocation. However, a high 
level of background signal in the nucleus is already present in control vehicle-treated slides. 
Examples of cells with high background signal are circled. Nuclear signal is also evident in 
5αTHB-treated cells, although this is less pronounced than in dexamethasone-treated cells. 



































Figure 4.3: Quantification of a preliminary immunofluorescence screen of the effects of 
dexamethasone (Dex, 100 nM) or 5αTHB (1µΜ, 3μM or 10μM) on GR nuclear 
translocation in serum-starved A549 cells. Quantification was originally performed using 
the following scoring method: 5: much more fluorescence signal in the nucleus (N) in 
comparison to cytoplasm (C) (N<<C), 4: more fluorescence signal in the N in comparison to C 
(N<C), 3: an equal amount of fluorescence signal in the N and C; N=C, 2: more fluorescence 
signal in the N than the C (N>C) and 1: much more fluorescence signal present in the N in 
comparison to the C (N>>C). Dexamethasone (positive control) only produced a slightly higher 
score in comparison to vehicle at all time-points. However, high nuclear background meant 
that vehicle-treated cells already had a high score; consequently, the dynamic range between 
vehicle and positive control was small.
































































































































Decreased background had already been achieved in Western blots using an 
alternative antibody (sc-1003) in comparison to sc-8992. These two antibodies were, 
therefore, compared using the current immunofluorescence protocol (figure 4.4). 
However, with both antibodies the score remained high for vehicle-treated cells. 
Furthermore, the background signal remained even in the absence of primary antibody. 
This can be visualised in figure 4.5a, in which in the green channel, cell nuclei can be 
seen in the absence of primary antibody. In further negative controls with no secondary 
antibody (figure 4.5c, green channel) and in the absence of both primary and secondary 
antibody (figure 4.5d, green channel) the fluorescence signal persisted. This eliminated 
the possibility of non-specific antibody binding, and hence suggested that the 
background was caused by auto-fluorescence from the cells themselves. Interestingly, 
no fluorescence was evident when live cells were viewed down the microscope before 
being fixed (figure 4.6). This was indicative of the fixing procedure causing the 
fluorescence. To avoid auto-fluorescence in the green emission spectrum, an 
alternative secondary antibody with a fluorophore which emits in the red emission 
spectrum (Fluorophore red 555) was compared with that previously used (Fluorophore 
green 488). In contrast to the green emission spectrum, auto-fluorescence from cell 
nuclei was not visible in the red channel in the absence of secondary antibody (figure 
4.5c and 4.5d). Quantification supported these improvements: a lack of signal in the 
red emission spectrum in the absence of secondary antibody meant that no score could 
be given to cells (figure 4.7d) in contrast to when viewed in the green emission 
spectrum where a score could still be given (figure 4.7c). It is evident from controls 
with no primary antibody that there was some non-specific binding of both the green 
and the red secondary antibodies, as a score could be given to the cells in both cases 
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(figures 4.7a and b). However, in the green channel there was additional nuclear 
background signal (figure 4.5a, green channel) leading to a score > 3 for vehicle-
treated cells (figure 4.7a), whereas in the red channel there was no extra background 
signal in the nucleus – just a general background fluorescence signal equally dispersed 
in the image (figure 4.5b, red channel), leading to a score < 3 for vehicle treated cells 










































Figure 4.4: Immunofluorescence optimisation: Comparing background signal and 
dynamic range between two primary antibodies. A549 cells were serum starved and then 
treated with vehicle (ethanol, 1 µL per 1 mL) alone or combined with dexamethasone (Dex, 
100 nM) for 24 hours. The cells were then fixed and stained for immunofluorescence analysis, 
using primary antibody combined with a green (G) fluorescent secondary antibody. 
Fluorescence was quantified in each cell according to the extent of fluorescent signal between 
the nucleus (N) and cytoplasm (C). Possible scores were 5 (N>>C), 4 (N>C), 3 (N=C), 2 (N<C) 
and 1 (N<<C). High background was evident previously using the sc-8992 antibody (a). An 
alternative antibody, sc-1003, (b) was compared in an attempt to reduce background signal in 
vehicle-treated cells. However, the background signal remained, and the vehicle-treated cells 
continued to have high scores. As a result the difference in score between vehicle- and 
dexamethasone-treated cells remained small. Furthermore, even with no primary antibody a 
fluorescence signal was evident. Single experiment; data are an average of 10 cells per image, 
from 5 images per slide, in duplicate. 
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Figure 4.5: Negative immunofluorescence controls demonstrate auto-fluorescence 
from fixed A549 cells in the green emission spectrum. A549 cells were serum starved, 
treated with vehicle, and then fixed for immunofluorescence analysis. Background signal in 
cell nuclei was evident in controls minus primary antibody (a, green channel) suggesting 
unspecific secondary antibody binding. In further controls with no secondary antibody (c) and 
with neither primary nor secondary antibody (d) signal was still evident from cell nuclei in this 
channel, indicating auto-fluorescence in the green emission spectrum. White arrows indicate 
areas with high background signal. Using an alternative secondary antibody emitting in the red 
emission spectrum, background signal was not evident in cell nuclei (b, red channel). 
Therefore, in contrast, fixed A549 cells do not auto-fluoresce in the red emission spectrum and 





DAPI Red Channel Green Channel 
(a) Vehicle,       
Minus 1° Antibody, 
Green 2° Fluorophore. 
(b) Vehicle,       
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(d) Vehicle,       













Figure 4.6: Unfixed A549 cells do not auto-fluoresce in the green or red emission 
spectra. Live A549 cells were viewed under a microscope before the fixing and 
immunofluorescence analysis procedure. Fluorescence signal was studied from both the 

























Figure 4.7: Paraformaldehyde-fixed A549 cells auto-fluoresce in the green, but not the 
red, emission spectra. Immunofluorescence analysis of vehicle (ethanol, 1 µL per 1 mL)-
treated serum-starved A549 cells was performed in the absence of primary antibody, to assess 
non-specific binding of green (a) and red (b) emitting secondary antibodies. Auto-fluorescence 
in each emission spectrum was also assessed by the absence of secondary antibody. In the 
absence of primary antibody a fluorescence signal remained in both the green (a) and red (b) 
emission spectra, indicating non-specific binding of the secondary antibody. In the absence of 
secondary antibody, fluorescence signal persisted in the green emission spectra (c) but not 
the red (d). Vehicle groups indicate the presence of both primary and secondary antibodies. 
Single experiment, data are average of 10 cells per image, from 5 images per slide, in 
duplicate.  
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Following improvements gained from viewing the slides in the red emission 
spectrum, the immunofluorescence analysis was re-performed using the red 555 
secondary antibody to compare vehicle- and dexamethasone-treated cells. 
Experiments with the green 488 secondary antibody were performed alongside for 
comparison. As seen previously in the red emission spectrum, in the absence of red 
555 secondary antibody (figures 4.8a and c, red channel) no cell nuclei could be 
visualised. Again this is in contrast to the green emission spectra in which cell nuclei 
could be seen auto-fluorescing in the absence of the green secondary antibody (figures 
4.8b and d, green channel). In addition to the autofluorescence, the signal in the green 
channel in figure 4.8d may have also arisen (to some extent) from overlap of emission 
spectra between the green and red secondary antibodies, demonstrated in figure 4.8e. 
Using a far red fluorophore with an emission spectrum further from the green 
wavelength could help to resolve this; however this was not attempted since despite 
the qualitative improvements, when quantified the dynamic range between vehicle- 
and dexamethasone-treated cells was still very narrow (figure 4.9a and b). 
A continuous quantification method, whereby the fluorescence signal is measured by 
ImageJ, was used (figure 4.9c and d) to re-quantify the assessment of positive controls, 
in a final attempt to widen the dynamic range. No major improvements were seen in 
comparison to the scoring method (figures 4.9a and b). Therefore, it was decided to 























Figure 4.8: Qualitative assessment of GR nuclear translocation in fixed A549 cells was 
improved using the red emission spectra for immunofluorescence analysis in 
comparison to green. A549 cells were serum starved and then treated for 24 hours with 
vehicle (ethanol, 1 µL per 1 mL) (a, b) or dexamethasone (100 nM, positive control) (c, d). The 
cells were then fixed and analysed using immunofluorescence. Secondary antibodies 
absorbing in the green emission spectra (green 2⁰ antibody; a and c) and red emission spectra 
(red 2⁰, b and d) were compared. Cell nuclei auto-fluoresced in the green channel (b and d, 
green channel) whereas they did not in the red channel (a and c, red channel).  This meant 
that there was a larger dynamic range between immunofluorescence of vehicle- and 
dexamethasone-treated cells when viewed using the red channel (b and d, respectively, red 
channel) than when viewed using the green channel (a and c, respectively, green channel). 
The signal in the green channel in (d) may arise from a combination of autofluorescence and 
the overlap between emission spectra for the green Alexafluor®488 and red Alexafluor®555 
conjugate secondary antibodies (shown in e).  
DAPI Red Channel Green Channel 
(a) Vehicle,        
Green Fluorophore. 
(b) Vehicle,           
Red Fluorophore. 



























Figure 4.9: Quantitative comparison between immunofluorescence analysis in red and 
green emission spectra, and of two different quantification methods. The dynamic range 
between dexamethasone positive control and vehicle immunofluorescence was narrow after 
analysis in both the green (a) and red (b) emission spectra when quantified using the scoring 
method. An alternative ImageJ quantification (c and d) of the corrected total cell fluorescence 
(CTCF) was investigated to improve the dynamic range. Single experiment, data are average 
of duplicate slides, and of 5 images per slide. For (a) and (b) the average score was taken for 
10 cells per image. 
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4.5.2.2. N/C separation method development 
High background was evident in the initial Western blot performed using the sc-8992 
antibody (figure 4.10a). Alternative antibodies and detection methods were, therefore, 
compared (figure 4.10b and c). Sc-1004 gave non-specific bands and, therefore, sc-
1003 was chosen as the preferred antibody, giving clear GR bands at the correct size, 
95kDa. Using this antibody both chemiluminescence (figure 4.10b) and fluorescence 
(fig 4.10c) detection methods gave the clear specific band at 95kDa. However, since 
fluorescence detection has a broader dynamic range for quantitative measurement, this 
was the method selected (Quantitative, Two- Color Western Blot Detection With 




































Figure 4.10: Method development for Western blot. Primary antibody optimisation followed 
the initial Western blot where sc-8992 antibody gave high background signal (a). This antibody 
was subsequently compared with alternative primary antibodies sc-1004 and sc-1003 using 
both chemiluminescence (b) and Licor fluorescence (c) detection methods. Sc-1004 gave non-
specific bands whereas sc-1003 produced clear GR bands at 95kDa, with only a small level 
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4.5.2.3. Assessment of GR translocation using the N/C separation technique 
4.5.2.3.1. Data analysis 
Nuclear (PARP) and cytoplasmic (GRB2) loading controls indicated successful 
separation of nuclear and cytoplasmic fractions from A549 cells (figure 4.11). Since 
the two fractions had different loading controls, the raw GR intensities were used to 
calculate N/C values, rather than intensities normalised to a loading control. For this 
reason n=6 was attempted as an initial sample size in order to account for any 
variations in sample loading.  
4.5.2.3.2. Assessment of controls 
Dexamethasone (100 nM, positive control) significantly increased the N/C ratio in 
comparison to vehicle (negative control) at all time-points (figure 4.12), indicating 
increased GR nuclear translocation. This was also evident from visual inspection and 
was seen more easily in the cytoplasmic fraction, as a less intense GR band for 
dexamethasone-treated samples (figure 4.11).  
4.5.2.3.3. Assessing GR translocation in response to 5αTHB 
The N/C ratio for cells treated with 5αTHB (at doses of 1, 3 and 10 µM) was not 
different from vehicle-treated cells at any time point (figure 4.12). 5αTHB gave a 
significantly smaller N/C ratio than dexamethasone at all doses and time points. This 
suggests that GR remained predominantly in the cytosol. Again this was supported 








Figure 4.11: GR nuclear translocation occurred after dexamethasone (Dex) but not 5α-
tetrahydrocorticosterone (5αTHB) treatment. A549 cells were cultured in serum-containing 
medium for 48 hours and then treated for 30 minutes, 6 hours or 24 hours with vehicle (ethanol, 
1 µL per 1 mL), Dex (100nM), or 5αTHB (1, 3 or 10µM). Nuclear and cytoplasmic protein 
fractions were then separated and the amount of GR compared between treatments using 
Western blot. Clear nuclear/cytoplasmic separation was achieved as seen by PARP and 
GRB2 restricted to nuclear and cytoplasmic fractions respectively. Cytoplasmic GR bands of 
Dex treated cells were less intense at all time points (in comparison to vehicle) indicative of 
GR nuclear translocation. Differences were not apparent with any dose of 5αTHB. Images are 

































Figure 4.12: Dexamethasone caused glucocorticoid receptor (GR) translocation into the 
nucleus, whereas 5α-tetreahydrocorticosterone (5αTHB) did not. A549 cells were 
cultured in serum-containing medium for48 hours and then treated for 30 minutes (a), 6 hours 
(b) or 24 hours (c) with vehicle (ethanol, 1 µL per 1 mL), dexamethasone (Dex, 100 nM), or 
5αTHB (1, 3 or 10µM). Nuclear and cytoplasmic protein fractions were then separated and the 
amount of GR compared between treatments using Western blot. GR band intensities were 
quantified and nuclear/cytoplasmic (N/C) ratios assessed. At all time-points the N/C ratio was 
increased by dexamethasone relative to vehicle control. 5αTHB, however, did not influence 
the N/C ratio at any concentration or time point. Data are mean ±SEM of n=6. Data were 
analysed by one-way ANOVA and comparisons made using Dunnett’s multiple comparisons 
test. **=P<0.01, ****=P<0.0001 vs vehicle control. ##=P<0.01, ###=P<0.001, ####=P<0.0001 
vs Dex.
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4.5.3. Does 5αTHB induce co-regulator peptide recruitment to the GR ligand-
binding domain? 
Dexamethasone (1 µM, positive control) caused clear increases and decreases in the 
interaction between GR and many of the co-regulator peptides investigated (right 
panel, figure 4.13). 5αTHB (1 µM) however did not affect the interaction between GR 








































Figure 4.13:  5αTHB did not stimulate co-regulator peptides to interact with the 
glucocorticoid receptor ligand binding domain (LBD). PamGene’s Microarray Assay for 
Real-time Coregulator-Nuclear Receptor Interaction (MARCoNI) was used to compare the 
effects of 5αTHB (1 µM) or dexamethasone (1 μΜ) on co-regulator recruitment to the GR 
ligand-binding domain (LBD). The heat map demonstrates increases (in red) and decreases 
(in blue) in interactions between GR with each co-regulator peptide studied. In contrast to 
5αTHB, dexamethasone induced clear changes in co-regulator recruitment, consistent with its 
effects to bind GR, stimulate GR-DNA binding and alter gene expression. Comparisons 
relative to control (dimethyl sulfoxide) were made using Student’s unpaired t-tests. Correction 
for multiple testing was performed using the Benjamin and Hochberg method. *=P<0.05, 
**=P<0.01, ***=P<0.001 V Control. 
5α      Dex 5α      Dex 
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4.5.4. Does 5αTHB mediate its anti-inflammatory effects through GR? 
In previous work 5αTHB suppressed IL6 release from murine BMDM (Yang, 
Nixon et al. 2011). However, the GR antagonist RU486 was shown to be a poor tool 
to assess whether this suppression of cytokine release by 5αTHB was mediated 
through GR. Therefore, as an alternative, we designed a GR knockdown experiment, 
in the same cell type, to assess whether GR knockdown would prevent the suppression 
of cytokine release by 5αTHB. First for comparison, hydrocortisone and 5αTHB 
concentration-response curves were performed in order to determine the IC50 for 
steroid-induced suppression of cytokine in the presence of GR, before the knockdown 
was carried out.  
4.5.4.1. ELISA Quality control 
 ELISA was used to measure cytokine levels in cell media. Quality control 
samples were not provided by the manufacturer’s kits, and insufficient BMDM cells 
were available from individual mice to produce quality control samples for comparison 
between each experiment. However, the RSD was calculated for each data point on 
the IL6 and TNFα standard curves, and curves were only accepted with RSDs within 






















Figure 4.14: ELISA standard curves for measuring IL6 and TNFα cytokine 
concentrations. Standard curves were accepted when the relative standard deviation (RSD) 
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4.5.4.2. Effects of steroid to suppress IL6 release from BMDM stimulated with 
100 ng/mL LPS. 
Originally, mouse BMDM were stimulated with 100 ng/mL LPS. This 
concentration was chosen based on the work of Gastaldello (2014) and Yang (2009), 
who successfully suppressed IL6 release from mouse BMDM using glucocorticoid. In 
an initial experiment N=4 was achieved; however, using the raw data there was not a 
significant increase in IL6 concentration in cell media after stimulation with 100 
ng/mL LPS (figure 4.15a). Furthermore, a significant concentration-dependent effect 
of HC treatment was not observed (overall P=0.65), although this was likely due to 
variability. In order to account for inter-assay variability, the data in each individual 
experiment was normalised to the IL6 concentration present in the media of LPS-only 
treated cells (figure 4.15b). This normalisation was successful in decreasing the 
variability, and after normalisation the differences in IL6 concentrations between 
groups were significant (overall P=0.0001). From the normalised data it was evident 
that LPS did successfully stimulate an inflammatory response from the cells, as there 
was a significant increase in the IL6 release in comparison to vehicle-only treated cells. 
Hydrocortisone induced a concentration-dependent suppression of this IL6 release. 
Suppression was seen from concentrations greater than 300 nM, and complete 
suppression was achieved by 1 µM. A concentration-response curve was plotted 
(figure 4.15c) from which it was calculated that the IC50 for suppression was 151.7 
nM. However, in contrast to hydrocortisone, and to the work performed previously 
(Yang, Nixon et al. 2011), 5αTHB did not suppress IL6 release from BMDM after 






















Figure 4.15: In murine bone marrow-derived macrophages (BMDM) stimulated with 100 
ng/mL LPS, hydrocortisone (HC) induced a concentration-dependent suppression of 
IL6 release whereas 5αTHB did not. BMDM were treated with lipopolysaccharide (LPS; 100 
ng/mL) to stimulate an inflammatory response, or with ethanol vehicle (V, 1 µL per 1 mL) as a 
negative control. One hour prior to this the cells had been primed with either vehicle (ethanol) 
(LPS), a HC concentration between 10 nM and 1000 nM, or a 5αTHB concentration between 
100 nM and 10000 nM. The cells were incubated for 24 hours, and then their media removed 
for measurement of IL6 concentration by ELISA. The concentration of IL6 released from 
BMDM after each treatment was plotted as a bar chart (a). LPS increased the concentration 
of IL6 released from BMDM. Hydrocortisone induced a concentration-dependent suppression 
of this IL6 release, achieving a significant suppression at a concentration of 1000 nM in 
comparison to LPS-stimulated cells which were not exposed to HC. 5αTHB did not have an 
effect on IL6 release. Concentration-response curves were plotted to show the effects of HC 
(b) and 5αTHB (c) on IL6 release. The IC50 for HC-induced suppression of IL6 release was 
determined as 151.7 nM. Data are mean ± SEM of n=4. Data were analysed by one-way 
ANOVA and comparisons made using Dunnett’s multiple comparisons test; ***=P<0.001, 
**=P<0.01, *=P<0.05 vs V. #=P<0.05 vs LPS.
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4.5.4.3. The effects of steroids on suppression of IL6 release from BMDM 
stimulated with 3 ng/mL LPS. 
Although 100 ng/mL was the LPS concentration used previously by 
Gastaldello (2014) and Yang (2009), a more significant suppression of IL6 with 
5αTHB was seen when the cells were stimulated with a lower concentration of LPS; 
the most significant suppression was seen with an LPS concentration of 3 ng/mL in 
the work of Gastaldello (2014), and with an LPS concentration of 10 ng/mL in the 
work of Yang (2009). Therefore, it was thought that perhaps 100 ng/mL LPS was too 
high a concentration, and that, after this stimulation, 5αTHB is no longer able to 
suppress IL6 cytokine release. It was, therefore, decided to stimulate mouse BMDM 
with a lower dose of LPS (3 ng/mL), and increase groups to n=8 in order to account 
for the variability seen in preliminary experiments (figure 4.16). 
After stimulation of BMDM with 3 ng/mL LPS, the concentration of IL6 
released from cells was again increased in comparison to vehicle– treated cells (figure 
4.16a). Hydrocortisone induced a concentration-dependent suppression of IL6 release, 
with an IC50 of 167 nM (figures 4.16a and b). Again, suppression was seen at 
concentrations of 300 nM and above, this time also achieving complete suppression 
with 300 nM. However, 5αTHB did not suppress the release of IL6 from BMDM 

























Figure 4.16: In mouse bone marrow-derived macrophage cells (BMDM) stimulated with 
3 ng/mL LPS, hydrocortisone (HC) induced a concentration-dependent suppression of 
IL6 release whereas 5αTHB had no effect. BMDM were treated with lipopolysaccharide 
(LPS; 3 ng/mL) to stimulate an inflammatory response, or with vehicle (V) as a negative 
control. One hour prior to this the cells had been primed with either vehicle (ethanol) (LPS), a 
HC dose between 10 nM and 1000 nM, or a 5αTHB dose between 100 nM and 10000 nM. 
The cells were incubated for 24 hours, and then their media removed for measurement of IL6 
concentration by ELISA. The concentration of IL6 released from BMDM after each treatment 
was plotted as a bar chart (a). LPS increased the concentration of IL6 released from BMDM. 
Hydrocortisone induced a concentration-dependent suppression of this IL6 release, achieving 
a significant suppression at a concentration of 300 nM in comparison to stimulated cells which 
were left untreated. 5αTHB did not have a significant effect on IL6 release. Concentration-
response curves were plotted to show the effects of HC (b) or 5αTHB (c) on IL6 release. The 
IC50 for HC-induced suppression of IL6 release was determined as 167 nM. Data are mean 
± SEM of n=8. Data were analysed by one-way ANOVA and comparisons made using 
Dunnett’s multiple comparisons test; ***=P<0.001, **=P<0.01, *=P<0.05 vs V. #=P<0.05 vs 
LPS. 




































































































































4.5.4.4. Steroid-induced suppression of TNFα release from BMDM 
stimulated with 3 ng/mL LPS. 
5αTHB not only suppressed IL6 release from BMDM in previous work, but 
also TNFα release (Yang, Nixon et al. 2011). Therefore, since the suppression of 
IL6 could not be recapitulated in this work, the ability of 5αTHB to suppress TNFα 
release from the same cells was also assessed. 
As with experiments investigating release of IL6, stimulation with 3 ng/mL 
LPS caused a significant increase in TNFα release from BMDM in comparison to 
unstimulated cells (figure 4.17a). Hydrocortisone induced a concentration-
dependent suppression of this stimulated TNFα release with an IC50 of 313 nM 
(figures 4.17a and b). Complete suppression was observed with concentrations of 
300 nM and above. 5αTHB however, did not significantly suppress TNFα release 
in comparison to stimulated controls at any concentration tested (figures 4.17a and 
c). A small effect was evident at the highest concentration of 5αTHB (1000 nM) 
which caused a significant decrease in TNFα released from cells in comparison to 
the lowest concentration (100 nM). However, since there was no difference in 
comparison to stimulated controls, and since no significant difference between 
these two concentrations of 5αTHB was evident in the previous IL6 concentration-

























Figure 4.17: In mouse bone marrow-derived macrophages (BMDM) stimulated with 3 
ng/mL LPS, hydrocortisone (HC) induced a concentration -dependent suppression of 
TNFα release, whereas 5αTHB had no effect. BMDM were treated with lipopolysaccharide 
(LPS; 3 ng/mL) to stimulate an inflammatory response, or with vehicle (V) as a negative 
control. One hour prior to this the cells had been primed with either vehicle (ethanol) (LPS), a 
HC concentration between 10 nM and 1000 nM, or a 5αTHB concentration between 100 nM 
and 10000 nM. The cells were incubated for 24 hours, and then their media removed for TNFα 
concentration measurement by ELISA. The concentration of TNFα released from BMDM after 
each treatment was plotted as a bar chart (a). LPS increased the concentration of TNFα 
released from BMDM. Hydrocortisone induced a concentration--dependent suppression of this 
TNFα release, achieving significance at 1000 nM in comparison to stimulated cells which were 
left untreated. 5αTHB did not have a significant effect on TNFα release. Concentration-
response curves were plotted to show the effects of HC (b) or 5αTHB (c) on TNFα release. 
The IC50 for HC-induced suppression of TNFα release was determined as 313 nM. Data are 
mean±SEM of n=10. Data were analysed by one-way ANOVA and comparisons made using 
Dunnett’s multiple comparisons test; ****=P<0.0001, *=P<0.05 vs V. ####=P<0.0001, 
###=P<0.001 vs LPS, $=P<0.05 vs 100 nM 5αTHB. 
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Recent work has suggested that the anti-inflammatory effects of 5αTHB may 
not be mediated by GR (Gastaldello, Livingstone et al. 2017). This is supported by 
work described in the previous chapter in which 5αTHB appeared to also target 
different mechanisms in the vasculature. Therefore, work described in this chapter 
addressed the role of GR in mediating responses induced by 5αTHB.  
During investigation of steroid binding to GR, dexamethasone and 
hydrocortisone both displaced a GR-selective ligand in a commercial human GR 
competition assay whereas 5αTHB only displaced the ligand at high concentrations. 
This suggested that 5αTHB binds only very minimally to human GR, which is in 
contrast to previous work demonstrating that corticosterone, 5αTHB and 5αDHB had 
similar affinities in displacing tritiated dexamethasone from binding sites in rat 
hepatocytes (McInnes, Kenyon et al. 2004). The difference between this current assay 
and the previous work is that in the latter, whole rat hepatocytes were used, whereas 
our current model system contained human GR and only the LBD. Firstly, the LBD 
may be in a slightly different conformation when in its isolated form, with 
consequences on ligand binding. Secondly, dexamethasone may bind to sites other 
than just cytosolic GR in the hepatocytes, and 5αTHB may instead have been 
displacing dexamethasone from these alternative sites. One alternative proposed was 
the ‘low affinity glucocorticoid binding sites’ (LAGs) which are known to be present 
in the cell microsomal fraction and nuclear envelope (Ambellan, Swanson et al. 1981, 
Roszak, Lefebvre et al. 1990). Consistent with this, although 5αTHB displaced 
dexamethasone from whole hepatocytes and also from the microsomal fraction, the 
binding affinity of 5αTHB was much lower in the cytosolic fraction (McInnes 2003). 
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Alternatively, another possible receptor which dexamethasone may bind to (and may 
have been displaced from) in the microsomal fraction is the membrane GR. Although 
membrane GR originates from the same gene as cytoplasmic GR, it is suggested to 
vary through differential splicing, promoter switching or post translational editing 
(Stahn, Lowenberg et al. 2007). Furthermore it is reported to differ from cytoplasmic 
GR in its ligand binding specificities (Mitre-Aguilar, Cabrera-Quintero et al. 2015). It 
is, therefore, quite plausible that 5αTHB may bind to membrane GR but not the 
cytoplasmic GR. Another difference between this binding assay (using isolated human 
GR LBD) and the previous work (using whole rat hepatocytes) is the species 
difference. This is despite the fact that there is strong evolutionary pressure on 
conservation of the GR gene, and that GR structure and function are well conserved 
among all vertebrate species studied so far (Stolte, van Kemenade et al. 2006).  Of 
these species, the amino acid sequences the of the mouse and rat GR most closely 
resemble that of human GR (Stolte, van Kemenade et al. 2006). This is reflected in the 
common use of murine models to study the effects of glucocorticoid, such as in the 
previous work investigating the effects of 5αTHB (Yang, Nixon et al. 2011, 
Gastaldello, Livingstone et al. 2017). However, although it is unlikely, it should be 
kept in mind that a small amino acid variation in the GR LBD due to species 
differences, may cause differences in ligand binding. 
In order to investigate whether 5αTHB can induce GR to translocate into the 
nucleus, two alternative methods of ‘immunofluorescence’ and ‘nuclear/ cytoplasmic 
(N/C) separation’ were evaluated. Using the original immunofluorescence method 
there was a very narrow dynamic range between vehicle- and dexamethasone- treated 
cells. This resulted from high background immunofluorescence signal in the nucleus, 
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caused by a combination of non-specific secondary antibody binding and auto-
fluorescence of cells in the green emission spectrum. It was determined that the fixing 
procedure (using paraformaldehyde) was causing cells to auto-fluoresce, consistent 
with the literature which reports non-specific binding of the secondary antibody to 
charged groups from unbound aldehydes used in fixation (Burry 2011). Furthermore 
it is reported that aldehyde-based chemicals can react with amines and proteins causing 
fluorescence with a green/yellow wavelength (Collins, 2006). The autofluorescence 
could be avoided by using alternative fixation methods or by aldehyde blocking 
(Thermofisher 2015, Collins 2006) but in this case a secondary antibody with a 
fluorophore which emits in the red (as opposed to green) emission spectrum was 
successful in eliminating the auto-fluorescence. However, due to non-specific 
secondary antibody binding, and also due to the nature of the scoring system used as 
the quantification method, the dynamic range between vehicle- and positive control 
(dexamethasone)-treated cells remained narrow. This meant that any attempts to 
identify intermediary effects were challenging. Improvements were attempted by 
using the alternative quantification method of continuous analysis by ImageJ. This was 
also performed blinded to treatment to eliminate bias. However, since cytoplasmic 
membranes could not be seen in images (only the nuclear outline as determined using 
DAPI staining) a caveat of this method was that cytoplasmic signal could not be 
determined, so the result is based only on nuclear signal. It may have been beneficial 
to include a membrane marker such as sodium-potassium-ATPase or cadherins 
(Abcam, 2016). However, since non-specific antibody binding was still present and 
could also limit reliability, it was decided instead to proceed by assessing steroid 
effects on GR nuclear translocation using the N/C separation method. The N/C 
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separation method had previously been used, albeit in a different cell type 
(myofibroblasts), by another group demonstrating that dexamethasone caused GR to 
be transported into the nucleus (Drebert, Bracke et al. 2015). In this current work, the 
model was successfully adopted to the nuclear and cytoplasmic separation of A549 
cells, with a marked improvement in the dynamic range over the immunofluorescence 
method. The method was used to demonstrate that 5αTHB did not stimulate human 
GR to translocate into the nucleus in A549 cells, unlike dexamethasone. This is 
consistent with previous work in the same cell type by Gastaldello, in which 5αTHB 
did not induce phosphorylation of the Serine 211 residue in GR (known to correlate 
with GR nuclear translocation) whereas corticosterone did (Gastaldello, 2014). 
However, it should be noted that the A549 cells used in these studies are an artificial 
model (a secondary cell line). The recruitment of cofactors to GR is known to be cell-
type specific (Chinenov, Gupte et al. 2013), and cofactors are known to be important 
for nuclear translocation as described in section 1.2.2. Therefore, it would also be 
beneficial to evaluate GR translocation in a primary cell line, where the conditions 
more closely resemble normal physiology. Indeed the results in A549 cells contrast 
with work by Yang (2009) in another secondary cell line (HEK293 cells). In her work 
she used fluorescence microscopy to monitor the movement of green fluorescent 
protein (GFP)-tagged GR (GFP-GR). Whereas dexamethasone (1 µM) or 
corticosterone (1 µM) induced nuclear translocation occurring within 15 and 30 
minutes, respectively, the translocation observed after addition of 5αTHB (1 µM) was 
much slower (2 hours) and remained largely incomplete. Aside from the possibility 
that different co-regulators may be present, another explanation for the discrepancies 
between this past work and ours may be the fact that GFP-GR is a modified protein 
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and may not be representative of endogenous GR. GFP binding to GR may, therefore, 
modify its physiological processes (McMaster and Ray 2007).  
 As described in section 1.2.2, GR binding and nuclear translocation are 
strongly linked since the conformational change which takes place due to GR binding 
enables exposure of NLS and the formation of interactions required for nuclear 
translocation. The fact that 5αTHB only bound GR at very high concentrations, and 
also did not cause its nuclear translocation in this current work is therefore consistent. 
However, this does not exclude the possibility that the effects of 5αTHB are GR 
mediated. Indeed the displacement assay involved only the LBD of GR. It may be that 
5αTHB binds at an allosteric GR site, resulting in non-genomic signalling, or 
alternatively it may act non-genomically through membrane GR. Indeed membrane 
GR is reported to have a different ligand binding specificity from cytosolic GR; for 
example, hydrocortisone had no binding affinity at membrane GR (Powell, Watson et 
al. 1999). As described in section 1.2.3.3, either binding to mGR or to an allosteric site 
could trigger signalling cascades which may result in the indirect modification of gene 
expression. This indirect regulation of gene expression would be consistent with the 
fact that 5αTHB suppressed topical inflammation only after 24 hours, whereas 
corticosterone-induced inhibition was evident after just 6 hours (Gastaldello, 
Livingstone et al. 2017). Alternatively, 5αTHB may bind to a different nuclear 
receptor, such as MR. Indeed endogenous GCs have a similar affinity for MR as 
aldosterone making MR a potential target (Nixon, Upreti et al. 2012). Whichever 
signalling mechanisms are used by 5αTHB, the results presented in this chapter 
suggest that 5αTHB does not cause GR to move into the nucleus. However, the 
question remains whether even a small amount of 5αTHB-bound GR, if able to enter 
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the nucleus, would be sufficient to alter GR-mediated gene regulation. To answer this, 
the effects of 5αTHB on co-regulator recruitment to GR were investigated. 
GR binding to DNA is assisted and regulated by the recruitment of many co-
regulator peptides, and ligand binding to GR allows it to adopt the conformation 
required to interact with these co-regulators. Pamgene’s MARCoNI assay was utilised 
for this study because it enables the profiling of the effect of steroids on GR interaction 
with a range of co-regulator peptides. Dexamethasone induced clear increases and 
decreases in the interaction between GR and many of the co-regulator peptides 
investigated whereas 5αTHB had no effect. This suggests that 5αTHB does not 
stimulate the recruitment of co-regulator proteins to the GR, and is consistent with the 
demonstration in this chapter that 5αTHB did not bind GR LBD nor induce GR nuclear 
translocation. One critique of this assay is that equal concentrations (1 µM) of 5αTHB 
and dexamethasone were used, although 5αTHB is known to be less potent. Indeed 10 
µM was required for 5αTHB binding to GR, whereas dexamethasone bound to a 
similar extent at 10 nM. Therefore, it is possible that a higher concentration of 5αTHB 
would influence interactions between co-regulator peptides and GR. Another critique 
is that since only the (human) GR LBD was used in this assay, it may be possible that 
5αTHB binds to an allosteric site on GR and affects recruitment of co-regulator 
peptides from there. Alternatively, co-regulator peptides could be recruited to sites 
other than the LBD. However, consistent with the assay, initial ChIPseq experiments 
(collaboration with Alasdair Jubb, unpublished work) show that dexamethasone, but 
not 5αTHB, caused GR to bind GRE on typical response genes in human peripheral 
blood mononuclear cells (PBMCs). Since direct GRE binding is only one GR-
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mediated mechanism which occurs in the nucleus, it would be interesting to also study 
the effect of 5αTHB on GR tethering to transcription factors such as AF1 and NFκB. 
The hypotheses addressed in this chapter was that the previously-demonstrated 
anti-inflammatory effects of 5αTHB were mediated via GR. In the work of both 
Gastaldello (2014) and Yang (Yang, Nixon et al. 2011), 5αTHB suppressed IL6 and 
TNFα release from murine BMDM. Suppression of IL6 and TNFα by glucocorticoids 
is reported to largely occur through GR tethering to transcription factors (such as NFκβ 
and AP1), as described in section 1.3. Gastaldello employed the GR antagonist RU486 
in this model in order to investigate the involvement of GR in these anti-inflammatory 
properties of 5αTHB. However, the experiments were inconclusive since RU486 
actually suppressed IL6 release on its own. In this current work it was therefore 
decided to perform GR knockdown in these cells. The experiments of Gastaldello and 
Yang, showing suppression of cytokines by 5αTHB in mouse BMDM, were first re-
performed in the absence of GR knockdown for control purposes. However 
unexpectedly, 5αTHB did not suppress IL6 release from LPS-stimulated BMDM 
whereas hydrocortisone did in a clear concentration-dependent manner. The lack of 
effect by 5αTHB could not be resolved by stimulating cells with a lower dose of LPS, 
nor by increasing the sample size to n=8 for increased power. This was not consistent 
with the work of Gastaldello and Yang. Furthermore in this current work 5αTHB also 
did not suppress release of the alternative cytokine TNFα from the same stimulated 
BMDM cells, also inconsistent with the work of Yang and Gastaldello. Since the effect 
of 5αTHB to suppress cytokines could not be recapitulated, the GR knockdown was 
not performed. It is unclear why the results in this chapter are inconsistent with 
previous findings. There are no major differences in how the experiments were 
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performed. The time course for treatment was the same, with cells being treated for 24 
hours with steroid, and LPS given 1 hour after the steroid. Since hydrocortisone did 
induce a concentration-dependent suppression of cytokine release in this work, the 
absence of effect by 5αTHB cannot be due to problems with the ELISA kits used to 
quantify cytokines. Fresh steroid solutions were prepared in ethanol between each 
concentration-response experiment. A small optimisation had been made to the 
BMDM plating technique from the previous experiments performed by Gastaldello. 
Whereas she re-suspended her cells to give a constant volume each time and then 
plated a specific volume of the suspension per well, in this current study the cells were 
counted and a constant number of cells plated per well. Since this ensured that the 
same number of cells was present in each well, it controlled for intra- and inter- 
variability. However, if anything, this modification could be expected to increase the 
reproducibility of the data and is unlikely to explain the absence of effect in the current 
data. Furthermore, in the work performed by Yang a specific number of cells per well 
was also plated. Another small modification made during this study was that the data 
from each individual experiment were normalised to the cytokine concentration 
present in the media of LPS-only treated cells. The normalised data were then 
combined. This was in order to further reduce inter-assay variability; however, in the 
work by Yang and Gastaldello the raw cytokine concentrations (pg/ mL) were instead 
compared. Again, normalising the data would be expected to increase the 
reproducibility. Although the effect of 5αTHB was not significant compared to 
vehicle, a small concentration-dependent effect can be seen in the TNFα 
concentration-response, where TNFα release was significantly decreased after 
treatment with the highest (1000 nM) dose of 5αTHB, in comparison to treatment with 
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the lowest (100 nM) 5αTHB dose. The result in this chapter is, therefore, not entirely 
inconsistent with the previous work. Indeed, also in the previous work, 5αTHB 
consistently required a higher concentration than corticosterone to suppress IL6 and 
TNFα release in this model, with a threefold difference in potency indicated by Yang. 
 Anti-inflammatory effects of 5αTHB aside from those solely involving 
cytokine release, have also been demonstrated in past work. For example, 5αTHB 
suppressed inflammatory cell infiltration in a mouse model of thioglycolate-induced 
peritonitis, where IL6 suppression by 5αTHB occurred but was lost at higher 
concentrations (Yang, Nixon et al. 2011). Furthermore, more recently 5αTHB 
suppressed swelling and cell infiltration in a croton oil-induced mouse ear model of 
dermatitis, whereas real-time PCR analysis of gene transcripts revealed that, in this 
model, there was an also an absence of effects on IL6 and TNFα transcript expression. 
Therefore, despite my negative findings, 5αTHB may be suppressing inflammation by 
signalling through other mechanisms which have not been tested. In Gastaldello’s 
mouse model of dermatitis, 5αTHB-induced suppression of inflammatory swelling 
was evident only after 24 hours, suggestive of mediation through alternative signalling 
pathways. Furthermore, in the thioglycolate-induced peritonitis model, whereas 
5αTHB and corticosterone suppressed infiltration of neutrophils to the same extent, 
5αTHB had less of an effect to suppress macrophage recruitment. There is, therefore, 
substantial evidence that 5αTHB acts through different mechanisms to suppress 
inflammation in comparison to other GCs.  
 In summary, the results of this chapter are consistent, indicating that 5αTHB 
does not work through the classical GR mechanism of action, namely by binding to 
GR LBD, stimulating GR nuclear translocation, and interacting with coregulatory 
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peptides. Therefore, this chapter suggests that 5αTHB does not have direct genomic 
effects through GR. Instead, 5αTHB may act through GR to initiate non-genomic 
mechanisms, either by binding the LBD at high concentrations, or by binding at an 
allosteric site. 5αTHB may also act through another receptor known to bind 
glucocorticoids, such as membrane GR or LAGs, which are also both associated with 
non-genomic effects of steroid (Falkenstein, Tillmann et al. 2000, Strehl and Buttgereit 
2013). Alternatively, 5αTHB may have direct genomic effects through another 
receptor such as MR or an unidentified receptor. A microarray has recently been 
performed in which 5αTHB was shown to regulate gene expression in human 
peripheral blood derived macrophages. The next chapter of this thesis will, therefore, 
involve a gene expression analysis of this microarray data, in hope of further 
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5. What is the mechanism of action of 5αTHB? 
5.1. Introduction 
 There is compelling evidence in vivo of the anti-inflammatory properties of 
5αTHB (Yang, Nixon et al. 2011, Gastaldello, Livingstone et al. 2017). Whilst its 
mechanisms remain unknown, evidence suggests that they are different from those of 
a typical glucocorticoid, and may underpin a safer therapeutic profile (Gastaldello, 
Livingstone et al. 2017). The requirement of GR for the effects of 5αTHB had not been 
substantiated by the work in this thesis or that of others (Gastaldello, Livingstone et 
al. 2017). Indeed the work presented in chapters 3 and 4 suggested that 5αTHB does 
not act through GR, at least not through genomic mechanisms. Therefore the receptor 
for 5αTHB, as well as its mechanisms of action, including whether they were largely 
genomic or non-genomic, remain unknown. 
 In previous work 5αTHB suppressed cytokine release from murine bone 
marrow derived macrophages (BMDM)(Gastaldello, 2014; Yang, 2009). 
Macrophages have high expression levels of transcriptionally-active GR, and GR 
binding sites have been identified in macrophage DNA, where they are enriched near 
to glucocorticoid-inducible genes (Jubb, Young et al. 2016, Jubb, Boyle et al. 2017). 
In past work, the GR antagonist RU486 attenuated the ability of both corticosterone 
and dexamethasone to suppress cytokine release from BMDM. However, it potentiated 
the suppression of cytokine release by 5αTHB (Gastaldello, 2014; Yang, 2009).  In 
this current work, a significant suppression of cytokine release from these cells by 
5αTHB could not be recapitulated. For this reason the targeted approach of GR 
knockdown to further investigate GR mediation of 5αTHB’s effects in these cells 
could not be followed through. An exploratory approach was, therefore, pursued in 
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order to gain additional insight into the mechanisms of action of 5αTHB. The 
transcriptional response of human monocyte derived macrophages to dexamethasone 
exposure had recently been assessed by local collaborators (Jubb, Young et al. 2016). 
This was therefore an ideal model to also compare the effects of 5αTHB, for analysis 




The hypothesis addressed in this chapter is that 5αTHB regulates a different set of 
gene transcripts to conventional glucocorticoids. 
5.3. Aims 
The aim is to use the results of a microarray to assess gene regulation by 5αTHB 
in human monocyte derived macrophages, in order to generate hypotheses for a 
possible mechanism of action of 5αTHB. The individual aims are: 
1. To identify actions of 5αTHB that may be mediated through classical GR 
genomic actions, by assessing genes commonly regulated by both 5αTHB and 
dexamethasone. 
2. To identify independent mechanisms of 5αTHB, by assessing genes only 







A microarray was performed in collaboration with Dr Alasdair Jubb in order to 
compare the effects of 5αTHB and dexamethasone to modulate gene expression in 
human monocyte derived macrophages (hMDMs). Dexamethasone was chosen as 
positive control as it has high affinity for GR and relatively low affinity for MR (Lan, 
Graham et al. 1982). All sample collection, preparation, analysis and data analysis to 
generate the gene lists described in table 5.2, was performed by Dr Alasdair Jubb. 
Whereas the genes regulated by dexamethasone have already been published (Jubb, 
Young et al. 2016), the 5αTHB-regulated gene lists were reserved for analysis in this 
thesis. 
5.4.1. Sample collection and RNA analysis by microarray. 
Human blood was collected from healthy volunteer donors aged 18-65 years: 
four donors had been used for the initial dexamethasone experiment and three were 
used for the follow up exploratory 5αTHB analysis. Ethical approval was provided by 
the South East Scotland Research Ethics Committee and full written consent obtained. 
From the blood samples, peripheral blood monocytes were then isolated by gradient 
separation of buffy coats followed by MACs CD14 +ve bead separation (Miltenyi 
Biotech, Surrey, UK) to isolate the monocyte fraction from the PBMCs. The full 
protocol is available at www.macrophages.com. Purified cells were cultured (RPMI 
supplemented with Penicillin/Streptomycin, Glutamax (Invitrogen) and 10% FCS) in 
the presence of recombinant human colony stimulating factor (CSF-1), also known as 
macrophage colony-stimulating factor (M-CSF)(104 U/mL) for 1 week, as per Hume 
lab standard operating procedure (Jubb, Young et al. 2016), to produce a stable 
population of monocyte-derived macrophages. Differentiated cells were re-plated at 
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1x106 cells/ mL and treated with either vehicle, dexamethasone (100nM, for 1h, 2h, 
4h, 10h, and 24h) or 5αTHB (1µM, for 2h, 8h, and 24h). In previous work, 5αTHB 
suppressed inflammation after 24 hours but not after 6 hours (Gastaldello, Livingstone 
et al. 2017). Therefore it was anticipated in this work that the majority of 5αTHB- 
regulated genes would be evident after 24 hours, and that the functional analysis of 
dexamethasone- and 5αTHB- regulated genes could be compared at this time point. It 
was for this reason that the 24 hour time point was chosen to assess the effect of 
5αTHB on gene expression, along with one early (2 hour) and one intermediate (8 
hour) time point. After treating the cells, RNA was then extracted using RNeasy 
column-based extraction with on-column DNase treatment (Qiagen), and RNA quality 
was checked using a 2100 Bioanalyzer (Agilent Technologies, Stockport, UK). RNA 
was prepared for microarrays using standard Affymetrix protocols by Edinburgh 
Genomics and gene expression was measured using an Affymetrix HT HG- U133 plus 
PM (human) expression array.  
5.4.2. Data analysis 
Quality and outliers were assessed using the R package ‘arrayQualityMetrics’ 
(Gautier, Cope et al. 2004). Background correction and generation of raw expression 
values was performed using the ‘affy’ package in R (Kauffmann, Gentleman et al. 
2009). To identify differentially expressed genes two complementary approaches had 
been taken for the response to dexamethasone (Jubb, Boyle et al. 2017)(Jubb, A, 2015). 
The first was using Biolayout Express 3D (Theocharidis, van Dongen et al. 2009) to 
assess for groups of genes with a correlated expression profile over the time course. 
This produced lists of genes that changes up or down at each phase of the response 
which were then filtered by requiring an absolute 2-fold change (log2 fold change of 
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1, adjusted p-value <0.05 (Benjamini-Hochberg)) to be retained in the analysis. In 
order to ensure genes with extreme profiles were not excluded by this approach the 
‘limma’ package in R was used to identify differentially expressed genes with a 
minimum log2 fold change of 1.5 adjusted p value of <0.05 (Benjamini-
Hochberg)(Smyth.G.K et al, 2005). The same approach was therefore taken to produce 
the gene lists for the response to 5αTHB (as described in table 5.1). The output for the 
purposes of the initial analysis in this thesis are lists of genes that responded to 
dexamethasone and/or 5αTHB at any time during the 24 hour time course. 
 
Comparison Undertaken Explanation 
Dexamethasone Dexamethasone-treated vs vehicle treated human PBMCs. 
5αTHB 5αTHB-treated vs vehicle treated human PBMCs. 
 
Table 5.1: A description of the comparisons undertaken vs (relative to) vehicle treated 










5.4.3. Functional analysis 
A functional analysis is a high throughput tool which uses the biological knowledge 
accumulated in public databases in order to functionally analyse a large gene list 
(Huang da, Sherman et al. 2009). It, therefore, allows us to identify the most enriched 
and relevant biology within a gene list (Huang da, Sherman et al. 2009, Hong, Zhang 
et al. 2014). Metascape (www.metascape.org)(Developed by Sanford Burnham, 
UCSD, GNF) enrichment analysis tool was employed for the work described in this 
thesis based on the method it uses for the enrichment and output of enriched terms, as 
well as for the background databases with which it is linked. The KEGG pathway 
(www.genome.jp/kegg) and GO Biological Process (www.geneontology.org) 
background databases are available for annotation and were used here. Metascape uses 
the Singular Enrichment Analysis (SEA) method which, due to its efficiency in 
extracting the biological meaning behind large gene lists, is the most traditional and 
popular strategy (Huang da, Sherman et al. 2009, Hong, Zhang et al. 2014). Gene 
identifiers (from the input gene list) are first converted into Entrez gene IDs, and then 
the Entrez gene IDs are used to extract biological information about each gene from 
various background databases. Using these databases each gene is annotated according 
to which biological process or pathway terms (‘annotation terms’) they are associated 
with. A statistical test is then applied to identify the annotation terms which are 
‘enriched’ for the genes in the list (so have a larger amount than expected) in 
comparison to control or reference background. The enriched annotation terms 
associated with the gene list therefore provide important insight into its biological 
themes. Metascape uses the hypergeometric statistical test to identify enriched 
annotation terms, and this is suitable for both small and large gene lists, so is flexible 
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depending on the length of the gene list (Hong, Zhang et al. 2014). For each gene list 
in table 2 enriched terms from publicly available databases (e.g. KEGG pathways, 
Gene Ontology (GO) terms) were sought using an enrichment p value cut off of 
p<0.05. A common limitation to this SEA strategy is that the large outputs of enriched 
annotation terms are often heavily overlapped and redundant, which can cause 
information to be overlooked (Huang da, Sherman et al. 2009). However, Metascape 
clusters redundant annotation terms, grouping them based on their similarities, and 
presenting the top 20 clusters in a heat map, focusing on the larger biological picture. 
For every ‘cluster’ representing a common pathway or process, the most enriched term 
is chosen as the representative term of the group. One limitation of clustering the 
annotation terms in this way is that the most enriched term within each cluster is chosen 
to represent it (forming the cluster name) on each diagram. Therefore, the cluster 
names may not necessarily represent all ontology terms included in it perfectly, and 
information could be missed. For this reason an appendix is also provided at the back 
of this thesis, which gives information on the individual terms within each cluster, as 











5.5.1. Time point assessment  
Of the genes which were differentially expressed between vehicle and 5αTHB 
treatments, 41 were regulated at the 2 hour time point, and 124 genes were regulated 
at the 8 hour time point. There were no differentially expressed genes after 24 hours 
following 5αTHB treatment of hMDMs. This was unexpected, and meant that the 
functional analysis of dexamethasone- and 5αTHB- regulated genes could not be 
compared at the 24 hour time point. Although the majority of 5αTHB- regulated genes 
were regulated at the intermediate 8 hour time point, gene expression in response to 
dexamethasone was not assessed after 8 hours, so a direct comparison of steroid effects 
at this time point also could not be made. Because of this limitation, all genes which 
were differentially expressed over the 24 hour period following steroid treatment were 
grouped together to perform the functional analyses described in section 5.5.3. 
 Since the time points were different between steroids, genes were grouped 
according to whether they first became differentially expressed at an early time point 
(between 0-2 hours), at an intermediate time point (between 2-8 hours by 5αTHB, or 
between 2-10 hours by dexamethasone), or at a late time point (between 8-24 hours by 
5αTHB, or between 10-24 hours by dexamethasone). Figures 5.1 and 5.2 demonstrate 
the proportion of genes regulated at an early, intermediate, and late time point after 














Figure 5.1: The proportion of genes which became differentially expressed at an early, 
intermediate, or late time point after dexamethasone treatment of human peripheral 
blood-derived macrophages. The early time point corresponds to genes which were 
regulated 0-2 hours post treatment (33 genes), intermediate corresponds to 2-10 hours post 










Figure 5.2: The proportion of genes which became differentially expressed at an early, 
intermediate, or late time point after 5αTHB treatment of human peripheral blood-
derived macrophages. The early time point corresponds to genes which were regulated 0-2 
hours post treatment (41 genes), intermediate corresponds to 2-8 hours post treatment (124 
genes), and late corresponds to 8-24 hours post treatment. None of the genes regulated by 
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5.5.2. Analysis of gene lists. 
A total of 350 genes were identified as being differentially expressed between vehicle 
and dexamethasone treatments (table 5.2; list 1) over the 24 hour time course after 
treatment. 165 genes were differentially expressed between vehicle and 5αTHB 
treatments (table 5.2; list 2). Only 38 genes were commonly differentially expressed 
in response to both dexamethasone and 5αTHB (table 5.2; list 3). This means that a 
remaining 312 genes were only regulated by dexamethasone and not by 5αTHB (table 
5.2; list 4). In addition, 127 genes were only regulated by 5αTHB and not by 
dexamethasone (table 5.2; list 5). The number of genes in each list is given in table 
5.2, and the data is demonstrated in figure 5.3.  
The 350 genes differentially expressed in response to dexamethasone have been 
published by Dr Alasdair Jubb (Jubb, Young et al. 2016). All other gene lists from table 












Gene list Description Total genes Genes up-regulated Genes down-regulated 




350 225 125 
2 All genes differentially 
expressed between 
5αTHB and vehicle 
treatments. 
165 133 32 




vehicle treatments and 
between 5αTHB and 
vehicle treatments. 
38 32 6 
4 Genes only differentially 
expressed between 
dexamethasone and 
vehicle treatments (not 
between 5αTHB and 
vehicle treatments). 
312 194 118 
5 Genes only differentially 
expressed between 
5αTHB and vehicle 
treatments (not between 
dexamethasone and 
vehicle treatments). 
127 101 26 
 
 
Table 5.2:  A summary of the gene lists generated from a microarray comparing dexamethasone 
and 5αTHB effects on gene expression in human peripheral blood derived macrophages. The 
number of significant differentially regulated genes with fold change > 1.5 and adjusted p value < 0.05 are 
























Figure 5.3:    A Venn diagram demonstrating the number of differentially expressed 




5.5.3. Enrichment analysis 
Enrichment analyses of GO biological processes and KEGG pathways were 
first performed using all genes regulated by either dexamethasone (list 1, table 5.2) or 
5αTHB (list 2, table 5.2) (section 2.2.1). Further enrichment analyses were then 
performed using the genes only regulated by either dexamethasone (list 4, table 5.2) 
or 5αTHB (list 5, table 5.2)(Section 2.2.2). Finally, enrichment analyses of the genes 
commonly regulated by both 5αTHB and dexamethasone (list 3, table 5.2) are 




312 genes                38 genes         127 genes  
 Dex only                    Both            5αTHB only 
240 
 
5.5.3.1. Enrichment analyses of all genes regulated by dexamethasone and 
5αTHB 
5.5.3.1.1. Enrichment of GO biological processes 
5.5.3.1.1.1. Enrichment of GO biological processes by all genes regulated by 
dexamethasone 
The top 20 GO biological process clusters identified as being significantly 
enriched, following analysis of the 350 genes regulated by dexamethasone, are given 
in figure 5.4a. Many of the most significantly-enriched clusters are related to 
inflammatory and immune responses. Examples are the GO biological processes of 
‘inflammatory response’, ‘response to cytokine’ and ‘regulation of cytokine 
production’. Other enriched processes include ‘regulation of cell migration’, ‘negative 
regulation of cell proliferation’ and ‘single organism cell adhesion’. 
Enrichment was subsequently assessed for up- and down-regulated genes 
separately, as different components of a given pathway or molecular function could be 
up- or down-regulated within a single comparison. The GO biological process terms 
which were significantly enriched for genes up-regulated and down-regulated by 












Figure 5.4: Gene Ontology Biological process clusters enriched for genes which were 
(a) differentially expressed (both up-regulated and down-regulated genes), (b) up- 
regulated, or (c) down-regulated in human peripheral blood-derived macrophages 






















5.5.3.1.1.2. Enrichment of GO biological processes by all genes regulated by 
5αTHB  
The top 20 significantly enriched (p<0.05) GO biological process clusters in 
the list of 165 differentially regulated genes after 5αTHB treatment (gene list 2, table 
5.2) are given in figure 5.5a. The most significantly enriched GO biological process 
cluster was ‘cellular response to lipid’; however, GO biological process clusters 
relating to inflammation were also enriched (such as ‘Inflammatory response’, 
‘cytokine production’ and ‘cytokine production involved in immune response’). These 
were less significantly enriched (higher p value) than by dexamethasone. Other 
enriched processes in the list of genes regulated by 5αTHB included ‘blood vessel 
development’, ‘hematopoietic or lymphoid organ development’ and ‘fat cell 
differentiation’.  
Up-regulated and down-regulated genes were also assessed separately as for 
dexamethasone. The top 20 significantly-enriched GO biological process clusters are 
given for the up-regulated genes in figure 5.5b, whereas only 4 GO biological process 












Figure 5.5: Gene Ontology Biological process clusters which were significantly enriched 
(p<0.05) in genes which were (a) differentially expressed (either up- and down-regulated), (b) 
up-regulated or (c) down-regulated (both adjusted p<0.05) in human peripheral blood-derived 























5.3.3.1.2. Enrichment of KEGG pathways. 
5.3.3.1.2.1. Enrichment of KEGG pathways by all genes regulated by 
dexamethasone 
All 350 genes differentially regulated in human PBMCs after dexamethasone 
treatment (list 1, table 5.2) were then used for an enrichment analysis of KEGG 
pathways. The top 20 significantly-enriched KEGG pathways are given in figure 5.6a. 
Many of these are involved with inflammatory and immune responses; such as ‘NFκB 
signalling pathway’ which was the most significantly enriched of the pathways. Others 
included ‘cytokine-cytokine receptor interaction’, ‘TNF signalling pathway’ and 
‘MAPK signalling pathway’. KEGG pathways relating to cancer were also commonly 
enriched, such as ‘proteoglycans in cancer’, ‘transcriptional misregulation in cancer’, 
‘bladder cancer’ and ‘endometrial cancer’. 
Separate lists of up-regulated and down-regulated genes were then analysed, 
and the significantly enriched KEGG pathways within these separate lists are given in 
figures 5.6b and c respectively. There were 15 significantly enriched KEGG pathways 
for the up-regulated genes. The most significant was the ‘FoxO signalling pathway’, 
followed by ‘transcriptional misregulation in cancer’, ‘mineral absorption’, 
‘proteoglycans in cancer’, ‘AMPK signalling pathway’ and ‘MAPK signalling 
pathway’. For down-regulated genes, 10 KEGG pathways were significantly enriched. 
The top 3 were the ‘NFκB signalling pathway’, ‘TNF signalling pathway’ and 



























Figure 5.6: KEGG pathways (at p value<0.05) which were significantly enriched for (a) all 
differentially-expressed genes, (b) up-regulated genes, and (c) down-regulated genes in 
human peripheral blood derived macrophages between 0-24 hours after treatment with 

























5.5.3.1.2.2. Enrichment of KEGG pathways by all genes regulated by 5αTHB 
An enrichment analysis of KEGG pathways for the list of 165 genes which 
were differentially expressed after 5αTHB treatment (list 2, table 5.2) was then 
performed. 13 KEGG pathways were significantly enriched, demonstrated in figure 
5.7a. The most significantly enriched KEGG pathway cluster was ‘Fc gamma R-
mediated phagocytosis’ which is related to an inflammatory response. Other enriched 
KEGG pathway clusters relating to inflammation were the ‘TNF signalling pathway’ 
(which did appear in the enrichment analysis of dexamethasone-regulated genes) and 
‘Th1 and Th2 cell differentiation’ (which did not). Another of the enriched KEGG 
pathways was ‘Aldosterone synthesis and secretion’  
The genes up-regulated and down-regulated by 5αTHB were then analysed 
separately. There were 8 KEGG pathways specifically up- regulated by 5αTHB (figure 
5.7b) but there were no down-regulated KEGG pathways. Fc gamma R-mediated 
phagocytosis was the most significantly enriched pathway in the list of up-regulated 
genes. This was followed by the ‘TGF-beta signalling pathway’, ‘Th1 and Th2 cell 






























Figure 5.7: KEGG pathways (at p value<0.05) which were significantly enriched for (a) all 
differentially expressed genes and (b) up-regulated genes in human blood derived 




























5.5.3.2. Enrichment analysis of genes only regulated by either dexamethasone 
or 5αTHB. 
In order to compare pathways and processes commonly regulated by both 
drugs, or specifically targeted by one or the other, an enrichment analysis was 
performed on the genes which were only regulated by either dexamethasone or 5αTHB 
(lists 4 and 5 respectively, able 5.2) and those which were commonly regulated by both 
drugs (list 3, table 5.2).  
5.5.3.2.1. Enrichment analysis of GO biological processes 
5.5.3.2.1.1. Enrichment of GO biological processes by genes regulated only 
by dexamethasone 
Many of the top GO Biological process clusters which were enriched in the 
genes only regulated by dexamethasone (and not 5αTHB)(list 4, table 5.2) were related 
to inflammatory and immune responses. Again, other enriched processes within these 
genes included cell migration and cell proliferation. The top 20 enriched GO biological 
process clusters are given in figure 5.8a.  
The genes were then separated according to whether they were up-regulated or down-
regulated in response to dexamethasone, and then enrichment analysis performed 
separately for each of these groups.  
For the 194 total up-regulated genes, the enriched GO biological process clusters are 
given in figure 5.8b, and for the 118 down-regulated genes, the enriched GO biological 





Figure 5.8: A list of the top 20 GO Biological process clusters which were enriched in genes 
found to be (a) differentially expressed (in either direction), (b) up-regulated or (c) down-
regulated between 0-24 hours after dexamethasone (100 nM) treatment, but not by 5αTHB 

























5.5.3.2.1.2. Enrichment of GO biological processes by genes only regulated 
by 5αTHB. 
With regard to the genes which were only regulated by 5αTHB (and not by 
dexamethasone) (list 5, table 5.2) the GO biological processes which were 
significantly enriched (p<0.05) are given in figure 5.9a. ‘Blood vessel development’ 
was the second most significantly enriched cluster, after ‘organic hydroxyl compound 
biosynthetic process’ and followed by ‘negative regulation of pathway-restricted 
SMAD protein phosphorylation’.  Other enriched processes included ‘leukocyte 
chemotaxis’, ‘fat cell differentiation’, ‘regulation of cellular localisation’ and 
‘regulation of fibroblast proliferation’.  
The up-regulated and down-regulated genes were then analysed separately. 
Figure 5.9b demonstrates that ‘blood vessel development’ is enriched by the genes 
which were up regulated by 5αTHB. Other processes enriched by the up-regulated 
genes were ‘fat cell differentiation’, ‘regulation of fibroblast proliferation’, ‘regulation 
of microtubule-based process’, ‘SMAD protein signal transduction’ and ‘negative 
regulation of neurogenesis’.  
Only 4 GO biological process clusters were significantly down-regulated at an 
enrichment p value of 0.05 (figure 5.9c). These were ‘steroid metabolic process’, 
‘response to lipoprotein particle’, ‘cellular response to interferon gamma’, and 









Figure 5.9: GO Biological process clusters which were enriched in the list of genes found to 
be (a) differentially expressed (in either direction), (b) up-regulated and (c) down-regulated 
between 0-24 hours after treatment with 5αTHB, but not by treatment with dexamethasone, in 

























5.5.3.2.2. Enrichment analysis of KEGG pathways 
5.5.3.2.2.1. Enrichment analysis of KEGG pathways by genes regulated only 
by dexamethasone 
The top 20 significantly enriched KEGG pathways in the genes regulated only 
by dexamethasone (but not 5αTHB)(list 4, table 5.2) are given in figure 5.10a. The 
results are similar to when the commonly regulated genes (by both dexamethasone and 
5αTHB) were included; except now the ‘TNF signalling pathway’ has been removed. 
In addition, the following new pathways appear on this heat map: ‘rheumatoid 
arthritis’, ‘amoebiasis’, ‘hepatitis B’, ‘apoptosis’, ‘AMPK signalling pathway’, 
‘Epstein-Barr virus infection’ and ‘circadian entrainment’.  
Genes up-regulated or down-regulated by dexamethasone (but not 5αTHB) 
were analysed separately. 19 KEGG pathways were significantly enriched by up 
regulated genes (p<0.05)(figure 5.10b).  
10 KEGG pathways were significantly enriched by down-regulated genes, 





































Figure 5.10: KEGG pathways which were enriched in the genes regulated only by 
dexamethasone (100 nM) (and not by 5αTHB) between 0-24 hours after treatment in human 
peripheral blood macrophages. Heat map (a) uses both up-regulated and down-regulated 
genes to determine enriched processes, whereas heat maps (b) and (c) use only genes which 
























5.5.3.2.2.2. Enrichment of KEGG pathways by genes regulated only by 5αTHB 
An enrichment analysis of KEGG pathways was then performed on genes 
which were only regulated by 5αTHB (and not dexamethasone). There were only 8 
KEGG pathways significantly enriched (p<0.05) in this list of genes (list 5, table 5.2) 
which are given in figure 5.11a. The most significantly enriched pathway was the 
TGF-beta signalling pathway. This was followed by ‘Fc-gamma R- mediated 
phagocytosis’ and ‘Th1 and Th2 cell differentiation’ which are both pathways related 
to inflammation and immunity. In comparison to the heat map of pathways enriched 
by all genes (regulated by both dexamethasone and 5αTHB) many pathways have now 
disappeared from the list, so may be commonly targeted by both 5αTHB and 
dexamethasone. These include ‘TNF signalling pathway’, ‘Aldosterone synthesis and 
secretion’, ‘sphingolipid signalling pathway’, ‘sphingolipid metabolism’, ‘mineral 
absorption’, ‘tight junction’ and ‘transcriptional misregulation in cancer’.  
When up-regulated and down-regulated genes were analysed separately, 7 
KEGG pathways were enriched for up-regulated genes (figure 5.11b) and these were 
very similar to the enriched pathways using all the 5αTHB up-regulated genes (figure 
5.11b). The only differences are that the KEGG pathway clusters of ‘Type II diabetes 
mellitus’ and ‘Mineral absorption’ have now disappeared; hence, genes commonly 
regulated by both drugs are required for these processes to be enriched.  




























Figure 5.11: KEGG pathways which were enriched in the genes regulated only by 5αTHB (1 
µM) between 0-24 hours after treatment in human peripheral blood macrophages. Heat map 
(a) gives the KEGG pathways which were enriched in the list of all genes differentially 
regulated by 5αTHB, and heat map (b) are gives the KEGG pathways which were enriched in 


























5.5.3.3. Enrichment analysis of genes commonly regulated by both 5αTHB and 
dexamethasone 
5.5.3.3.1. Enrichment of GO biological processes by genes commonly 
regulated by both 5αTHB and dexamethasone 
Finally, an enrichment analysis was performed on the genes which were 
commonly regulated both by 5αTHB and by dexamethasone (list 3, table 5.2). 15 GO 
biological process clusters were enriched for these genes, which are given in figure 
5.12a.  
The up-regulated and down-regulated genes were then separated. 12 GO 
biological processes were significantly enriched for up-regulated genes (figure 5.12b). 
Many of these enriched processes were related to inflammation and immunity such as 
the negative regulation of leukocyte apoptotic process, inflammatory response and 
lymphocyte activation. Processes related to the negative regulation of apoptosis were 
among the most significantly enriched processes (‘negative regulation of leukocyte 
apoptotic process’ and ‘negative regulation of apoptotic process’) although ‘regulation 
of cellular carbohydrate metabolic process’ was the most significantly enriched. Other 
enriched processes were ‘locomotory behaviour’, ‘response to lipid’, ‘membrane lipid 
metabolic process’ and ‘regulation of vesicle-mediated transport’.  











Figure 5.12: GO Biological process clusters which were enriched in the list of genes which 
were commonly differentially expressed between 0-24 hours after both 5αTHB (1 µM) and 
dexamethasone (100 nM) treatment. (a) are the GO Biological processes which were enriched 
by this total gene list, and (b) are the biological processes which were enriched only for the 



























5.5.3.3.2. Enrichment of KEGG pathways by genes commonly regulated by 
both 5αTHB and dexamethasone 
In the genes which were commonly regulated by both dexamethasone and 
5αTHB, there were 2 significantly enriched (p<0.05) KEGG pathways, which were 
‘sphingolipid signalling pathway’ and ‘cGMP-PKG’ signalling pathway’. 2 genes 
(ADORA3 and PRKCE) were present in both enriched KEGG pathway clusters. 
Again, up-regulated and down-regulated genes were analysed separately. One KEGG 
pathway (cGMP-PKG) was enriched in the list of up-regulated genes whereas there 



















Previous work suggested that 5αTHB retains some glucocorticoid activities but 
acts through a different mechanism from typical glucocorticoids (Gastaldello, 
Livingstone et al. 2017). The findings so far presented in this thesis (chapters 3 and 4) 
are consistent with this previous work. The mechanisms of action of 5αTHB remain 
unknown, and to gain some insight an exploratory approach was taken in this chapter 
whereby the transcriptional response of human monocyte derived macrophages 
(hMDMs) were compared between 5αTHB and the selective GR agonist 
dexamethasone. A microarray of the steroid-treated hMDMs showed that 165 genes 
were regulated by 5αTHB, and 350 by dexamethasone, whereas only 38 of these genes 
were commonly regulated by both steroids. It was unexpected that differential 
expression of all 5αTHB- regulated genes occurred in under 8 hours, whereas some 
dexamethasone-regulated genes required 24 hours to become differentially expressed. 
This contrasts with the in vivo work of Gastaldello et al, in which 5αTHB required 24 
hours to suppress swelling and cell infiltration whereas corticosterone required only 6 
hours (Gastaldello, Livingstone et al. 2017). However since Gastaldello assessed 
inflammation at only two time points (6 and 24 hours), it is possible that 5αTHB had 
an effect just after the 6 hour time point which was only detected at the later 24 hour 
time point, which would be consistent with the work presented here. It should be noted 
that the model used by Gastaldello et al used mice whilst the current work was 
performed in human cells. Furthermore, the croton oil model used by Gastaldello et al 
(Gastaldello, Livingstone et al. 2017) is an in vivo model and, therefore, is influenced 
by the full immune response and requires time for protein translation and the effect to 
become evident, whereas the microarray used in the current work was performed on 
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RNA taken from individual macrophages. However, since 5αTHB did not cause 
differential expression of any genes after 24 hours in this current work, a functional 
analysis of gene expression at this time point could not be performed. Instead, the 
functional analyses of dexamethasone- and 5αTHB- regulated genes were compared 
by using all genes regulated by each steroid over the course of the 24 hours after 
treatment, keeping the limitation in mind that gene regulation by 5αTHB was assessed 
at fewer time points than dexamethasone. 
The 38 genes commonly regulated by both dexamethasone and 5αTHB included 
typical glucocorticoid responsive genes (such as Per1, Fkbp51, and Gilz) which 
contain GRE in their promoters for transactivation by GR. Whilst this may suggest 
mediation of effects through GR, it is not conclusive proof since all members of the 
NR3C nuclear receptor subfamily (mineralocorticoid, glucocorticoid, androgen, and 
progesterone receptors) have overlapping DNA binding preferences (Hudson, Youn et 
al. 2014). Furthermore MR also has overlapping preferences with GR for ligand 
binding, and MR has been shown to regulate all three of these genes (Fernandes-Rosa, 
Hubert et al. 2011, Hudson, Youn et al. 2014, Petrovich, Asher et al. 2014, Fletcher, 
Morgan et al. 2017). Interestingly, evidence has suggested that at least Per1 and 
Fkbp51 can be regulated by GR-MR heterodimers (Petrovich, Asher et al. 2014, 
Mifsud and Reul 2016). Therefore, in future work the involvement of MR, and perhaps 
of GR-MR heterodimers, for 5αTHB’s effects should be investigated. Although there 
were some genes commonly regulated by both dexamethasone and 5αTHB, the fact 
that there were only 38 provides strong evidence that the two steroids largely act 
through different mechanisms in macrophages. One point to keep in mind is that a 
reason for the lack of commonly regulated genes may be that the selection criteria used 
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to select genes were too stringent, with the consequence that many more commonly 
regulated genes could have been missed. It was also considered that these 38 
commonly regulated genes may be the genes which are key to achieving the anti-
inflammatory effects of both compounds. In a functional analysis performed on these 
commonly-regulated genes to assess this, whereas three GO biological processes 
related to inflammation were enriched (‘Negative regulation of leukocyte apoptotic 
process’, ‘Lymphocyte activation’, and ‘Inflammatory response’), there was 
enrichment of only two KEGG pathway terms, with just 3 genes responsible for 
enrichment of each term. This could indicate that, whilst dexamethasone and 5αTHB 
may target some of the same inflammatory processes, they may achieve this by acting 
through different molecular pathways.   
 Whereas dexamethasone caused differential expression of 350 genes in this 
study, a previous study had identified only 133 genes regulated by dexamethasone; 
however, this data is not directly comparable since in the previous study the cells were 
undifferentiated monocytes (Ehrchen, Steinmuller et al. 2007). In addition to the 
typical glucocorticoid responsive genes reported above, other transcription factors 
(Nfil3, Jdp2, Irf1, Bcl) and anti-inflammatory genes (Sesn1, Fcar, Cd163) were also 
identified among dexamethasone- regulated genes, which have been reported in 
previous studies to be glucocorticoid regulated (Ehrchen, Steinmuller et al. 2007, 
Chinenov, Coppo et al. 2014). This suggested that the microarray results are reliable. 
Many of the GO biological processes which were enriched for dexamethasone-
regulated genes relate to inflammation. Furthermore the KEGG pathways enriched by 
dexamethasone-regulated genes in this study are consistent with the mechanisms 
known to be used by glucocorticoids to suppress inflammation. For example the most 
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enriched KEGG pathways among down-regulated genes include the NFκB and TNF 
signalling pathways, and among up-regulated genes include the MAPK signalling 
pathway which, as discussed in section 1.3, are all known to be involved in the 
suppression of inflammation by glucocorticoids. Among the genes only regulated by 
dexamethasone (i.e. when the 38 genes commonly regulated by dexamethasone and 
5αTHB are taken away) the situation is very similar, with many enriched GO 
biological processes and KEGG signalling pathways relating to inflammation, perhaps 
suggesting that the overlapping genes are not crucial for the anti-inflammatory effect 
of dexamethasone. 
The fact that 5αTHB caused differential expression of 165 genes demonstrates 
that it has effects on gene transcription in human peripheral blood macrophages, as 
opposed to acting solely via membrane receptors and second messenger signalling, for 
example. Among 5αTHB- regulated genes, the most enriched GO biological process 
is ‘cellular response to lipid’. On inspection of the enrichment table for figure 3 in the 
appendices, the redundant processes within this cluster reflect a cellular response to 
steroid hormone, suggesting that 5αTHB does in some way engage in mechanisms 
associated with a classical steroid. The ‘inflammatory response’ GO biological process 
is also enriched among 5αTHB regulated genes, as are ‘cytokine production’ and 
‘cytokine production involved in the immune response’, although not as significantly 
as their enrichment by dexamethasone-regulated genes. Another enriched cluster was 
‘blood vessel development’ and, on inspection of the enrichment table for figure 3 in 
the appendices, the redundant terms within this cluster relate to angiogenesis, vascular 
development, and endothelial cell migration. Therefore, perhaps 5αTHB affects the 
release of growth factors from immune cells, which then act on the vasculature. 
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Whereas chapter 3 suggests that 5αTHB acts directly on the vasculature (for example 
to alter expression of adhesion molecules) the result here may, therefore, suggest that 
5αTHB also acts indirectly on the vasculature through effects on immune cells 
(Gastaldello, Livingstone et al. 2017). The work here is in an inflammatory cell, and 
5αTHB has been suggested to suppress inflammation mainly by reducing vascular 
permeability and subsequent inflammatory cell recruitment (Gastaldello, Livingstone 
et al. 2017). Genes involved in a reduction of vascular permeability may therefore have 
caused enrichment of the ‘blood vessel development’ term. Another explanation could 
be that 5αTHB induces a specific phenotype in the macrophages, which promotes 
angiogenesis. The M2 phenotype is known to promote angiogenesis and tissue healing 
(Shapouri-Moghaddam, Mohammadian et al. 2018). These functions are important 
after the initial proinflammatory response of the classical M1 macrophages, in order 
to restore tissue homeostasis (Shapouri-Moghaddam, Mohammadian et al. 2018). 
Further evidence for the presence of the M2 macrophage is presented by the 
demonstration that ‘SMAD protein signal transduction’ is another enriched process 
among up-regulated genes. SMAD signalling is activated by TGFβ, and a specific type 
of M2 macrophage (known as M2c) is known to release TGFβ (Gratchev 2017, 
Shapouri-Moghaddam, Mohammadian et al. 2018). Furthermore, the KEGG pathways 
enriched by 5αTHB-regulated genes include ‘Fc gamma R-mediated phagocytosis’, 
‘TGF-beta signalling pathway’, and ‘Th1 and Th2 cell differentiation’. Enrichment of 
these terms is consistent with the possibility that the macrophages treated with 5αTHB 
have developed the M2c phenotype. This relates to the concept that macrophages are 
not a homogenous cell population but may adopt distinct phenotypes and functions, 
depending on the presence of various stimuli (such as cytokines, growth factors, and 
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hormones) present in their microenvironment (Ehrchen, Steinmuller et al. 2007, 
Schmieder, Michel et al. 2012, Chazaud 2014, Gratchev 2017, Shapouri-Moghaddam, 
Mohammadian et al. 2018). The polarised phenotypes that macrophages acquire have 
been broadly classified into two major groups: Pro-inflammatory, classically-activated 
macrophages (M1) and anti-inflammatory, alternatively-activated macrophages (M2), 
which promote Th1 and Th2 responses, respectively (Rickard and Young 2009, Mills 
2012, Schmieder, Michel et al. 2012, Shapouri-Moghaddam, Mohammadian et al. 
2018). A change in phenotype from M1 to M2 can, therefore, explain enrichment of 
the term ‘Th1 and Th2 cell differentiation’. M1 macrophages are polarised by a 
microbial trigger, such as LPS, or by Th1 cytokines, such as IFN-γ or TNFα (Rickard 
and Young 2009, Schmieder, Michel et al. 2012). They have robust antimicrobial 
activity, secreting various pro-inflammatory cytokines (such as IL6 and TNFα), 
chemokines, as well as reactive oxygen and nitrogen intermediates. Although this is 
effective in killing pathogens it also results in tissue destruction  (Schmieder, Michel 
et al. 2012, Shapouri-Moghaddam, Mohammadian et al. 2018). In contrast, M2 
macrophages actually suppress inflammation and function to promote tissue repair and 
remodelling, re-establishing homeostasis. They do this in part through an increase in 
angiogenesis, which is, therefore, consistent with enrichment of terms relating to the 
vasculature (Rickard and Young 2009, Schmieder, Michel et al. 2012, Chazaud 2014, 
Shapouri-Moghaddam, Mohammadian et al. 2018). There are a variety of M2 cells 
depending on the stimulus used for polarisation. For this reason M2 macrophages have 
been further classified into M2a, M2b, and M2c subfamilies (Schmieder, Michel et al. 
2012, Chazaud 2014). The M2c subset can be induced by glucocorticoids, IL10, or 
TGFβ, and also release TGFβ as a mediator (Zizzo, Hilliard et al. 2012).  The presence 
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of this M2c macrophage phenotype would, therefore, be consistent with enrichment of 
the ‘TGF beta signalling pathway’ KEGG term as well as with the GO biological 
process terms relating to SMAD signalling (Ehrchen, Steinmuller et al. 2007). 
Furthermore, M2c cells have a pro-healing function and increased phagocytic activity, 
consistent with enrichment of the term relating to phagocytosis (Zizzo, Hilliard et al. 
2012). The increased phagocytic activity of M2c cells is associated with an up 
regulation of Mertk, and, interestingly, this gene was increased in the microarray in 
response to dexamethasone and 5αTHB, suggesting that this phenotype was also 
present in dexamethasone-treated cells to some extent (Shapouri-Moghaddam, 
Mohammadian et al. 2018).  
Limitations of the enrichment analysis should not be ignored. First of all the 
macrophages were unstimulated, so they may not optimally model an inflammatory 
response. This is important since the macrophage phenotype is described to change 
upon stimulation, with microbial triggers such as LPS being reported to cause classical 
activation of macrophages into a pro inflammatory M1 phenotype (Rickard and Young 
2009, Mills 2012, Schmieder, Michel et al. 2012, Shapouri-Moghaddam, 
Mohammadian et al. 2018). It must be noted that these macrophages had not been 
stimulated, and LPS stimulation is known to alter macrophage phenotype. Future work 
will compare the effect of dexamethasone and 5αTHB on gene expression in LPS-
stimulated cells. Another limitation is that Metascape is limited by current knowledge 
of genes and of processes to which they relate. Therefore, it may be that many of the 
5αTHB-regulated genes have a role in a large suppression of inflammation through 
mechanisms which are entirely undiscovered. However, since this information is not 
known the genes will not cause an enrichment of inflammatory terms in the database, 
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and, consequently, this will not be reflected in the Metascape diagrams. Metascape can 
be used only to provide hints of what may be happening, to direct future investigation.  
In summary, the work described in this chapter suggest that 5αTHB acts largely 
through different mechanisms from dexamethasone in immune cells. The enrichment 
analysis of 5αTHB- regulated genes tentatively suggests the presence of a particular 
macrophage phenotype known as M2c. 5αTHB may, therefore, either selectively target 
these cells, or may induce a phenotypic change in macrophage cells into the reparative 
M2c subtype. This is, therefore, consistent with 5αTHB acting to suppress 
inflammation without detrimental effects to wound repair processes. The hypothesis 
that 5αTHB induces a phenotypic change in macrophages into the M2c phenotype will 
be investigated in future work. This could be achieved by testing surface marker 
expression typical of M2c cells in human peripheral blood macrophages after 5αTHB 
treatment, to confirm the change in phenotype. Although the work described in this 
chapter suggests that GR is probably not involved in mediating the effects of 5αTHB 
(since 5αTHB and dexamethasone largely regulated different genes) this is not 
conclusive and in the future the same microarray may be performed after GR 
knockdown, in order to provide conclusive evidence. Mediation of the effects of 
5αTHB through MR will be tested in the future. Indeed ‘Aldosterone synthesis and 
secretion’ was an enriched KEGG pathway in the list of all of the 5αTHB-regulated 
genes, although this was not present on the heat map of enriched KEGG pathways in 
genes which were only regulated by 5αTHB. This chapter provides further evidence 
that 5αTHB acts through different mechanisms to glucocorticoids and suggests 
alternative mechanisms by which 5αTHB may suppress inflammation. The hypotheses 
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generated in this chapter will be investigated in future work, perhaps leading to the 
development of a safer class of anti-inflammatory therapy. 
 










































6. Summary and Future Work 
 
 There has been a huge drive to find a selective modulator of GR activity over 
the past few years. This is in an attempt to better treat inflammatory diseases, since the 
current glucocorticoid treatments have side effects which restrict their use. The work 
described in this thesis was based on a glucocorticoid metabolite, 5αTHB, which is 
under investigation as a selective modulator of GR activity for topical anti-
inflammatory treatment. The anti-inflammatory effects of 5αTHB had been robustly 
demonstrated in vivo, on the skin and in a model of peritonitis (Yang, Nixon et al. 
2011, Gastaldello, Livingstone et al. 2017). However, the role of GR in mediating the 
effects of 5αTHB had not been established (Gastaldello, Livingstone et al. 2017). The 
work described in this thesis, therefore, investigated the mechanisms of action of 
5αTHB, as well as further exploring the potential of 5αTHB as a topical steroid by 
studying its effects to delay wound repair, a side effect which is a particular problem 
of topical glucocorticoid treatments. 
6.1. Is 5αTHB less detrimental to wound repair processes than current 
glucocorticoids? 
 The wound healing process involves many stages and cell types, and 
communication between the cells through release of growth factors and other 
mediators is crucial for coordinating the healing response (Eming, Brachvogel et al. 
2007, Barrientos, Stojadinovic et al. 2008). In this thesis an attempt to compare steroid 
effects on different aspects of the wound repair process was performed, by using a 
scratch wound assay to measure the migration of endothelial, dermal fibroblast, and 
keratinocyte cells. However neither 5αTHB nor dexamethasone effected migration of 
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any cell type. In the literature it has since been demonstrated that paracrine signalling 
plays an important role in coordinating the behaviour of these cells. In future work the 
indirect effects of 5αTHB on cell behaviour should therefore be considered. 
Angiogenesis is crucial for wound repair. Work described in this thesis using 
an aortic ring assay model provided further evidence that 5αTHB is a less potent 
inhibitor of angiogenesis than other topical glucocorticoids. It is therefore likely to be 
suitable for use as a safer topical anti-inflammatory treatment. This thesis expands on 
past work by showing that 5αTHB suppresses angiogenesis, at least in part, through 
direct effects on the vasculature. Furthermore, evidence was presented to suggest that 
5αTHB may act indirectly through macrophages to promote, rather than inhibit, 
angiogenesis and tissue repair. The mechanisms of how angiogenesis is suppressed by 
5αTHB were investigated by comparing steroid effects on gene expression in the 
mouse aorta. Glucocorticoids are reported to suppress angiogenesis mainly through 
effects on inflammatory signalling and on the ECM in the vessel basement membrane 
(Morgan, Keen et al. 2018). However unlike dexamethasone and hydrocortisone, 
5αTHB had no effect on gene transcript abundance relating to components of the 
basement membrane, and also had no effect on transcript abundance of the 
inflammatory signalling gene Cxcl5, which was one of the most strongly down-
regulated genes in a previous microarray investigating the effects of hydrocortisone in 
the aortic ring assay (Morgan, Keen et al. 2018).. Instead, 5αTHB tended to increase 
transcript levels of the monocyte chemoattractant gene Mcp1, and decreased transcript 
levels of the endothelial adhesion protein Pecam1. The gene expression analysis 
presented in this thesis, therefore, strongly suggested that 5αTHB was using different 
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mechanisms than dexamethasone and hydrocortisone to suppress angiogenesis in the 
mouse aorta.  
Pecam1, which was selectively downregulated by 5αTHB in this work, 
encodes a protein which is expressed on the surface of all vascular cells, including 
platelets, endothelial cells, monocytes, neutrophils, and some T cells (Ilan and Madri 
2003, Solowiej, Biswas et al. 2003, Woodfin, Voisin et al. 2007, Lertkiatmongkol, 
Liao et al. 2016). Pecam1 protein is highly enriched and one of the most abundant 
components at endothelial cell-cell junctions (Lertkiatmongkol, Liao et al. 2016), 
where it participates in cell-cell adhesion and the maintenance of junction integrity and 
permeability (Ilan and Madri 2003, Solowiej, Biswas et al. 2003). It is not clear from 
this current work which cell type was mainly responsible for the downregulation of 
Pecam1, and future work may investigate whether 5αTHB is able to decrease Pecam1 
expression specifically in endothelial cells. If so, then 5αTHB may be acting to 
suppress angiogenesis by interfering with the formation of new cell-cell contacts 
between endothelial cells. Another explanation could be that 5αTHB is inducing 
endothelial cells to undergo endothelial-to-mesenchymal transition (EndMT) since 
this is associated with a loss of Pecam1 as well as decreased angiogenesis 
(Miscianinov, Martello et al. 2018). EndMT causes endothelial cells to acquire a 
mesenchymal-like phenotype and undergo cytoskeletal rearrangement to develop a 
more stretched, fibroblast-like morphology (Miscianinov, Martello et al. 2018). Future 
work could address whether 5αTHB is able to induce EndMT in endothelial cells, both 
through direct and indirect effects. This could be achieved by observing the endothelial 
cells to assess whether they are developing a fibroblast-like morphology, after 
treatment with 5αTHB, as well as after culture with media taken from 5αTHB- treated 
272 
 
inflammatory cells. Endothelial cell gene expression could also be assessed: 
endothelial cells undergoing EndMT could be expected to have decreased expression 
of vascular endothelial cadherin (VE-Cadherin) and Pecam1, and increased expression 
of α-smooth muscle actin (αSMA), vimentin (Vim), N-cadherin, and ECM proteins 
such as collagen type 1 and 3 (Miscianinov, Martello et al. 2018).  
Angiogenesis is just one stage during wound repair. In future work the ultimate 
effect of 5αTHB on wound repair should be compared in vivo with the effects of 
hydrocortisone (topical glucocorticoid) and dexamethasone (GR agonist). A mouse 
model of skin wound healing is available in which wound vascularisation and rate of 
closure can be reproducibly measured (Miscianinov, Martello et al. 2018). This model 
is also reported to be excellent for studying the impact of EndMT on vessel growth 
during wound healing, so would also help to gain insight into whether 5αTHB is 
inducing this process (Miscianinov, Martello et al. 2018). If 5αTHB is found to be less 
detrimental than glucocorticoids to the wound repair process, then the mechanisms 
underpinning why can then be investigated further. 
6.2. Does 5αTHB work through GR? 
 Whereas 5αTHB was originally assumed to be an inert metabolite of 
corticosterone, it was later discovered to possess biological effects (McInnes, Kenyon 
et al. 2004). Various early model systems suggested, as would naturally be assumed, 
that its effects were mediated through GR (McInnes, Kenyon et al. 2004). However 
more recent experimental results have been contradictory. In the most recent work in 
vivo, RU486 attenuated the corticosterone-mediated suppression of inflammatory 
swelling in a mouse ear model of dermatitis, but did not block the effect of 5αTHB 
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(Gastaldello, Livingstone et al. 2017). This thesis presents new evidence to support the 
more recent work that suggests 5αTHB does not act through GR. In this work 5αTHB 
only minimally bound the isolated human GR, did not stimulate GR translocation into 
the nucleus, and did not cause changes in GR interaction with co-regulator peptides.  
From the work described in chapter 5, 5αTHB predominantly regulated a 
different set of genes than dexamethasone in human macrophages. This provided 
evidence that 5αTHB has a distinct profile of biological action compared with 
conventional glucocorticoids, supporting the concept that it may not work through GR. 
There is also evidence from the aortic ring assay model of angiogenesis to suggest that 
GR was not involved for the effects of 5αTHB. The decrease in transcript abundance 
of Pecam1 by 5αTHB in aortic rings was not antagonised by RU486, and although 
5αTHB increased expression of Per1 this was to a lesser extent than dexamethasone 
and hydrocortisone and was not prevented by RU486. Studies of suppression of vessel 
growth suggested that RU486 also did not antagonise the dose-dependent effect of 
5αTHB whereas it suppressed the effect of dexamethasone, although caution should 
be taken when interpreting this data due to a lack of power in the experiments and the 
fact that RU486 alone suppressed vessel growth. Further work is needed to gain a 
definitive conclusion of whether GR is required for the effects of 5αTHB in the aortic 
ring assay model, and this should be addressed in future work. This could not be 
achieved using GR knockout mice since they die after birth due to respiratory failure 
(Cole, Blendy et al. 1995) however mice heterozygous for GR could be used in which 
GR is expressed to a lesser extent than wild type animals. A conditional knockout 
mouse model could also be generated in which GR is specifically disrupted in 
endothelial cells. In previous work by Logie et al., dexamethasone inhibited tube-like 
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structure formation by cultured endothelial cells and this was blocked by RU486, 
demonstrating that glucocorticoid-induced suppression of angiogenesis is at least in 
part mediated through effects on GR in endothelial cells (Logie, Ali et al. 2010). 
Another approach could be to knockdown GR in the aortic ring assay, which can be 
achieved by transfecting the rings with siRNA (Baker, Robinson et al. 2012).  
6.3. How does 5αTHB work? 
A microarray of steroid effects in human peripheral blood-derived 
macrophages in chapter 5 suggested that 5αTHB mainly acts through different 
mechanisms from the selective GR ligand dexamethasone, but did cause differential 
expression of Per1, Fkbp51, and Gilz, which are regulated through GRE. Similarly, in 
chapter 3, 5αTHB increased transcripts of Per1 in the mouse aorta, which was not 
antagonised by RU486. Since MR is also able to bind GRE, and since endogenous 
glucocorticoids are also able to bind MR, this seems the next most logical receptor to 
investigate for mediation of 5αTHB effects. This could be achieved in future work by 
assessing antagonism with the MR antagonist spironolactone. Alternatively, model 
systems could be used to investigate the effects of 5αTHB on MR translocation, such 
as the nuclear/cytoplasmic separation model. Initial results of experiments addressing 
the influence of 5αTHB on recruitment of co-regulator peptides at MR, are promising. 
However, MR is known to promote inflammation in macrophages (Bene, Alcaide et 
al. 2014). Therefore if 5αTHB is discovered to work through MR, further 
investigations of the downstream mechanisms will be required. Interestingly, 
differential regulation of Per1 and Fkbp51 has also been linked to MR-GR 
heterodimers, so mediation of the effect of 5αTHB through these heterodimers may 
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also be an avenue to explore in the future (Petrovich, Asher et al. 2014, Mifsud and 
Reul 2016). 
A functional analysis of the genes which were differentially expressed by 
5αTHB in the microarray, found enrichment of terms associated with a specific 
macrophage phenotype known as M2c. Two alternative hypotheses that may arise 
from this work are that 5αTHB may (a) specifically target this M2c subtype, or (b) 
induce a phenotypic change in macrophages into this M2c subtype. Future work should 
address these hypotheses and this could be achieved by staining 5αTHB-treated 
macrophages for Arg-1 in mouse, or MMR/CD206, TLR-1, or TLR-8 in human. 
Alternatively gene expression of IL10, TGFβ, CCL16, CCL18, and CXC13 could be 
tested which can be expected to increase in macrophages of the M2c phenotype 
(Shapouri-Moghaddam, Mohammadian et al. 2018). It must be noted that the 
macrophages in chapter 5 had not been stimulated, and the microarray should be 
performed in LPS-stimulated cells in future work for comparison. Furthermore, the 
macrophage subtypes (M1, M2, M2c) have been defined in vitro using well-defined 
stimuli. Realistically this is an oversimplified concept of the in vivo situation where 
macrophages are likely to be exposed to a combination of stimuli (Shapouri-
Moghaddam, Mohammadian et al. 2018) and hence switch between one phenotype 
and another, as well as possessing intermediate phenotypes (Chazaud 2014, Shapouri-
Moghaddam, Mohammadian et al. 2018). The effect of steroids on M2c polarisation 
could therefore also be tested by immunostaining for M2c macrophages on tissue taken 
from in vivo models.   
One of the enriched pathways related to the M2c macrophage phenotype in 
5αTHB regulated genes was the TGFβ pathway. Endothelial to mesenchymal 
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transition (EndMT) of endothelial cells is known to be dependent on the TGFβ 
pathway (Miscianinov, Martello et al. 2018). Since chapter 3 suggested that 5αTHB 
may be causing EndMT of endothelial cells in aortic rings, it may be possible that 
5αTHB causes M2c polarisation of inflammatory cells, which then indirectly cause 
EndMT of endothelial cells through release of TGFβ. 5αTHB effects on gene 
expression relating to TGFβ signalling in endothelial cells and inflammatory cells 
could therefore be investigated in future work. TGFβ signals by binding to a 
heteromeric receptor complex formed by the TGFβ type I receptor (Tgfbr1) and the 
TGFβ type 2 receptor (Tgfbr2). This leads to activation of Smad2 and Smad3 proteins, 
which translocate to the nucleus and mediate TGFβ signalling by regulating 
transcription of target genes (Gratchev 2017, Miscianinov, Martello et al. 2018). In the 
microarray performed in hMDMs (described in chapter 5) 5αTHB caused upregulation 
of Smad7 and Tgif1 genes which are both inhibitors of TGFβ signalling (Gratchev 
2017)( https://www.ncbi.nlm.nih.gov/gene/7050). Therefore, genes relating to TGFβ 




 In summary this thesis has shown that 5αTHB is less angiostatic than the topical 
glucocorticoid hydrocortisone and therefore is a promising candidate for a safer topical 
anti-inflammatory therapy. The thesis gives further evidence that 5αTHB acts through 
distinct mechanisms to glucocorticoids, likely independent of GR, and provides 
hypotheses for further exploration. Identification of the mechanisms used by 5αTHB 
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in future work may lead to the development of a whole new prototype of anti-
inflammatory drug which could also be used systemically. This would allow safer 
treatment of patients requiring long term anti-inflammatory therapy, preventing much 
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